US20190239957A1 - Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems - Google Patents
Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems Download PDFInfo
- Publication number
- US20190239957A1 US20190239957A1 US16/382,889 US201916382889A US2019239957A1 US 20190239957 A1 US20190239957 A1 US 20190239957A1 US 201916382889 A US201916382889 A US 201916382889A US 2019239957 A1 US2019239957 A1 US 2019239957A1
- Authority
- US
- United States
- Prior art keywords
- therapeutic
- electrodes
- nasal
- energy
- nerves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000001225 therapeutic effect Effects 0.000 title abstract description 296
- 230000004007 neuromodulation Effects 0.000 title abstract description 160
- 210000001983 hard palate Anatomy 0.000 claims abstract description 22
- 210000005037 parasympathetic nerve Anatomy 0.000 claims abstract description 19
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims abstract description 13
- 206010039083 rhinitis Diseases 0.000 claims abstract description 13
- 206010009137 Chronic sinusitis Diseases 0.000 claims abstract description 9
- 210000001519 tissue Anatomy 0.000 claims description 105
- 230000001537 neural effect Effects 0.000 claims description 67
- 210000003928 nasal cavity Anatomy 0.000 claims description 38
- 210000002850 nasal mucosa Anatomy 0.000 claims description 19
- 238000002679 ablation Methods 0.000 claims description 17
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 210000003097 mucus Anatomy 0.000 claims description 6
- 206010001076 Acute sinusitis Diseases 0.000 claims description 5
- 208000036071 Rhinorrhea Diseases 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 210000001331 nose Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 208000027744 congestion Diseases 0.000 claims description 3
- 239000012781 shape memory material Substances 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 201000009151 chronic rhinitis Diseases 0.000 claims description 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims 12
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 abstract description 124
- 238000011282 treatment Methods 0.000 abstract description 77
- 238000005516 engineering process Methods 0.000 abstract description 59
- 210000004086 maxillary sinus Anatomy 0.000 abstract description 3
- 210000003484 anatomy Anatomy 0.000 description 41
- 210000004379 membrane Anatomy 0.000 description 37
- 239000012528 membrane Substances 0.000 description 37
- 239000000835 fiber Substances 0.000 description 32
- 239000012530 fluid Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 22
- 210000001944 turbinate Anatomy 0.000 description 21
- 230000001734 parasympathetic effect Effects 0.000 description 20
- 238000013507 mapping Methods 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 15
- 210000001367 artery Anatomy 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 210000004877 mucosa Anatomy 0.000 description 13
- 201000009890 sinusitis Diseases 0.000 description 13
- 239000003507 refrigerant Substances 0.000 description 12
- 230000037361 pathway Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 230000036982 action potential Effects 0.000 description 8
- 230000006854 communication Effects 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000012800 visualization Methods 0.000 description 8
- 208000003098 Ganglion Cysts Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000005400 Synovial Cyst Diseases 0.000 description 7
- 230000002567 autonomic effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 210000005166 vasculature Anatomy 0.000 description 7
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- RWRIWBAIICGTTQ-UHFFFAOYSA-N difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000013566 allergen Substances 0.000 description 5
- 229960004784 allergens Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003695 paranasal sinus Anatomy 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- GTLACDSXYULKMZ-UHFFFAOYSA-N pentafluoroethane Chemical compound FC(F)C(F)(F)F GTLACDSXYULKMZ-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000004878 submucosal gland Anatomy 0.000 description 4
- 230000003685 thermal hair damage Effects 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028748 Nasal obstruction Diseases 0.000 description 3
- 230000037424 autonomic function Effects 0.000 description 3
- 230000002638 denervation Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000037417 hyperactivation Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000002847 impedance measurement Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 238000000608 laser ablation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000003227 neuromodulating effect Effects 0.000 description 3
- 239000001272 nitrous oxide Substances 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 208000015768 polyposis Diseases 0.000 description 3
- 210000000598 pterygopalatine fossa Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 210000002187 accessory nerve Anatomy 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000000315 cryotherapy Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001214 frontal sinus Anatomy 0.000 description 2
- 201000000615 hard palate cancer Diseases 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- SQEHCNOBYLQFTG-UHFFFAOYSA-M lithium;thiophene-2-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CS1 SQEHCNOBYLQFTG-UHFFFAOYSA-M 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004228 maxillary nerve Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000010004 neural pathway Effects 0.000 description 2
- 210000000118 neural pathway Anatomy 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 230000009958 parasympathetic pathway Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000004664 postganglionic parasympathetic fiber Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002474 sphenoid bone Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028740 Nasal dryness Diseases 0.000 description 1
- 206010028762 Nasal septum deviation Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004079 adrenergic fiber Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- HTXDPTMKBJXEOW-UHFFFAOYSA-N dioxoiridium Chemical compound O=[Ir]=O HTXDPTMKBJXEOW-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910000457 iridium oxide Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002441 meningeal artery Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 239000002074 nanoribbon Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007604 neuronal communication Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 210000004977 neurovascular bundle Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000021715 photosynthesis, light harvesting Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000005126 pseudostratified columnar epithelium Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000001614 vomer Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
- A61B18/24—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/12—Devices for heating or cooling internal body cavities
- A61F7/123—Devices for heating or cooling internal body cavities using a flexible balloon containing the thermal element
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0546—Nasal electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/37518—Anchoring of the implants, e.g. fixation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A61N5/022—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B18/0218—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques with open-end cryogenic probe, e.g. for spraying fluid directly on tissue or via a tissue-contacting porous tip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00292—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
- A61B2017/003—Steerable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00017—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids with gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00023—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids closed, i.e. without wound contact by the fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00029—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids open
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00005—Cooling or heating of the probe or tissue immediately surrounding the probe
- A61B2018/00011—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids
- A61B2018/00029—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids open
- A61B2018/00035—Cooling or heating of the probe or tissue immediately surrounding the probe with fluids open with return means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/0016—Energy applicators arranged in a two- or three dimensional array
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/00226—Balloons extending from a surface, i.e. Blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/00232—Balloons having an irregular shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/00238—Balloons porous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/00244—Balloons adapted to separate target tissue from other tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/0025—Multiple balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/0025—Multiple balloons
- A61B2018/00255—Multiple balloons arranged one inside another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/0025—Multiple balloons
- A61B2018/00261—Multiple balloons arranged in a line
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/00267—Expandable means emitting energy, e.g. by elements carried thereon having a basket shaped structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00321—Head or parts thereof
- A61B2018/00327—Ear, nose or throat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00434—Neural system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00577—Ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00642—Sensing and controlling the application of energy with feedback, i.e. closed loop control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00666—Sensing and controlling the application of energy using a threshold value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/00702—Power or energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
- A61B2018/00797—Temperature measured by multiple temperature sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00839—Bioelectrical parameters, e.g. ECG, EEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00875—Resistance or impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00982—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body combined with or comprising means for visual or photographic inspections inside the body, e.g. endoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0212—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0225—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument for clamping tissue, e.g. forceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0237—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0237—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes
- A61B2018/0243—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes cooling of the hot side of the junction, e.g. heat sink
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0237—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes
- A61B2018/0243—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes cooling of the hot side of the junction, e.g. heat sink
- A61B2018/025—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes cooling of the hot side of the junction, e.g. heat sink by circulating liquid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0237—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes
- A61B2018/0243—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes cooling of the hot side of the junction, e.g. heat sink
- A61B2018/0256—Characteristics of handpieces or probes with a thermoelectric element in the probe for cooling purposes cooling of the hot side of the junction, e.g. heat sink by circulating gas, e.g. air
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
- A61B2018/0268—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
- A61B2018/0268—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow
- A61B2018/0275—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow using porous elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
- A61B2018/0268—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow
- A61B2018/0281—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow using a tortuous path, e.g. formed by fins or ribs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
- A61B2018/0268—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow
- A61B2018/0281—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow using a tortuous path, e.g. formed by fins or ribs
- A61B2018/0287—Characteristics of handpieces or probes using a circulating cryogenic fluid with restriction of flow using a tortuous path, e.g. formed by fins or ribs the fluid flowing through a long thin tube with spiral shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0293—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument interstitially inserted into the body, e.g. needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1467—Probes or electrodes therefor using more than two electrodes on a single probe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2218/00—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2218/001—Details of surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body having means for irrigation and/or aspiration of substances to and/or from the surgical site
- A61B2218/002—Irrigation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0002—Head or parts thereof
- A61F2007/0006—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0054—Heating or cooling appliances for medical or therapeutic treatment of the human body with a closed fluid circuit, e.g. hot water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/06—Electrodes for high-frequency therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
Definitions
- the present technology relates generally to devices, systems, and methods for therapeutically modulating nerves in or associated with a nasal region of a patient.
- various embodiments of the present technology are related to therapeutic neuromodulation systems and methods for the treating rhinitis and other indications.
- Rhinosinusitis is characterized as an inflammation of the mucous membrane of the nose and refers to a group of conditions, including allergic rhinitis, non-allergic rhinitis, chronic rhinitis, chronic sinusitis, and medical resistant rhinitis.
- Symptoms of rhinosinusitis include nasal blockage, obstruction, congestion, nasal discharge (e.g., rhinorrhea and/or posterior nasal drip), facial pain, facial pressure, and/or reduction or loss of smell.
- Allergic rhinitis can include further symptoms, such as sneezing, watery rhinorrhea, nasal itching, and itchy or watery eyes.
- Severe rhinitis can lead to exacerbation of coexisting asthma, sleep disturbances, and impairment of daily activities.
- rhinosinusitis can fall within four subtypes: acute rhinosinusitis, recurrent rhinosinusitis, chronic rhinosinusitis with nasal polyposis (i.e., soft, non-cancerous growths on the lining of the nasal passages or sinuses), and chronic rhinosinusitis without nasal polyposis.
- Acute rhinosinusitis refers to symptoms lasting for less than twelve weeks, whereas chronic rhinosinusitis (with and without nasal polyposis) refers to symptoms lasting longer than twelve weeks.
- Recurrent rhinosinusitis refers to four or more episodes of acute rhinosinusitis within a twelve-month period, with resolution of symptoms between each episode.
- Non-allergic rhinosinusitis can be caused by environmental irritants (e.g., exhaust fumes, cleaning solutions, latex, perfume, dust, etc.), medications (e.g., NSAIDs, oral contraceptives, blood pressure medications including ACE inhibitors, antidepressants, etc.), foods (e.g., alcoholic beverages, spicy foods, etc.), hormonal changes (e.g., pregnancy and menstruation), and/or nasal septum deviation.
- environmental irritants e.g., exhaust fumes, cleaning solutions, latex, perfume, dust, etc.
- medications e.g., NSAIDs, oral contraceptives, blood pressure medications including ACE inhibitors, antidepressants, etc.
- foods e.g., alcoholic beverages, spicy foods, etc.
- hormonal changes e.g., pregnancy and menstruation
- Triggers of allergic rhinitis can include exposure to seasonal allergens (e.g., exposure to environmental allergens at similar times each year), perennial allergens that occur any time of year (e.g., dust mites, animal dander, molds, etc.), and/or occupational allergens (e.g., certain chemicals, grains, latex, etc.).
- seasonal allergens e.g., exposure to environmental allergens at similar times each year
- perennial allergens that occur any time of year e.g., dust mites, animal dander, molds, etc.
- occupational allergens e.g., certain chemicals, grains, latex, etc.
- the treatment of rhinosinusitis can include a general avoidance of rhinitis triggers, nasal irrigation with a saline solution, and/or drug therapies.
- Pharmaceutical agents prescribed for rhinosinusitis include, for example, oral H1 antihistamines, topical nasal H1 antihistamines, topical intranasal corticosteroids, systemic glucocorticoids, injectable corticosteroids, anti-leukotrienes, nasal or oral decongestants, topical anticholinergic, chromoglycate, and/or anti-immunoglobulin E therapies.
- Immunotherapy including sublingual immunotherapy (“SLIT”), has also been used to treat allergic rhinitis by desensitizing the patient to particular allergens by repeated administration of an allergen extract.
- SLIT sublingual immunotherapy
- immunotherapy requires an elongated administration period (e.g., 3-5 years for SLIT) and may result in numerous side effects, including pain and swelling at the site of the injection, urticarial (i.e., hives), angioedema, asthma, and anaphylaxis.
- Surgical interventions have also been employed in an attempt to treat patients with drug therapy resistant, severe rhinitis symptoms.
- surgeries were performed to sever parasympathetic nerve fibers in the vidian canal to decrease parasympathetic tone in the nasal mucosa.
- More recent attempts at vidian neurectomies were found to be 50-88% effective for the treatment of rhinorrhea, with other ancillary benefits including improvements in symptoms of sneezing and nasal obstruction.
- These symptomatic improvements have also been correlated to histologic mucosal changes with reductions in stromal edema, eosinophilic cellular infiltration, mast cell levels, and histamine concentrations in denervated mucosa.
- the site of neurectomy includes preganglionic secretomotor fibers to the lacrimal gland, and therefore the neurectomy often resulted in the loss of reflex tearing, i.e., lacrimation, which in severe cases can cause vision loss. Due to such irreversible complications, this technique was soon abandoned.
- the position of the vidian neurectomy relative to the target end organ may result in re-innervation via the autonomic plexus and otic ganglion projections traveling with the accessory meningeal artery.
- FIG. 1A is a cut-away side view illustrating the anatomy of a lateral nasal wall.
- FIG. 1B is an enlarged side view of the nerves of the lateral nasal wall of FIG. 1A .
- FIG. 1C is a front view of a left palatine bone illustrating geometry of microforamina in the left palatine bone.
- FIG. 2 is a partially schematic view of a therapeutic neuromodulation system for therapeutically modulating nerves in a nasal region in accordance with an embodiment of the present technology.
- FIGS. 3A-3E are partial cut-away side views illustrating various approaches for delivering a distal portion of a therapeutic neuromodulation device to a target site within a nasal region in accordance with embodiments of the present technology.
- FIG. 4 is an isometric view of a distal portion of a therapeutic neuromodulation device configured in accordance with an embodiment of the present technology.
- FIGS. 5A-5G are isometric views of electrode configurations of therapeutic neuromodulation devices for therapeutic neuromodulation in accordance with embodiments of the present technology.
- FIGS. 6A and 6B are partially schematic diagrams illustrating electrode configurations at a distal portion of a therapeutic neuromodulation device for nerve detection configured in accordance with embodiments of the present technology.
- FIG. 7 is a graph illustrating threshold levels of electrical conductivity of nasal tissue with respect to temperature.
- FIGS. 8 and 9 are isometric views of a distal portion of a therapeutic neuromodulation device configured in accordance with an embodiment of the present technology.
- FIG. 10A is an isometric view of a distal portion of a therapeutic neuromodulation device configured in accordance with another embodiment of the present technology
- FIG. 10B is an isometric view illustrating the therapeutic neuromodulation device of FIG. 10A at a treatment site.
- FIGS. 11A-11D are isometric views illustrating a distal portion of a therapeutic neuromodulation device configured in accordance with yet another embodiment of the present technology.
- FIG. 12 is a side view of a distal portion of a therapeutic neuromodulation device configured in accordance with a further embodiment of the present technology.
- FIG. 13 is a side view of a distal portion of a therapeutic neuromodulation device configured in accordance with a still further embodiment of the present technology.
- FIG. 14 is an isometric side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology.
- FIG. 15 is an isometric side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology.
- FIG. 16 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology.
- FIG. 17 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology.
- FIG. 18 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology.
- FIG. 19 is a side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology.
- FIG. 20 is a partial cut-away side view illustrating target sites proximate to ostia of nasal sinuses for a therapeutic neuromodulation device configured in accordance with embodiments of the present technology.
- the present technology is generally directed to devices for therapeutic nasal neuromodulation and associated systems and methods.
- the disclosed devices are configured to provide an accurate and localized non-invasive application of energy to disrupt the parasympathetic motor sensory function in the nasal region.
- Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-20 .
- FIGS. 1A-20 Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-20 .
- FIGS. 1A-20 Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-20 .
- FIGS. 1A-20 Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-20 .
- FIGS. 1A-20 Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-20 .
- FIGS. 1A-20 Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-20 .
- embodiments of the present technology can have different configurations, components, and/or procedures than those shown or described herein.
- a person of ordinary skill in the art will understand that embodiments of the present technology can have configurations, components, and/or procedures in addition to those shown or described herein and that these and other embodiments can be without several of the configurations, components, and/or procedures shown or described herein without deviating from the present technology.
- distal and proximal within this description, unless otherwise specified, the terms can reference relative positions of portions of a therapeutic neuromodulation device and/or an associated delivery device with reference to an operator and/or a location within the nasal cavity.
- proximal can refer to a position closer to the operator of the device or access point at the entrance point of a patient's nostril
- distal can refer to a position that is more distant from the operator of the device or further from the access point at the entrance of the patient's nostril.
- posterior, anterior, inferior and superior are used in accordance with standard medical terminology.
- therapeutic modulation of nerves and “therapeutic neuromodulation” refer to the partial or complete incapacitation or other effective disruption of neural activity, including partial or complete ablation of nerves.
- Therapeutic neuromodulation for example, can include partially or completely inhibiting, reducing, and/or blocking neural communication along neural fibers.
- FIG. 1A is a cut-away side view illustrating the anatomy of a lateral nasal wall
- FIG. 1B is an enlarged side view of the nerves of the lateral nasal wall of FIG. 1A
- the sphenopalatine foramen (“SPF”; FIG. 1A ) is an opening or conduit defined by the palatine bone and the sphenoid bone through which the sphenopalatine vessels and the posterior superior nasal nerves travel into the nasal cavity. More specifically, the orbital and sphenoidal processes of the perpendicular plate of the palatine bone define the sphenopalatine notch, which is converted into the SPF by the articulation with the surface of the body of the sphenoid bone.
- the location of the SPF is highly variable within the posterior region of the lateral nasal cavity, which makes it difficult to visually locate the SPF.
- the SPF is located in the middle meatus (“MM”; FIG. 1A ); however, anatomical variations also result in the SPF being located in the superior meatus (“SM”; FIG. 1A ) or at the transition of the superior and middle meatuses.
- the inferior border of the SPF has been measured at about 19 mm above the horizontal plate of the palatine bone (i.e., the nasal sill), which is about 13 mm above the horizontal lamina of the inferior turbinate (“IT”; FIG.
- the anatomical variations of the SPF are expected to correspond to alterations of the autonomic and vascular pathways traversing into the nasal cavity.
- the posterior nasal nerves also referred to as lateral posterior superior nasal nerves
- PPG pterygopalatine ganglion
- FIG. 1A the sphenopalatine ganglion
- the sphenopalatine artery branches into two main portions: the posterior lateral nasal branch and the posterior septal branch.
- the main branch of the posterior lateral nasal artery travels inferiorly into the inferior turbinate IT (e.g., between about 1.0 mm and 1.5 mm from the posterior tip of the inferior turbinate IT), while another branch enters the middle turbinate MT and branches anteriorly and posteriorly.
- inferior turbinate IT e.g., between about 1.0 mm and 1.5 mm from the posterior tip of the inferior turbinate IT
- the accessory foramena are typically smaller than the SPF and positioned inferior to the SPF.
- the variability in location, size, and quantity associated with the accessory foramen and the associated branching arteries and nerves that travel through the accessory foramen gives rise to a great deal of uncertainty regarding the positions of the vasculature and nerves of the sphenopalatine region.
- the natural anatomy extending from the SPF often includes deep inferior and/or superior grooves that carry neural and arterial pathways, which make it difficult to locate arterial and neural branches.
- the grooves can extend more than 5 mm long, more than 2 mm wide, and more than 1 mm deep, thereby creating a path significant enough to carry both arteries and nerves.
- the variations caused by the grooves and the accessory foramen in the sphenopalatine region make locating and accessing the arteries and nerves (positioned posterior to the arteries) extremely difficult for surgeons.
- FIG. 1 Recent microanatomic dissection of the pterygopalatine fossa (PPF) have further evidenced the highly variable anatomy of the region surrounding the SPF, showing that a multiplicity of efferent rami that project from the pterygopalatine ganglion (“PPG”; FIG. 1 ) to innervate the orbit and nasal mucosa via numerous groups of small nerve fascicles, rather than an individual postganglionic autonomic nerves (e.g., the posterior nasal nerve). Studies have shown that at least 87% of humans have microforamina and micro rami in the palatine bone.
- PPG pterygopalatine ganglion
- FIG. 1C is a front view of a left palatine bone illustrating geometry of microforamina and micro rami in a left palatine bone.
- the solid regions represent nerves traversing directly through the palatine bone, and the open circles represent nerves that were associated with distinct microforamina.
- FIG. 1C illustrates that a medial portion of the palatine bone can include at least 25 accessory posterolateral nerves.
- the respiratory portion of the nasal cavity mucosa is composed of a type of ciliated pseudostratified columnar epithelium with a basement membrane.
- Nasal secretions e.g., mucus
- goblet cells e.g., goblet cells
- submucosal glands e.g., submucosal glands
- transudate from plasma e.g., fet cells
- Nasal seromucous glands and blood vessels are highly regulated by parasympathetic innervation deriving from the vidian and other nerves.
- Parasympathetic (cholinergic) stimulation through acetylcholine and vasoactive intestinal peptide generally results in mucus production.
- the parasympathetic innervation of the mucosa is primarily responsible submucosal gland activation/hyper activation, venous engorgement (e.g., congestion), and increased blood flow to the blood vessels lining the nose. Accordingly, severing or modulating the parasympathetic pathways that innervate the mucosa are expected to reduce or eliminate the hyper activation of the submucosal glands and engorgement of vessels that cause symptoms associated with rhinosinusitis and other indications.
- postganglionic parasympathetic fibers that innervate the nasal mucosa were thought to travel exclusively through the SPF as a sphenopalatine neurovascular bundle.
- the posterior nasal nerves are branches of the maxillary nerve that innervate the nasal cavity via a number of smaller medial and lateral branches extending through the mucosa of the superior and middle turbinates ST, MT (i.e., nasal chonchea) and to the nasal septum.
- the nasopalatine nerve is generally the largest of the medial posterior superior nasal nerves. It passes antero-inferiorly in a groove on the vomer to the floor of the nasal cavity.
- the posterior superior nasal nerves pass through the pterygopalatine ganglion PPG without synapsing and onto the maxillary nerve via its ganglionic branches.
- the sinonasal parasympathetic pathway actually comprises individual rami project from the pterygopalatine ganglion (PPG) to innervate the nasal mucosa via multiple small nerve fascicles (i.e., accessory posterolateral nerves), not a single branch extending through the SPF.
- PPG pterygopalatine ganglion
- These rami are transmitted through multiple fissures, accessory foramina, and microforamina throughout the palatine bone and may demonstrate anastomotic loops with both the SPF and other accessory nerves.
- embodiments of the present technology are configured to therapeutically modulate nerves at precise and focused treatment sites corresponding to the sites of rami extending through fissures, accessory foramina, and microforamina throughout the palatine bone (e.g., target region T shown in FIG. 1B ).
- the targeted nerves are postganglionic parasympathetic nerves that go on to innervate the nasal mucosa.
- This selective neural treatment is also expected to decrease the rate of postoperative nasal crusting and dryness because it allows a clinician to titrate the degree of anterior denervation through judicious sparing of the rami orbitonasalis.
- embodiments of the present technology are also expected to maintain at least some sympathetic tone by preserving a portion of the sympathetic contributions from the deep petrosal nerve and internal maxillary periarteriolar plexi, leading to improved outcomes with respect to nasal obstruction.
- embodiments of the present technology are configured to target a multitude of parasympathetic neural entry locations (e.g., accessory foramen, fissures, and microforamina) to the nasal region to provide for a complete resection of all anastomotic loops, thereby reducing the rate of long-term re-innervation.
- parasympathetic neural entry locations e.g., accessory foramen, fissures, and microforamina
- FIG. 2 is a partially schematic view of a therapeutic neuromodulation system 200 (“system 200 ”) for therapeutically modulating nerves in a nasal region in accordance with an embodiment of the present technology.
- the system 200 includes a therapeutic neuromodulation catheter or device 202 , a console 204 , and a cable 206 extending therebetween.
- the therapeutic neuromodulation device 202 includes a shaft 208 having a proximal portion 208 a , a distal portion 208 b , a handle 210 at a proximal portion 208 a of the shaft 208 , and a therapeutic assembly or element 212 at the distal portion 208 b of the shaft 208 .
- the shaft 208 is configured to locate the distal portion 208 b intraluminally at a treatment or target site within a nasal region proximate to postganglionic parasympathetic nerves that innervate the nasal mucosa.
- the target site may be a region, volume, or area in which the target nerves are located and may differ in size and shape depending upon the anatomy of the patient.
- the target site may be a 3 cm area inferior to the SPF.
- the target site may be larger, smaller, and/or located elsewhere in the nasal cavity to target the desired neural fibers.
- the therapeutic assembly 212 can include at least one energy delivery element 214 configured to therapeutically modulate the postganglionic parasympathetic nerves.
- the therapeutic assembly 212 can therapeutically modulate the postganglionic parasympathetic nerves branching from the pterygopalatine ganglion and innervating the nasal region and nasal mucosa, such as parasympathetic nerves (e.g., the posterior nasal nerves) traversing the SPF, accessory foramen, and microforamina of a palatine bone.
- parasympathetic nerves e.g., the posterior nasal nerves traversing the SPF, accessory foramen, and microforamina of a palatine bone.
- the therapeutic assembly 212 includes at least one energy delivery element 214 configured to provide therapeutic neuromodulation to the target site.
- the energy delivery element 214 can include one or more electrodes configured to apply electromagnetic neuromodulation energy (e.g., RF energy) to target sites.
- the energy delivery element 214 can be configured to provide therapeutic neuromodulation using various other modalities, such as cryotherapeutic cooling, ultrasound energy (e.g., high intensity focused ultrasound (“HIFU”) energy), microwave energy (e.g., via a microwave antenna), direct heating, high and/or low power laser energy, mechanical vibration, and/or optical power.
- HIFU high intensity focused ultrasound
- the therapeutic assembly 212 can be configured to deliver chemicals or drugs to the target site to chemically ablate or embolize the target nerves.
- the therapeutic assembly 212 can include a needle applicator extending through an access portion of the shaft 208 and/or a separate introducer, and the needle applicator can be configured to inject a chemical into the target site to therapeutically modulate the target nerves, such as botox, alcohol, guanethidine, ethanol, phenol, a neurotoxin, or another suitable agent selected to alter, damage, or disrupt nerves.
- the therapeutic assembly 212 can include one or more sensors (not shown), such as one or more temperature sensors (e.g., thermocouples, thermistors, etc.), impedance sensors, and/or other sensors.
- the sensor(s) and/or the energy delivery element 214 can be connected to one or more wires (not shown; e.g., copper wires) extending through the shaft 208 to transmit signals to and from the sensor(s) and/or convey energy to the energy delivery element 214 .
- the therapeutic neuromodulation device 202 can be operatively coupled to the console 204 via a wired connection (e.g., via the cable 206 ) and/or a wireless connection.
- the console 204 can be configured to control, monitor, supply, and/or otherwise support operation of the therapeutic neuromodulation device 202 .
- the console 204 can further be configured to generate a selected form and/or magnitude of energy for delivery to tissue or nerves at the target site via the therapeutic assembly 212 , and therefore the console 204 may have different configurations depending on the treatment modality of the therapeutic neuromodulation device 202 .
- the console 204 can include an energy generator 216 configured to generate RF energy (e.g., monopolar, bipolar, or multi-polar RF energy), pulsed electrical energy, microwave energy, optical energy, ultrasound energy (e.g., intraluminally-delivered ultrasound and/or HIFU), direct heat energy, radiation (e.g., infrared, visible, and/or gamma radiation), and/or another suitable type of energy.
- RF energy e.g., monopolar, bipolar, or multi-polar RF energy
- pulsed electrical energy e.g., microwave energy, optical energy, ultrasound energy (e.g., intraluminally-delivered ultrasound and/or HIFU), direct heat energy, radiation (e.g., infrared, visible, and/or gamma radiation), and/or another suitable type of energy.
- RF energy e.g., monopolar, bipolar, or multi-polar RF energy
- microwave energy e.g., microwave energy
- optical energy e.g.,
- the console 204 can include a refrigerant reservoir (not shown), and can be configured to supply the therapeutic neuromodulation device 202 with refrigerant.
- the console 204 can include a chemical reservoir (not shown) and can be configured to supply the therapeutic neuromodulation device 202 with one or more chemicals.
- the system 200 can further include a controller 218 communicatively coupled to the therapeutic neuromodulation device 202 .
- the controller 218 is housed in the console 204 .
- the controller 218 can be carried by the handle 210 of the therapeutic neuromodulation device 202 , the cable 206 , an independent component, and/or another portion of the system 200 .
- the controller 218 can be configured to initiate, terminate, and/or adjust operation of one or more components (e.g., the energy delivery element 214 ) of the therapeutic neuromodulation device 202 directly and/or via the console 204 .
- the controller 218 can be configured to execute an automated control algorithm and/or to receive control instructions from an operator (e.g., a clinician).
- the controller 218 and/or other components of the console 204 e.g., memory
- a memory includes one or more of various hardware devices for volatile and non-volatile storage, and can include both read-only and writable memory.
- a memory can comprise random access memory (RAM), CPU registers, read-only memory (ROM), and writable non-volatile memory, such as flash memory, hard drives, floppy disks, CDs, DVDs, magnetic storage devices, tape drives, device buffers, and so forth.
- RAM random access memory
- ROM read-only memory
- writable non-volatile memory such as flash memory, hard drives, floppy disks, CDs, DVDs, magnetic storage devices, tape drives, device buffers, and so forth.
- a memory is not a propagating signal divorced from underlying hardware; a memory is thus non-transitory.
- the console 204 can be configured to provide feedback to an operator before, during, and/or after a treatment procedure via evaluation/feedback algorithms 220 .
- the evaluation/feedback algorithms 220 can be configured to provide information associated with the temperature of the tissue at the treatment site, the location of nerves at the treatment site, and/or the effect of the therapeutic neuromodulation on the nerves at the treatment site.
- the evaluation/feedback algorithm 220 can include features to confirm efficacy of the treatment and/or enhance the desired performance of the system 200 .
- the evaluation/feedback algorithm 220 in conjunction with the controller 218 , can be configured to monitor temperature at the treatment site during therapy and automatically shut off the energy delivery when the temperature reaches a predetermined maximum (e.g., when applying RF energy) or predetermined minimum (e.g., when applying cryotherapy).
- the evaluation/feedback algorithm 220 in conjunction with the controller 218 , can be configured to automatically terminate treatment after a predetermined maximum time, a predetermined maximum impedance rise of the targeted tissue (i.e., in comparison to a baseline impedance measurement), a predetermined maximum impedance of the targeted tissue), and/or other threshold values for biomarkers associated with autonomic function.
- This and other information associated with the operation of the system 200 can be communicated to the operator via a display 222 (e.g., a monitor or touchscreen) on the console 204 and/or a separate display (not shown) communicatively coupled to the console 204 .
- a display 222 e.g., a monitor or touchscreen
- a separate display not shown
- the therapeutic assembly 212 and/or other portions of the system 200 can be configured to detect various parameters of the heterogeneous tissue at the target site to determine the anatomy at the target site (e.g., tissue types, tissue locations, vasculature, bone structures, foramen, sinuses, etc.), locate nerves and/or other structures, and allow for neural mapping.
- the therapeutic assembly 212 can be configured to detect impedance, dielectric properties, temperature, and/or other properties that indicate the presence of neural fibers in the target region. As shown in FIG.
- the console 204 can include a nerve monitoring assembly 221 (shown schematically) that receives the detected electrical and/or thermal measurements of tissue at the target site taken by the therapeutic assembly 212 , and process this information to identify the presence of nerves, the location of nerves, and/or neural activity at the target site. This information can then be communicated to the operator via a high resolution spatial grid (e.g., on the display 222 ) and/or other type of display.
- the nerve monitoring assembly 221 can be operably coupled to the energy delivery element 214 and/or other features of the therapeutic assembly 212 via signal wires (e.g., copper wires) that extend through the cable 206 and through the length of the shaft 208 .
- the therapeutic assembly 212 can be communicatively coupled to the nerve monitoring assembly 221 using other suitable communication means.
- the nerve monitoring assembly 221 can determine neural locations and activity before therapeutic neuromodulation to determine precise treatment regions corresponding to the positions of the desired nerves, during treatment to determine the effect of the therapeutic neuromodulation, and/or after treatment to evaluate whether the therapeutic neuromodulation treated the target nerves to a desired degree. This information can be used to make various determinations related to the nerves proximate to the target site, such as whether the target site is suitable for neuromodulation. In addition, the nerve monitoring assembly 221 can also compare the detected neural locations and/or activity before and after therapeutic neuromodulation, and compare the change in neural activity to a predetermined threshold to assess whether the application of therapeutic neuromodulation was effective across the treatment site.
- the nerve monitoring assembly 221 can determine electroneurogram (ENG) signals based on recordings of electrical activity of neurons taken by the therapeutic assembly 212 before and after therapeutic neuromodulation.
- ENG electroneurogram
- Statistically meaningful e.g., measurable or noticeable
- decreases in the ENG signal(s) taken after neuromodulation can serve as an indicator that the nerves were sufficiently ablated.
- the system 200 can further include a channel 224 extending along at least a portion of the shaft 208 and a port 226 at the distal portion 208 b of the shaft in communication with the port 226 .
- the channel 224 is a fluid pathway to deliver a fluid to the distal portion 208 b of the shaft 208 via the port 226 .
- the channel 224 can deliver saline solution or other fluids to rinse the intraluminal nasal pathway during delivery of the therapeutic assembly 212 , flush the target site before applying therapeutic neuromodulation to the target site, and/or deliver fluid to the target site during energy delivery to reduce heating or cooling of the tissue adjacent to the energy delivery element 214 .
- the channel 224 allows for drug delivery to the treatment site.
- a needle (not shown) can project through the port 226 to inject or otherwise deliver a nerve block, a local anesthetic, and/or other pharmacological agent to tissue at the target site.
- the therapeutic neuromodulation device 202 provides access to target sites deep within the nasal region, such as at the immediate entrance of parasympathetic fibers into the nasal cavity to therapeutically modulate autonomic activity within the nasal cavity.
- the therapeutic neuromodulation device 202 can position the therapeutic assembly 212 inferior to the SPF at the site of access foramen and/or microforamina (e.g., as shown in FIGS. 1B and 1C ).
- the shaft 208 can be a steerable device (e.g., a steerable catheter) with a small bend radius (e.g., a 5 mm bend radius, a 4 mm bend radius, a 3 mm bend radius or less) that allows the clinician to navigate through the tortuous nasal anatomy.
- the steerable shaft can further be configured to articulate in at least two different directions.
- the steerable shaft 208 can include dual pull wire rings that allow a clinician to form the distal portion 208 b of the shaft 208 into an “S”-shape to correspond to the anatomy of the nasal region.
- the articulating shaft 208 can be made from a substantially rigid material (e.g., a metal material) and include rigid links at the distal portion 208 b of the shaft 208 that resist deflection, yet allow for a small bend radius (e.g., a 5 mm bend radius, a 4 mm bend radius, a 3 mm bend radius or less).
- the steerable shaft 208 may be a laser-cut tube made from a metal and/or other suitable material. The laser-cut tube can include one or more pull wires operated by the clinician to allow the clinician to deflect the distal portion 208 b of the shaft 208 to navigate the tortuous nasal anatomy to the target site.
- the distal portion 208 b of the shaft 208 is guided into position at the target site via a guidewire (not shown) using an over-the-wire (OTW) or a rapid exchange (RX) technique.
- the distal end of the therapeutic assembly 212 can include a channel for engaging the guidewire.
- Intraluminal delivery of the therapeutic assembly 212 can include inserting the guide wire into an orifice in communication with the nasal cavity (e.g., the nasal passage or mouth), and moving the shaft 208 and/or the therapeutic assembly 212 along the guide wire until the therapeutic assembly 212 reaches a target site (e.g., inferior to the SPF).
- the therapeutic neuromodulation device 202 can be configured for delivery via a guide catheter or introducer sheath (not shown) with or without using a guide wire.
- the introducer sheath can first be inserted intraluminally to the target site in the nasal region, and the distal portion 208 b of the shaft 208 can then be inserted through the introducer sheath.
- the therapeutic assembly 212 can be deployed through a distal end opening of the introducer sheath or a side port of the introducer sheath.
- the introducer sheath can include a straight portion and a pre-shaped portion with a fixed curve (e.g., a 5 mm curve, a 4 mm curve, a 3 mm curve, etc.) that can be deployed intraluminally to access the target site.
- the introducer sheath may have a side port proximal to or along the pre-shaped curved portion through which the therapeutic assembly 212 can be deployed.
- the introducer sheath may be made from a rigid material, such as a metal material coated with an insulative or dielectric material.
- the introducer sheath may be substantially straight and used to deliver the therapeutic assembly 212 to the target site via a substantially straight pathway, such as through the middle meatus MM ( FIG. 1A ).
- Image guidance may be used to aid the clinician's positioning and manipulation of the distal portion 208 b of the shaft 208 and the therapeutic assembly 212 .
- an endoscope (not shown) can be positioned to visualize the target site, the positioning of the therapeutic assembly 212 at the target site, and/or the therapeutic assembly 212 during therapeutic neuromodulation.
- the distal portion 208 b of the shaft 208 is delivered via a working channel extending through an endoscope, and therefore the endoscope can provide direct in-line visualization of the target site and the therapeutic assembly 212 .
- an endoscope is incorporated with the therapeutic assembly 212 and/or the distal portion 208 b of the shaft 208 to provide in-line visualization of the assembly 212 and/or the surrounding nasal anatomy.
- image guidance can be provided with various other guidance modalities, such as image filtering in the infrared (IR) spectrum to visualize the vasculature and/or other anatomical structures, computed tomography (CT), fluoroscopy, ultrasound, optical coherence tomography (OCT), and/or combinations thereof.
- image guidance components may be integrated with the therapeutic neuromodulation device 202 to provide image guidance during positioning of the therapeutic assembly 212 .
- the therapeutic modulation may be applied via the energy delivery element 214 and/or other features of the therapeutic assembly 212 to precise, localized regions of tissue to induce one or more desired therapeutic neuromodulating effects to disrupt parasympathetic motor sensory function.
- the therapeutic assembly 212 can selectively target postganglionic parasympathetic fibers that innervate the nasal mucosa at a target or treatment site proximate to or at their entrance into the nasal region.
- the therapeutic assembly 212 can be positioned to apply therapeutic neuromodulation at least proximate to the SPF ( FIG. 1A ) to therapeutically modulate nerves entering the nasal region via the SPF.
- the therapeutic assembly 212 can also be positioned to inferior to the SPF to apply therapeutic neuromodulation energy across accessory foramen and microforamina (e.g., in the palatine bone) through which smaller medial and lateral branches of the posterior superior lateral nasal nerve enter the nasal region.
- the purposeful application of the energy at the target site may achieve therapeutic neuromodulation along all or at least a portion of posterior nasal neural fibers entering the nasal region.
- the therapeutic neuromodulating effects are generally a function of, at least in part, power, time, and contact between the energy delivery elements and the adjacent tissue.
- therapeutic neuromodulation of autonomic neural fibers are produced by applying RF energy at a power of about 2-20 W (e.g., 5 W, 7 W, 10 W, etc.) for a time period of about 1-20 sections (e.g., 5-10 seconds, 8-10 seconds, 10-12 seconds, etc.).
- the therapeutic neuromodulating effects may include partial or complete denervation via thermal ablation and/or non-ablative thermal alteration or damage (e.g., via sustained heating and/or resistive heating). Desired thermal heating effects may include raising the temperature of target neural fibers above a desired threshold to achieve non-ablative thermal alteration, or above a higher temperature to achieve ablative thermal alteration.
- the target temperature may be above body temperature (e.g., approximately 37° C.) but less than about 90° C. (e.g., 70-75° C.) for non-ablative thermal alteration, or the target temperature may be about 100° C. or higher (e.g., 110° C., 120° C., etc.) for the ablative thermal alteration.
- Desired non-thermal neuromodulation effects may include altering the electrical signals transmitted in a nerve.
- a cryotherapeutic applicator may be used to cool tissue at a target site to provide therapeutically-effective direct cell injury (e.g., necrosis), vascular injury (e.g., starving the cell from nutrients by damaging supplying blood vessels), and sublethal hypothermia with subsequent apoptosis.
- Exposure to cryotherapeutic cooling can cause acute cell death (e.g., immediately after exposure) and/or delayed cell death (e.g., during tissue thawing and subsequent hyperperfusion).
- Embodiments of the present technology can include cooling a structure positioned at or near tissue such that the tissue is effectively cooled to a depth where the targeted postganglionic parasympathetic nerves reside.
- the cooling structure is cooled to the extent that it causes therapeutically effective, cryogenic posterior nasal nerve modulation.
- the system 200 can determine the locations of the nerves, accessory foramen, and/or microforamina before therapy such that the therapeutic neuromodulation can be applied to precise regions including parasympathetic neural fibers.
- the system 200 may identify a target site that has a length and/or width of about 3 mm inferior to the SPF, and the therapeutic assembly 212 can apply therapeutic neuromodulation to the identified target site via one or more applications of therapeutic neuromodulation.
- the target site may be smaller or larger (e.g., a 3 cm-long target region) based on the detected locations of neural fibers and foramena.
- This neural and anatomical mapping allows the system 200 to accurately detect and therapeutically modulate the postganglionic parasympathetic neural fibers that innervate the mucosa at the numerous neural entrance points into the nasal cavity. Further, because there are not any clear anatomical markers denoting the location of the SPF, accessory foramen, and microforamina, the neural mapping allows the operator to identify and therapeutically modulate nerves that would otherwise be unidentifiable without intricate dissection of the mucosa. In addition, anatomical mapping can also allow the operator to identify certain structures that the operator may wish to avoid during therapeutic neural modulation (e.g., certain arteries).
- Sufficiently modulating at least a portion of the parasympathetic nerves is expected to slow or potentially block conduction of autonomic neural signals to the nasal mucosa to produce a prolonged or permanent reduction in nasal parasympathetic activity. This is expected to reduce or eliminate activation or hyperactivation of the submucosal glands and venous engorgement and, thereby, reduce or eliminate the symptoms of rhinosinusitis.
- the system 200 applies therapeutic neuromodulation to the multitude of branches of the posterior nasal nerves rather than a single large branch of the posterior nasal nerve branch entering the nasal cavity at the SPF, the system 200 provides a more complete disruption of the parasympathetic neural pathway that affects the nasal mucosa and results in rhinosinusitis. Accordingly, the system 200 is expected to have enhanced therapeutic effects for the treatment of rhinosinusitis and reduced re-innervation of the treated mucosa.
- the system 200 can be configured to therapeutically modulate nerves and/or other structures to treat different indications.
- the system 200 can be used to locate and/or therapeutically modulate nerves that innervate the para-nasal sinuses to treat chronic sinusitis.
- the system 200 and the devices disclosed herein can be configured therapeutically modulate the vasculature within the nasal anatomy to treat other indications, such as epistaxis (i.e., excessive bleeding from the nose).
- the system 200 and the therapeutic neuromodulation devices described herein can be used to apply therapeutically effective energy to arteries (e.g., the sphenopalatine artery and its branches) as they enter the nasal cavity (e.g., via the SPF, accessory foramen, etc.) to partially or completely coagulate or ligate the arteries.
- the system 200 can be configured to partially or completely coagulate or ligate veins and/or other vessels.
- the system 200 would be modified to deliver energy at significantly higher power (e.g., about 100 W) and/or longer times (e.g., 1 minute or longer) than would be required for therapeutic neuromodulation.
- the system 100 could apply the anatomical mapping techniques disclosed herein to locate or detect the targeted vasculature and surrounding anatomy before, during, and/or after treatment.
- FIGS. 3A-3E are partial cut-away side views illustrating various approaches for delivering a distal portion of the therapeutic neuromodulation device 202 of FIG. 2 to a target site within a nasal region in accordance with embodiments of the present technology.
- the distal portion 208 b of the shaft 208 extends into the nasal passage NP, through the inferior meatus IM between the inferior turbinate IT and the nasal sill NS, and around the posterior portion of the inferior turbinate IT where the therapeutic assembly 212 is deployed at a treatment site.
- FIG. 3A in various embodiments the distal portion 208 b of the shaft 208 extends into the nasal passage NP, through the inferior meatus IM between the inferior turbinate IT and the nasal sill NS, and around the posterior portion of the inferior turbinate IT where the therapeutic assembly 212 is deployed at a treatment site.
- the treatment site can be located proximate to the access point or points of postganglionic parasympathetic nerves (e.g., branches of the posterior nasal nerve and/or other parasympathetic neural fibers that innervate the nasal mucosa) into the nasal cavity.
- the target site can be elsewhere within the nasal cavity depending on the location of the target nerves.
- An endoscope 330 and/or other visualization device is delivered proximate to the target site by extending through the nasal passage NP and through the middle meatus MM between the inferior and middle turbinates IT and MT. From the visualization location within the middle meatus MM, the endoscope 330 can be used to visualize the treatment site, surrounding regions of the nasal anatomy, and the therapeutic assembly 212 .
- the shaft 208 of the therapeutic neuromodulation device 202 can include a positioning member 332 positioned proximal to the therapeutic assembly 212 and the target site.
- the positioning member 332 is a balloon that is expanded in an opening (e.g., in one of the meatuses) against opposing structures (e.g., between the turbinates) to consistently hold the distal portion 208 b of the shaft 208 in a desired position relative to the target site and provide stability for deployment of the therapeutic assembly 212 .
- the positioning member 332 may include other expandable structures (e.g., a mesh baskets) or anchor features that can be deployed to maintain a desired position of the shaft 208 within the nasal cavity.
- the positioning member 332 can be positioned distal to the therapeutic assembly 212 and expanded in a region distal to the therapeutic assembly 212 and the treatment site.
- the positioning member 332 is positioned on an introducer sheath (not shown) through which the shaft 208 and/or other devices (e.g., a fluid line for delivery of saline or local anesthetics, an endoscope, a sensor, etc.) can pass.
- the positioning member 332 can be positioned proximal to the target site (e.g., similar to the position shown in FIG. 3A ) or distal to the treatment site.
- the introducer sheath When positioned distally, the introducer sheath can include a side exit port through which the therapeutic assembly 212 and other features can be deployed at the target site.
- the positioning member 332 When the positioning member 332 is positioned on the introducer sheath, the positioning member 332 can provide stability for delivery and deployment of the distal portion 208 b of the shaft 208 and the therapeutic assembly 212 .
- the positioning member 332 can be incorporated on the shaft 208 , an associated introducer sheath, and/or other deliver features of the system 200 ( FIG. 2 ) when the therapeutic assembly 212 is delivered through different intraluminal passageways.
- FIG. 3B illustrates a differ embodiment in which the distal portion 208 b of the shaft 208 extends into the nasal passage NP, through the middle meatus MM between the inferior turbinate IT and the middle turbinate, and in posterior direction where the therapeutic assembly 212 is deployed at a treatment site.
- the endoscope 330 and/or other visualization device is delivered alongside the shaft 208 through the same intraluminal pathway as the therapeutic assembly 212 .
- the pathway through the middle meatus MM may provide for generally straight access to the target site depending on the specific region of interest and anatomical variations of the patient. Accordingly, an approach through the middle meatus MM may require less steering and/or articulation of the shaft 208 and the endoscope 330 .
- the endoscope can provide in-line or side-by-side visualization of the therapeutic assembly 212 .
- FIG. 3C illustrates another intraluminal pathway in which the distal portion 208 b of the shaft 208 and the endoscope 330 travel next to each other such that the endoscope 330 can provide in-line or side-by-side visualization of the distal portion 208 b of the shaft 208 , the therapeutic assembly 212 , and/or the nasal anatomy.
- the intraluminal pathway extends through the inferior meatus IM to a posterior treatment site.
- the distal portion 208 b of the shaft 208 extends to the treatment site via the middle meatus MM, and the endoscope 330 extends through the inferior meatus IM to a position proximate to the target site.
- the endoscope 330 may have an articulating, steerable, or curved distal end that directs the endoscope 330 superiorly to visualize the nasal anatomy and the therapeutic assembly 332 at the target site.
- the distal end portion of the endoscope 330 can be configured to bend at least 30° to visualize the treatment site.
- the distal portion 208 b of the shaft 208 can be delivered to the treatment site via the mouth.
- therapeutic neuromodulation can be applied at a treatment site posterior to the nasal cavity (e.g., posterior to the SPF).
- the endoscope 330 (not shown) can extend into the nasal passage NP, through the middle meatus MM or the inferior meatus IM to a position proximate to the treatment site. Alternatively, the endoscope 330 (not shown) can travel along the same pathway as the shaft 208 .
- FIG. 4 is an isometric view of a distal portion of a therapeutic neuromodulation device 402 configured in accordance with an embodiment of the present technology.
- the therapeutic neuromodulation device 402 can be used in conjunction with the system 200 described above with respect to FIGS. 2-3E .
- the therapeutic neuromodulation device 402 can include a shaft 408 having a proximal portion (not shown) and a distal portion 408 b , and a therapeutic assembly 412 at the distal portion 408 b of the shaft 408 .
- the therapeutic assembly 412 is transformable between a low-profile delivery state to facilitate intraluminal delivery of the therapeutic assembly 412 to a treatment site within the nasal region and an expanded state (shown in FIG. 4 ).
- the therapeutic assembly 412 includes a plurality of struts 440 that are spaced apart from each other to form a frame or basket 442 when the therapeutic assembly 412 is in the expanded state.
- the struts 440 can carry one or more energy delivery elements, such as a plurality of electrodes 444 .
- the struts 440 can position at least two of the electrodes 444 against tissue at a target site within the nasal region (e.g., proximate to the palatine bone inferior to the SPF).
- the electrodes 444 can apply bipolar or multi-polar radiofrequency (RF) energy to the target site to therapeutically modulate postganglionic parasympathetic nerves that innervate the nasal mucosa proximate to the target site.
- the electrodes 444 can be configured to apply pulsed RF energy with a desired duty cycle (e.g., 1 second on/0.5 seconds off) to regulate the temperature increase in the target tissue.
- the basket 442 includes eight branches 446 spaced radially apart from each other to form at least a generally spherical structure, and each of the branches 446 includes two struts 440 positioned adjacent to each other. In other embodiments, however, the basket 442 can include fewer than eight branches 446 (e.g., two, three, four, five, six, or seven branches) or more than eight branches 446 . In further embodiments, each branch 446 of the basket 442 can include a single strut 440 , more than two struts 440 , and/or the number of struts 440 per branch can vary.
- the branches 446 and struts 440 can form baskets or frames having other suitable shapes for placing the electrodes 444 in contact with tissue at the target site.
- the struts 440 can form an ovoid shape, a hemispherical shape, a cylindrical structure, a pyramid structure, and/or other suitable shapes.
- the therapeutic assembly 412 can further include an internal or interior support member 448 that extends distally from the distal portion 408 b of the shaft 408 .
- a distal end portion 450 of the support member 448 can support the distal end portions of the struts 440 to form the desired basket shape.
- the struts 440 can extend distally from the distal portion 408 b of the shaft 408 and the distal end portions of the struts 440 can attach to the distal end portion 450 of the support member 448 .
- the support member 448 can include an internal channel (not shown) through which electrical connectors (e.g., wires) coupled to the electrodes 444 and/or other electrical features of the therapeutic element 412 can run.
- the internal support member 448 can also carry an electrode (not shown) at the distal end portion 450 and/or along the length of the support member 448 .
- the basket 442 can transform from the low-profile delivery state to the expanded state ( FIG. 4 ) by manipulating a handle (e.g., the handle 210 of FIG. 2 ) and/or other feature at the proximal portion of the shaft 408 and operably coupled to the basket 442 .
- a handle e.g., the handle 210 of FIG. 2
- an operator can push the support member 448 distally to bring the struts 440 inward toward the support member 448 .
- An introducer or guide sheath (not shown) can be positioned over the low-profile therapeutic assembly 412 to facilitate intraluminal delivery or removal of the therapeutic assembly 412 from or to the target site.
- the therapeutic assembly 412 is transformed between the delivery state and the expanded state using other suitable means.
- the individual struts 440 can be made from a resilient material, such as a shape-memory material (e.g., Nitinol) that allows the struts 440 to self-expand into the desired shape of the basket 442 when in the expanded state.
- a shape-memory material e.g., Nitinol
- the struts 440 can be made from other suitable materials and/or the therapeutic assembly 412 can be mechanically expanded via a balloon or by proximal movement of the support member 448 .
- the basket 442 and the associated struts 440 can have sufficient rigidity to support the electrodes 444 and position or press the electrodes 444 against tissue at the target site.
- the expanded basket 442 can press against surrounding anatomical structures proximate to the target site (e.g., the turbinates, the palatine bone, etc.) and the individual struts 440 can at least partially conform to the shape of the adjacent anatomical structures to anchor the therapeutic element 412 at the treatment site during energy delivery.
- the expansion and conformability of the struts 440 can facilitate placing the electrodes 444 in contact with the surrounding tissue at the target site.
- At least one electrode 444 is disposed on individual struts 440 .
- two electrodes 444 are positioned along the length of each strut 440 .
- the number of electrodes 444 on individual struts 440 be only one, more than two, zero, and/or the number of electrodes 444 on the different struts 440 can vary.
- the electrodes 444 can be made from platinum, iridium, gold, silver, stainless steel, platinum-iridium, cobalt chromium, iridium oxide, polyethylenedioxythiophene (“PEDOT”), titanium, titanium nitride, carbon, carbon nanotubes, platinum grey, Drawn Filled Tubing (“DFT”) with a silver core made by Fort Wayne Metals of Fort Wayne, Ind., and/or other suitable materials for delivery RF energy to target tissue.
- PEDOT polyethylenedioxythiophene
- DFT Drawn Filled Tubing
- each electrode 444 can be operated independently of the other electrodes 444 .
- each electrode can be individually activated and the polarity and amplitude of each electrode can be selected by an operator or a control algorithm (e.g., executed by the controller 218 of FIG. 2 ).
- a control algorithm e.g., executed by the controller 218 of FIG. 2 .
- Various embodiments of such independently controlled electrodes 444 are described in further detail below with reference to FIGS. 5A-5G .
- the selective independent control of the electrodes 444 allows the therapeutic assembly 412 to deliver RF energy to highly customized regions.
- a select portion of the electrodes 444 can be activated to target neural fibers in a specific region while the other electrodes 444 remain inactive.
- electrodes 444 may be activated across the portion of the basket 442 that is adjacent to tissue at the target site, and the electrodes 444 that are not proximate to the target tissue can remain inactive to avoid applying energy to non-target tissue.
- Such configurations facilitate selective therapeutic modulation of nerves on the lateral nasal wall within one nostril without applying energy to structures in other portions of the nasal cavity.
- the electrodes 444 can be electrically coupled to an RF generator (e.g., the generator 216 of FIG. 2 ) via wires (not shown) that extend from the electrodes 444 , through the shaft 408 , and to the RF generator.
- an RF generator e.g., the generator 216 of FIG. 2
- wires not shown
- each electrode 444 couples to a corresponding wire that extends through the shaft 408 .
- multiple electrodes 444 can be controlled together and, therefore, multiple electrodes 444 can be electrically coupled to the same wire extending through the shaft 408 .
- the RF generator and/or components operably coupled (e.g., a control module) thereto can include custom algorithms to control the activation of the electrodes 444 .
- the RF generator can deliver RF power at about 200-300 W to the electrodes 444 , and do so while activating the electrodes 444 in a predetermined pattern selected based on the position of the therapeutic element 412 relative to the treatment site and/or the identified locations of the target nerves.
- the RF generator delivers power at lower levels (e.g., less than 15 W, 15-50 W, 50-150 W, etc.) and/or higher power levels.
- the therapeutic assembly 412 can further include one or more temperature sensors 452 disposed on the struts 440 and/or other portions of the therapeutic assembly 412 and configured to detect the temperature adjacent to the temperature sensor 452 .
- the temperature sensors 452 can be electrically coupled to a console (e.g., the console 204 of FIG. 2 ) via wires (not shown) that extend through the shaft 408 .
- the temperature sensors 452 can be positioned proximate to the electrodes 444 to detect the temperature at the interface between tissue at the target site and the electrodes 444 .
- the temperature sensors 452 can penetrate the tissue at the target site (e.g., a penetrating thermocouple) to detect the temperature at a depth within the tissue.
- the temperature measurements can provide the operator or the system with feedback regarding the effect of the therapeutic neuromodulation on the tissue.
- the operator may wish to prevent or reduce damage to the tissue at the treatment site (e.g., the nasal mucosa), and therefore the temperature sensors 452 can be used to determine if the tissue temperature reaches a predetermined threshold for irreversible tissue damage. Once the threshold is reached, the application of therapeutic neuromodulation energy can be terminated to allow the tissue to remain intact.
- the energy delivery can automatically terminate based on an evaluation/feedback algorithm (e.g., the evaluation/feedback algorithm 220 of FIG. 2 ) stored on a console (e.g., the console 204 of FIG. 2 ) operably coupled to the temperature sensors 452 .
- an evaluation/feedback algorithm e.g., the evaluation/feedback algorithm 220 of FIG. 2
- a console e.g., the console 204 of FIG. 2
- FIGS. 5A-5G are isometric views of examples of electrode configurations of therapeutic neuromodulation devices (identified individually as first through fourth therapeutic neuromodulation devices 502 a - 502 d , respectively; referred to collectively as therapeutic neuromodulation devices 502 ) for therapeutic neuromodulation in accordance with embodiments of the present technology.
- the therapeutic neuromodulation devices 502 of FIGS. 5A-5G can include features generally similar to the features of the therapeutic neuromodulation device 402 of FIG. 4 .
- the therapeutic neuromodulation devices 502 include a plurality of struts 440 that form a basket 442 when in an expanded state, and a plurality of electrodes 444 disposed on one or more of the struts 440 .
- the first through third therapeutic neuromodulation device 502 a - c shown in FIGS. 5A-5E include a single strut 440 corresponding to each branch 446 of the basket 442
- the fourth therapeutic neuromodulation device 502 d shown in FIGS. 5F and 5G includes two adjacent struts 440 in each branch 446 of the basket 442 .
- the branches 446 of the therapeutic neuromodulation devices 502 may have different quantities of struts 440 , and apply RF energy in the same manner as described below with reference to FIGS. 5A-5G . As shown in FIGS.
- the electrodes 444 can be independently controlled and activated via instructions from a controller (e.g., the controller 218 of FIG. 2 ) or a generator (e.g., the generator 216 of FIG. 2 ) to apply RF energy across selected regions or segments of the therapeutic assembly 412 .
- a controller e.g., the controller 218 of FIG. 2
- a generator e.g., the generator 216 of FIG. 2
- two electrodes 444 of the therapeutic assembly 412 are activated in the first therapeutic neuromodulation device 502 a . More specifically, a first electrode 444 a on a first strut 440 a is activated at a positive polarity, and a second electrode 444 b on a second strut 440 b spaced radially apart from the first strut 440 a is activated at a negative polarity. The remainder of the electrodes 444 remain inactive. Accordingly, as indicated by the arrows, current can flow from the first electrode 444 a to the second electrode 444 b through the target tissue across a circumferential or peripheral segment of the therapeutic assembly 412 .
- This configuration may be used to therapeutically modulate nerves positioned proximate to the peripheral segment.
- different or additional electrodes 444 can be activated to have a selected polarity to apply therapeutic neuromodulation across selected regions of the therapeutic assembly 412 in a predetermined manner.
- the first therapeutic neuromodulation device 502 a is configured to have three selectively active electrodes 444 .
- a first electrode 444 a on a first strut 440 a is activated at a positive polarity
- second and third electrodes 444 b and 444 c on corresponding second and third struts 440 b and 440 c are activated at a negative polarity.
- the remainder of the electrodes 444 remain inactive.
- current can flow through the tissue from the first electrode 444 a to the second and third electrodes 444 b and 444 c across a segment of the therapeutic assembly 412 , and therefore therapeutically modulate nerves positioned proximate to the peripheral segment.
- the second and third activated electrodes 444 b and 444 c are positioned on struts 440 b , 440 c that are radially spaced apart from but adjacent to the first strut 440 a carrying the first active electrode 444 a .
- a first electrode on a first strut 440 a is selectively activated at a positive polarity, and a plurality of electrodes 444 (identified individually as second through fifth electrodes 444 b - 444 e , respectively) within the first hemispherical region 501 a are selectively activated at a negative polarity such that RF energy is applied across the first hemispherical region 501 a .
- This electrode activation configuration may be used to apply RF energy across one side of the basket 442 to therapeutically modulate nerves on the lateral nasal wall in one nostril.
- a different set of electrodes 444 can be activated across a hemispherical region of the therapeutic assembly 412 based on the orientation of the basket 442 with respect to the lateral nasal wall.
- the basket 442 has a generally symmetrical shape (e.g., circular, oval, etc.) and because the electrodes 444 can be selectively activated, the orientation of the basket 442 with respect to the target site on the lateral nasal wall does not matter. Instead, the operator can deploy the therapeutic assembly 412 at the target site irrespective of orientation, and selectively activate the electrodes 444 in a desired arrangement to apply RF energy across the target site.
- the second therapeutic neuromodulation device 502 b is configured to selectively control the polarity of a plurality of the electrodes 444 across at least a portion of the therapeutic assembly 412 to apply RF energy in a sesquipolar fashion (i.e., the sequential or transient bipolar pairing of electrodes).
- a first electrode 444 a is biased at a positive polarity and second through seventh electrodes 444 b - 444 g are controlled to have negative polarities.
- the second through seventh electrodes 444 b - 444 g are spaced substantially equal distances apart from the first electrode 444 a such that the electrodes 444 are dimensionally predisposed to multiplex in sequence.
- the first through seventh electrodes 444 a - 444 g are concurrently activated.
- the first electrode 444 a will pair with the individual negative electrodes 444 in a sequential manner based on the path of least resistance.
- This path of least resistance is dictated by the natural anatomy of the treatment site in contact with the electrodes 444 .
- the first electrode 444 a may initially pair with the second electrode 444 b .
- a second pairing e.g., with the third electrode 444 c
- the first electrode 444 a will continue to sequentially pair with the remaining activated negative electrodes in a similar manner until a threshold is reached and the electrodes 444 are in a state of equilibrium in which there is homogenized current flow between all of the electrode pairs.
- the therapeutic assembly 412 increases the size of the ablation zone (i.e., the region in which therapeutic neuromodulation energy is applied).
- this sequential pairing of the electrodes 444 may occur in a circular direction (e.g., in a counter clockwise or clockwise direction) based on the impedance changes between the electrodes 444 .
- the sequential pairing of electrodes 444 may occur in a different pattern based on the anatomical surroundings and/or the positioning of the electrodes 444 .
- the activated electrodes 444 are positioned in a quadrant of the therapeutic element 412 with equal radial distances between the individual electrode pairs.
- the activated electrodes 444 can be positioned across larger or smaller regions of the therapeutic element 412 to apply energy across larger or smaller treatment regions.
- the sesquipolar application of RF energy allows the therapeutic assembly 412 to intelligently apply RF energy across a target site to therapeutically modulate nerves proximate to the treatment site.
- the naturally occurring impedance changes between the electrode pairs cause the therapeutic assembly 412 to radially increase the zone of energy application with each pairing.
- the electrodes 444 can be configured to sequentially pair with each other in a manner such that the zone of energy application increases in a transverse and/or longitudinal manner based on the naturally occurring impedance changes between the electrodes 444 .
- a controller e.g., the controller 218 of FIG. 2
- instructions e.g., software
- portions of the struts 440 themselves can define the electrodes 444 .
- the struts 440 are made from an electrically conductive material and coated with an insulative material (e.g., poly-xylene polymers, including Paralyene C). Portions of the struts 440 can remain uncoated to define electrodes 444 .
- the locations of the uncoated portions of the struts 440 i.e., the electrodes 444
- the uncoated portions can be spaced equally apart from a central electrode 444 to allow for sesquipolar RF application.
- the conductive struts 440 serve as the electrical connectors and, therefore, the therapeutic assembly 412 does not require as many wires as if the electrodes 444 were separate elements positioned on the struts 440 .
- the third therapeutic neuromodulation device 502 c includes a return electrode 503 at the distal end portion 450 of the support member 448 and selective polarity control of the individual electrodes 444 on the struts 440 to provide radial multiplexing of the electrodes 444 .
- the return electrode 503 has a negative polarity, and the other electrodes 444 have a positive polarity.
- all of the electrodes 444 are activated, but in other embodiments the electrodes 444 can be selectively activated based on a desired energy application zone. As indicated by the arrows, this configuration applies RF energy across a distal hemispherical region of the basket 442 .
- the return electrode 503 can be positioned elsewhere on the therapeutic assembly 412 , and the electrodes 444 , 503 can be used to apply RF energy across different regions of the basket 442 .
- the return electrode 503 can be activated in conjunction with two or more of the electrodes 444 on the struts to apply RF energy in a sesquipolar manner.
- the fourth therapeutic neuromodulation device 502 d includes branches 446 having two adjacent struts 440 , and the electrodes 444 on the adjacent struts are spaced apart from each other in a longitudinal direction and selectively activated to apply energy in a radial direction across discrete zones.
- a first electrode 444 a on a first strut 440 a of a first branch 446 a may be selectively activated to have a first polarity
- a second electrode 444 b on the adjacent second strut 440 b of the first branch 446 a may be selectively activated to have a second polarity opposite the first polarity.
- the first and second electrodes 444 a and 444 b can then apply bipolar RF energy in a radial direction within a specific region of the therapeutic assembly 412 .
- the individual struts 440 can include multiple electrodes 444 disposed thereon, and the adjacent strut 440 in the same branch 446 can have a corresponding quantity of electrodes 444 to allow for bipolar coupling of each of the electrode pairs along discrete regions of the branch 446 .
- the electrodes of one strut 440 can all have the same polarity (e.g., coupled to a first wire; not shown), and the electrodes 444 of the adjacent strut 440 in the same branch 446 can all have the opposite polarity (e.g., coupled to a second wire; not shown).
- the electrodes 444 on an individual strut 440 can be independently controlled to have a desired polarity.
- the electrode pairing configurations shown in FIG. 5F can be used to detect impedance across selected regions of the therapeutic assembly 412 defined by the bipolar electrode pairs. The impedance measurements can then be used to identify the presence of neural fibers in the selected regions. If nerves are detected in one or more specific regions associated with an electrode pair, the same electrode pair can be used to apply RF energy to that region and therapeutically modulate the nerves in that region.
- the fourth therapeutic neuromodulation device 502 d is configured to selectively control the polarity of a plurality of the electrodes 444 across at least a portion of the therapeutic assembly 412 to apply RF energy in a multi-polar manner in a circular or spiral pattern.
- electrodes 444 of one branch 446 can be activated to have negative polarities and electrodes 444 of another branch 446 can be activated to have positive polarities.
- the arrangement of the electrodes 444 and the variable distances between the electrodes 444 can differ such that the energy application zone has a different shape or pattern.
- the positive and negative electrodes 444 are spaced apart from each other at variable distances. Impedance changes resulting from the surrounding anatomical structures causes the electrodes to pair with each other in a sequential manner and, thereby, continuously increase the zone or region in which energy is applied in a radial direction and in a generally spiral manner.
- Electrodes at the distal and proximal regions of the basket 442 apply energy to shallower depths in the target tissue than the electrode pairs positioned on the medial region of the basket 442 . Accordingly, the electrodes pairs positioned closer together can therapeutically modulate nerves at shallower depths than the electrode pairs spaced further apart from each other. As shown in the illustrated embodiment, some of the electrodes 444 and/or entire branches 446 of the basket 442 can remain inactive to achieve the desired depth of energy application and/or neuromodulation pattern.
- Various embodiments of the present technology can include features that measure bio-electric, dielectric, and/or other properties of heterogeneous tissue at target sites within the nasal region to determine the presence, location, and/or activity of neural fibers and, optionally, map the locations of the detected nerves.
- the features discussed below can be incorporated into any of the systems and/or devices disclosed herein to provide an accurate depiction of nerves at the target site.
- Neural detection can occur (a) before the application of a therapeutic neuromodulation energy to determine the presence or location of nerves at the target site and/or record baseline levels of neural activity; (b) during therapeutic neuromodulation to determine the effect of the energy application on the neural fibers at the treatment site; and/or (c) after therapeutic neuromodulation to confirm the efficacy of the treatment on the targeted nerves.
- such neural detection and mapping can provide an accurate representation of the neural anatomy to adequately treat the parasympathetic nerves, not just the one or two main branches of the posterior nasal nerves traversing the SPF.
- the systems disclosed herein can use bioelectric measurements, such as impedance, resistance, voltage, current density, and/or other parameters (e.g., temperature) to determine the anatomy, in particular the neural anatomy, at the target site.
- bioelectric measurements such as impedance, resistance, voltage, current density, and/or other parameters (e.g., temperature) to determine the anatomy, in particular the neural anatomy, at the target site.
- the location of the neural anatomy can then be used to determine where the treatment site(s) should be with respect to various anatomical structures for therapeutically effective neuromodulation of the targeted parasympathetic nasal nerves.
- the information can be used to determine the treatment site(s) with respect to the location of the turbinates or meatuses.
- the bioelectric properties can be detected via electrodes (e.g., the electrodes 444 of the therapeutic neuromodulation devices 402 - 502 d of FIGS. 4-5G ).
- the electrode pairings on a device e.g., the therapeutic assemblies 412 described with respect to FIGS. 4-5G
- FIGS. 6A and 6B are partially schematic diagrams illustrating configurations of electrodes 644 for nerve detection configured in accordance with embodiments of the present technology. As shown in FIG. 6A , the further the electrodes 644 are apart from each other, the deeper into the tissue the current flows.
- electrodes 644 can be selectively activated based on the depth at which the desired measurements should be taken. As shown in FIG. 6B , the spacing between the electrodes 644 along a plane (e.g., the surface of the tissue, can affect the region in which the measurements are taken. Thus, electrodes 644 can be selectively activated to obtain information (e.g., impedance) at a desired depth and across a desired region.
- the bioelectric properties can be detected using optical coherent tomography (OCT), ultrasound, and/or other suitable detection modalities.
- the measurement of bioelectric properties can provide information associated not only with neural fiber locations, but also the identification of gross anatomy (e.g., turbinates, meatuses, bone, etc.), which can be used to facilitate system delivery and identification of the target nerves with respect to the gross anatomy.
- gross target identification can be determined by evaluating of the incident electromagnetic field on soft and hard tissues within the nasal region, which is in turn dependent upon the local geometry and the dielectric properties of those features.
- measurements for neuro-mapping can be obtained by applying a constant current to electrodes and measuring the voltage differences between adjacent pairs of electrodes to produce a spectral profile or map the tissues at the target site.
- Impedance data can be obtained while applying high, medium, and/or low frequencies to the target tissue. At high frequencies, the current passes directly through cell membranes, and the resultant measurements are indicative of the tissue and liquids both inside and outside the cells. At low frequencies, cell membranes impede current flow to provide different defining characteristics of the tissue. Accordingly, bioimpedance can be used to measure targeted shapes or electrical properties of tissue and/or other structures of the nasal cavity.
- complex neural mapping can be performed using frequency difference reconstruction, which requires measurement data (e.g., impedance) at two different frequencies.
- the spatial orientation, direction, and activity of the detected nerve bundles can be used to further identify and characterize the nerves.
- the measured bioelectric properties can distinguish between terminating axons (i.e., entering a detection region, but not exiting), branching axons (i.e., entering the detection region and increasing in number upon exiting the detecting region), travelling axons (i.e., entering and exiting the detection region within no change in geometry or numerical value), and/or other properties of nerves.
- axon orientations relative to the electrode array can be identified to indicate whether the neural fibers extend parallel (X direction), perpendicular (Y direction), depth penetrating (Z direction), and/or any relative position or angulation to these parameters. This information can then be used to selectively treat specific neural fibers. For example, selected electrode configurations can be applied to treat a specific region and/or the therapeutic assembly can be moved or manipulated to treat the nerves from a different orientation or location.
- FIG. 7 is a graph illustrating threshold levels of electrical conductivity of nasal tissue with respect to temperature.
- a first curve 701 depicts the electrical conductivity ( ⁇ ) of tissue in response to temperature and indicates that a temperature of about 70° C. corresponds to a first threshold of the irreversible change in impedance of the tissue.
- a second curve 703 shows that the electrical conductivity of the tissue permanently increases significantly (i.e., impedance decreases) after the tissue has been exposed to temperatures of 70° C., as it may during therapeutic neuromodulation.
- the therapeutic neuromodulation was stopped when the tissue temperature was detected to be about 70° C., it is expected that there would be a permanent measurable change in the conductivity of the tissue without reaching a phase in which the tissue is structurally changed or damaged (e.g., due to vaporization, desiccation, etc.). However, if the tissue is exposed to temperatures above a second thermal threshold of about 90° C., the tissue undergoes a high degree of tissue desiccation, and thus a significant decrease in electrical conductivity (i.e., and a higher level of in the electrical impedance). A third curve 705 illustrates this lower electrical conductivity of the tissue after exposure to temperatures above 90° C.
- systems disclosed herein can be configured to stop neuromodulation when the temperature reaches about 70° C. (e.g., 70-80° C.) to avoid structural changes or damage to the mucosa, but still providing what is expected to be therapeutically effective neuromodulation.
- 70° C. e.g., 70-80° C.
- Neural detection and mapping can provide a pre-procedural assessment of the neural anatomy, a mid-procedure assessment and feedback on temporal changes in tissue during neuromodulation, and/or a post procedural assessment of the neural activity as a confirmation of effectiveness.
- the bioelectric measurements taken pre-, mid-, and post-procedurally can be taken multiple times during each stage of the procedure to assess and confirm findings.
- Pre-procedural assessment can be used to evaluate the bioelectric properties of the native/host tissue to determine a baseline for subsequent actions and as a reference guide against source biological signatures to identify anatomical targets of interest (e.g., nerves, microforamina, etc.).
- This information can be determined by placing a multi-electrode array in a known spatial configuration to detect and then map electro-anatomical characteristics (e.g., variations in the impedance of different tissue types).
- the resultant anatomical mapping can comprise a composition of multiple (high density) activation sequence in multiple planes, relying on the variations in impedance to identify different tissue types and structures.
- the impedance measurements can be used to confirm that the electrodes maintain good contact with tissue at the target site.
- the data can be used to determine whether the mid- or post-procedural recorded spectra has a shape consistent with the expected tissue types.
- Post-procedurally the information can be used to determine whether the targeted nerves were therapeutically treated.
- the action potentials of neural fibers can be detected via electrodes and or other contacts to dynamically map the locations and/or activity of nerves in the target region.
- the recorded action potentials can be used to numerically measure, map, and/or produce images of fast neuronal depolarization to generate an accurate picture of neural activity.
- the depolarization of the neuronal membrane can cause drops in voltage of about 110 ⁇ V, has about 2 ms, and have an impedance/resistance from 1000 ⁇ cm to 25 ⁇ cm.
- the metabolic recovery processes associated with action potential activity i.e., to restore ionic gradients to normal
- the detection of the bioelectric properties associated with these features has the advantage that the changes are much larger (e.g., approximately a thousand times larger) and, therefore, easier to measure.
- a nontherapeutic stimulation e.g., RF energy
- RF energy can be applied to the tissue at the detection region via two or more electrodes of an electrode array to enhance the recording of action potentials.
- the stimulating energy application can temporarily activate the neural fibers and the resultant action potential can be recorded.
- two or more electrodes of a therapeutic assembly can deliver a stimulating pulse of energy, and two or more other electrodes can be configured to detect the resultant action potential.
- the stimulating energy pulses are expected to enhance the action potential signal, making it easier to record.
- FIGS. 8 and 9 are isometric views of a distal portion of a therapeutic neuromodulation device 802 (“device 802 ”) configured in accordance with an embodiment of the present technology.
- the device 802 can include various features generally similar to the features of the therapeutic neuromodulation devices 402 and 502 a - d described above with reference to FIGS. 4-5G .
- the device 802 includes a therapeutic assembly 812 at a distal portion 408 b of a shaft 408 .
- the therapeutic assembly 812 includes a plurality of struts 440 that form branches 446 and define an expandable frame or basket 442 , and one or more electrodes 444 disposed on one or more of the struts 440 . As shown in FIGS.
- the device 902 can further include an expandable member 856 (e.g., a balloon) carried by the support member 448 and expandable within the basket 442 .
- the expandable member 856 can include a plurality of electrodes 858 disposed on the outer surface of the expandable member 856 .
- the electrodes 858 can be used for detection of bioelectric features (e.g., impedance) to allow for mapping of the neural anatomy at the target site before, during, and/or after therapeutic neuromodulation via the other electrodes 444 .
- the electrodes 858 can be configured to apply energy for therapeutic neuromodulation.
- the electrodes 858 can be positioned on the expandable member 856 in a substantially symmetrical manner and a uniform distribution. This provides an expansive array with which impedance and/or other properties can be detected across the tissue and, therefore, may provide a more detailed mapping of the tissue and nerves at the treatment site. In other embodiments, the electrodes 858 can be clustered toward the medial portion of the expandable member 856 and/or around different portions of the expandable member 856 .
- the electrodes 858 can be selectively activated at a specific polarity, and therefore the electrode array can be configured in a variety of static configurations and a dynamically change sequences (e.g., sesquipolar application of current) that may be advantageous for mapping functions.
- the expandable member 856 can be inflated or otherwise expanded ( FIG. 9 ) to place at least a portion of the electrodes 858 into contact with tissue at the target site.
- the electrodes 858 can measure various bioelectric properties of the tissue (e.g., impedance, action potentials, etc.) to detect, locate, and/or map the nerves at the treatment site.
- the electrodes 444 on the struts 440 and/or a portion of the electrodes 858 on the expandable member 856 can apply a stimulating pulse of RF energy, and the electrodes 858 can detect the resultant neural response.
- the expandable member 856 can be deflated or collapsed ( FIG.
- the electrodes 444 on the struts 440 can apply therapeutically effective neuromodulation energy to the target site.
- the ablation pattern of the electrodes 444 can be based on the neural locations identified via the information detected from the sensing electrodes 858 on the expandable member 856 .
- the expandable member 856 may remain expanded during neuromodulation, and the electrodes 858 can detect neural activity during the neuromodulation procedure or the electrodes 858 can themselves be configured to apply neuromodulation energy to the treatment site.
- the electrodes 858 on the expandable member 856 can again be placed into contact with tissue at the target site, and used to record bioelectric properties (e.g., impedance).
- the detected properties e.g., impedances
- the detected properties taken before, during, and/or after neuromodulation can be compared to each other to determine whether the neuromodulation was therapeutically effective. If not, the electrodes 444 can again apply therapeutic neuromodulation energy to the same treatment site, or the configuration of the active electrodes 444 can be changed to apply therapeutic neuromodulation energy in a different pattern or sequence, and/or the therapeutic assembly 812 can be moved to a different treatment site.
- FIG. 10A is an isometric view of a distal portion of a therapeutic neuromodulation device 1002 (“device 1002 ”) configured in accordance with another embodiment of the present technology
- FIG. 10B is an isometric view illustrating the therapeutic neuromodulation device 1002 of FIG. 10A at a treatment site.
- the device 1002 can include various features generally similar to the features of the therapeutic neuromodulation devices 402 , 502 a - d , and 802 described above with reference to FIGS. 4-5G, 8 and 9 .
- the device 1002 includes a shaft 1008 and a therapeutic assembly 1012 at a distal portion 1008 b of the shaft 1008 .
- the therapeutic assembly 1012 includes a plurality of struts 1040 that form branches 1046 and define an expandable frame or basket 1042 , and one or more electrodes 1044 disposed on one or more of the struts 1040 .
- the device 1002 can further include a secondary or return electrode 1060 disposed along the distal portion of the shaft 1008 .
- the return electrode 1060 is a ring electrode having a ring-like shape, but in other embodiments the return electrode 1060 may have other shapes or configurations.
- the return electrode 1060 may be biased at a negative polarity, and at least a portion of the electrodes 1044 on the struts 1040 and/or on other portions of the therapeutic assembly 1012 may be biased at a positive polarity.
- bipolar RF energy can flow across a region spanning from the therapeutic assembly 1012 to the return electrode 1060 on this distal portion 1008 b of the shaft 1008 .
- the RF energy can be applied in a sesquipolar manner (i.e., imbalanced bipolar energy).
- the therapeutic assembly 1012 can be positioned inferior to the SPF and superior to the inferior turbinate IT and at least a portion of the microforamina MF and nerves N traversing the palatine bone.
- the return electrode 1060 can be positioned inferior to the inferior turbinate IT and at least a portion of the microforamina NIF and nerves N traversing the palatine bone.
- RF energy can then be applied across a wide region spanning from the therapeutic assembly 1012 to the return electrode 1060 .
- the device 1002 can apply energy across the top and bottom portions of the inferior turbinate, where a high density of microforamina reside.
- FIGS. 11A-11D are isometric views illustrating distal portions of therapeutic neuromodulation devices 1102 (referred to individually as a first device 1102 a and a second device 1102 b ) configured in accordance with further embodiments of the present technology.
- the first device 1102 a can include various features generally similar to the features of the therapeutic neuromodulation devices 402 , 502 a - d , 802 and 1002 described above with reference to FIGS. 4-5G and 8-10B .
- the first device 1102 a includes a shaft 1108 and a therapeutic assembly 1112 at a distal portion 1108 b of the shaft 1108 .
- the therapeutic assembly 1112 includes a flexible membrane 1162 that carries a plurality of electrodes 1144 and/or other energy delivery elements arranged in an array across the flexible membrane 1162 .
- the flexible membrane 1162 can be configured to transform from a low-profile delivery state ( FIG. 11A ), to an expanded state ( FIG. 11B ) via self-expansion or mechanical expansion means, and back to the low-profile delivery or retrieval state ( FIG. 11C ) for removal of the device from the nasal cavity.
- the flexible membrane In the expanded state shown in FIG. 11B , the flexible membrane can conform to the irregular anatomy of the nasal space (e.g., turbinates, sinus, and/or other para-nasal) to enhance the contact area between the flexible membrane 1162 (and the electrodes 1144 disposed thereon) with the non-planar anatomy.
- the flexible membrane 1162 can be made from a flexible and dynamic material to support the electrodes 1144 .
- the flexible membrane 1162 can comprise polymer filaments and/or other materials that add support and structure to the flexible membrane 1162 .
- the flexible membrane 1162 can have pre-set geometry to retain a predetermined shape.
- the flexible membrane 1162 and/or the electrode array on the flexible membrane 1162 can retain spherical curvature (e.g., as shown in FIG. 11A ).
- the shaft 1108 can be movable relative to the flexible membrane 1162 to allow for deployment and recapture of the flexible membrane 1162 .
- the flexible membrane 1162 may be curled or otherwise folded into a circular shape when in the delivery state ( FIG. 11A ).
- components of the shaft 1108 can be rotated and/or moved axially relative to the flexible membrane 1162 to unwind or otherwise expand the flexible membrane 1162 such that the flexible membrane 1162 at least partially opens and conforms to the structures of the surrounding anatomy to place the electrodes 1144 into contact with tissue at the target site.
- the shaft 1108 can again be moved axially or rotational manner to close wind or otherwise fold the flexible membrane 1162 .
- the electrodes 1144 may be interconnected through a plurality of connectors 1164 , such as nano-ribbons, nano-wires, direct inking, multidirectional printing/deposition, and/or other suitable electrical connectors.
- the interconnections 1164 between the electrodes 1144 can include periodic undulating conduits or lines having a “U”, “S”, or elliptical shapes. These undulating connectors 1164 may form a multidimensional spring within the flexible membrane 1162 and/or impose a predetermined shape on the flexible membrane 1162 that facilitates apposition of the flexible membrane 1162 to the tissue at the target site to improve energy conductivity/transference.
- the electrodes 1144 may be surface mounted on the flexible membrane 1162 or embedded within a multi-layered composite structure of the flexible membrane 1162 .
- the electrodes 1144 may be relatively small in size, having diameters ranging from 50-2,000 microns.
- the electrodes 1144 may be configured to deliver energy in a mono-polar, bipolar, or multipolar manner.
- multipolar electrodes can be used in a bipolar arrangement and in a quad-polar arrangement to facilitate a linear and an angulated (diagonal) energy connectivity between the electrodes 1144 .
- the electrodes 1144 can be connected to a connection pad (not shown) housed within the shaft 1108 and/or features connected to proximal portions of the shaft 1108 , such as a handle or console.
- the electrodes 1144 can be connected to the connection pad through a conductive connector cable (e.g., a metallic cable, a polymeric cable, and/or combinations thereof).
- the flexible membrane 1162 may also house a feedback system (not shown) to control the delivery of the RF energy and maintain predefined treatment parameters.
- the electronic circuits of the flexible membrane 1162 may include thermal sensors that provide temperature feedback to control energy dissipation and depth penetration of the RF energy.
- the features of electronic circuits of the flexible membrane 1162 may also measure resistance and temperature at the treatment site to determine the effects of the therapeutic energy application. This information may be used to regulate energy application and avoid collateral damage to host tissue.
- energy delivery via the electrodes 1144 may be automatically terminated if the detected temperature and/or resistance reaches a predetermined threshold maximum (e.g., a threshold temperature associated with tissue damage).
- Energy delivery via the electrodes 1144 may be automatically or manually adjusted if the detected temperature and/or resistance is below a predetermined threshold range indicative of parameters associated with therapeutically effective modulation of the parasympathetic nasal nerves.
- the feedback system can be incorporated to components communicatively coupled with the electrodes 1144 and any additional sensors on the flexible membrane 1162 .
- the feedback system can be stored on the console 204 of FIG. 2 and executed by the controller 218 ( FIG. 2 ).
- the second device 1102 b can include various features generally similar to the features of the first device 1102 a described above with reference to FIGS. 11A-11C .
- the device 1102 b of FIG. 11D includes the flexible membrane 1162 that carries a plurality of electrodes 1144 and associated electrical connectors 1164 disposed on or embedded in the flexible membrane 1162 .
- the device 1102 b further includes an expandable frame 1166 carrying the flexible membrane 1162 .
- the frame 1166 may have a U-shape and can be made from a shape memory material (e.g., Nitinol). In other embodiments, the frame may have different shapes and/or be made from different materials suitable for supporting the flexible membrane 1162 .
- the frame 1166 facilitates the deployment of the flexible membrane 1162 against the anatomy of the nasal cavity, and provides support for the flexible membrane 1162 and the associated array of electrodes 1144 .
- the U-shaped frame 1166 can enhance the ability of the flexible membrane 1162 to contact the non-planar anatomy at the target site.
- the frame 1166 may act as a cantilever spring to establish a positive directional apposition of the membrane 1162 to the target surface tissue to improve energy conductivity/transference from the electrodes 1144 to the target tissue.
- FIG. 12 is a side view of a distal portion of a therapeutic neuromodulation device 1202 (“device 1202 ”) configured in accordance with a further embodiment of the present technology.
- the device 1202 includes include various features generally similar to the features of the therapeutic neuromodulation devices 402 , 502 a - d , 802 , 1002 and 1102 described above with reference to FIGS. 4-5G and 8-11 .
- the device 1202 includes a shaft 1208 and a therapeutic assembly 1212 including a plurality of energy delivery elements, such as electrodes 1244 , at a distal portion 1208 b of the shaft 1208 .
- the therapeutic assembly 1212 includes four electrodes 1244 are arranged along a spiral/helical section 1268 at the distal portion 1208 b of the shaft 1208 .
- the therapeutic assembly 1212 may include one, two, three, or more than four electrodes 1244 , and/or may include different energy delivery elements.
- the therapeutic assembly 1212 can also include a temperature sensor 1252 (e.g., a thermocouple) and/or other type of sensor to detect various properties at the treatment site before, during, and/or after applying therapeutic neuromodulation energy, and provide feedback that may be used to control the operation of the therapeutic assembly 1212 .
- a temperature sensor 1252 e.g., a thermocouple
- Such sensors can be incorporated in any of the other embodiments of therapeutic assemblies disclosed herein.
- the spiral/helical section 1168 of the shaft 1208 is positioned in a low-profile delivery state in which the section 1268 is substantially straitened or flattened within an introducer sheath and/or via mechanical components associated with the shaft 1208 .
- the operator can transform the spiral/helical section 1268 to an expanded state (shown in FIG. 12 ) to place one or more of the electrodes 1244 in contact with the target tissue.
- One or more of the electrodes 1244 can then be selectively activated to apply RF energy (e.g., monopolar and/or bipolar RF energy) to tissue at a target site in the nasal region to therapeutically modulate nerves proximate to the treatment site.
- RF energy e.g., monopolar and/or bipolar RF energy
- the distal section of the shaft 1208 can have other suitable shapes, sizes, and/or configurations that facilitate placing the electrodes 1244 in contact with tissue at the target site.
- the distal portion 1208 b of the shaft 1208 can have a semi-circular, curved, bent, or straight shape and/or the therapeutic assembly 1212 can include multiple support members configured to carry one or more of the electrodes 1244 .
- FIG. 13 is a side view of a distal portion of a therapeutic neuromodulation device 1302 (“device 1302 ”) configured in accordance with a still further embodiment of the present technology.
- the device 1302 includes include various features generally similar to the features of the therapeutic neuromodulation devices 402 , 502 a - d , 802 , 1002 , 1102 and 1202 described above with reference to FIGS. 4-5G and 8-12 .
- the device 1302 includes a shaft 1308 and a therapeutic assembly 1312 including a plurality of energy delivery elements, such as an array of electrodes 1344 , at a distal portion 1308 b of the shaft 1308 .
- a therapeutic assembly 1312 including a plurality of energy delivery elements, such as an array of electrodes 1344 , at a distal portion 1308 b of the shaft 1308 .
- the therapeutic assembly 1312 includes a balloon 1370 that carries the electrodes 1344 .
- a support member 1372 can extend through the length of the balloon 1370 to support the balloon 1370 and, optionally, include a channel through which a guidewire (not shown) can extend to facilitate delivery of the therapeutic assembly 1312 to the target site. In other embodiments, the support member 1372 may be omitted.
- the electrodes 1344 can be made from conductive ink that is printed, sprayed, and/or otherwise disposed on the surface of the balloon 1370 . Such conductive ink electrodes facilitates the use of complex electrode configurations.
- thermocouples (not shown) can also be incorporated onto the surface of the balloon 1370 using conductive ink and/or other suitable methods.
- the electrodes 1344 can be made from foil and adhered to the surface of the balloon 1370 .
- the electrodes 1344 can be made from other suitable materials that may be disposed on the surface of the balloon 1370 and/or embedded within the material of the balloon 1370 .
- the balloon 1370 can be made from various different materials and have various different shapes. As shown in FIG. 13 , for example, the balloon 1370 can have an ovoid shape when in the expanded state, which is expected to improve the conformance to anatomical variations at the target site within the nasal cavity. In other embodiments, the balloon 1370 can have a circular shape, a spherical shape, an irregular shape, and/or other suitable shape for expansion within the nasal anatomy.
- the balloon 1370 can be made from a compliant material (e.g., a urethane material) that allows the balloon 1370 to conform to anatomical variances when expanded within the nasal region.
- the balloon may be made from a non-compliant material (e.g., polyethylene terephthalate, nylon, etc.) that allows the balloon 1370 to have a defined shape when expanded and facilitates the attachment of electrodes 1344 to the balloon surface.
- the balloon 1370 may be dip-coated and form a bulbous tip at the distal end of the shaft 1308 .
- the balloon 1370 may be inflated with a fluid via an opening or port 1374 in the support member 1372 and/or an opening in the shaft 1308 in fluid communication with the interior of the balloon 1370 .
- the support member 1372 and/or the shaft 1308 can include a channel extending along the length of the shaft 1308 and connected to a fluid supply at the proximal portion of the shaft 1308 such that fluid can be delivered to the balloon 1370 .
- the balloon 1370 can inflate against the nasal anatomy at the target site to places the electrodes 1344 in contact with tissue at the target site.
- the electrodes 1344 deliver RF energy to tissue to therapeutically modulate nerves at the treatment site.
- the array of electrodes 1344 can be arranged on the balloon 1370 and/or selectively activated to apply transverse bipolar RF energy across a radial regions of the balloon 1370 (i.e., extending around circumferential portions of the balloon 1370 ).
- the array of electrodes 1344 can be arranged on the balloon 1370 and/or selectively activated to apply longitudinal bipolar RF energy across longitudinal regions of the balloon 1370 (i.e., extending between proximal and distal portions of the balloon 1370 ).
- the therapeutic assembly 1312 may include features that facilitate with positioning of the balloon 1370 within the nasal anatomy and proper placement of the electrodes 1344 at the treatment site.
- an endoscope 1371 may be positioned on the surface of the balloon 1370 to provide direct, in-line visualization of the balloon 1370 and the target site during placement at the target site.
- the therapeutic assembly 1312 can also include graduated markings 1373 along the support member 1372 and/or the surface of the balloon 1370 to depict spatial orientation and/or depth positioning of the therapeutic assembly 1312 .
- the balloon 1370 can be configured to allow for a slow perfusion of fluid through the balloon wall to cool the electrodes 1344 while energy is applied to the target tissue.
- a “weeping” balloon 1370 can include laser-driller holes and/or other small openings or pores along at least a portion of the balloon 1370 to allow for the slow perfusion of a fluid (e.g., saline solution) through the balloon wall.
- a fluid e.g., saline solution
- the saline solution is expected to improve the electrical conductivity between the electrodes 1344 and the target tissue and may enhance the effect of the RF energy on the nerves at the target site.
- a cooled fluid can be circulated through the balloon 1470 during activation of the electrodes 1444 to cool the electrodes 1444 and the surrounding tissue during energy delivery.
- FIG. 14 is a side view of a distal portion of a therapeutic neuromodulation device 1402 (“device 1402 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1402 includes include various features generally similar to the features of the therapeutic neuromodulation device 1302 described above with reference to FIG. 13 .
- the device 1402 includes a shaft 1408 and a therapeutic assembly 1412 at a distal portion 1408 b of the shaft 1408 .
- the therapeutic assembly 1412 includes a balloon 1470 , a support member 1472 supporting the balloon 1470 , and a plurality of energy delivery elements, such as an array of electrodes 1444 disposed on the balloon 1470 .
- FIG. 14 is a side view of a distal portion of a therapeutic neuromodulation device 1402 (“device 1402 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1402 includes include various features generally similar to the features of the therapeutic neuromodulation device 1302 described above with reference to FIG. 13 .
- the electrodes 1444 are part of a flex circuit 1476 adhered to the surface of the balloon 1470 .
- the flex circuit 1476 facilitates the creation of complex electrode arrays that can create highly customizable neuromodulation patterns.
- the flex circuit 1476 can include a conductive return electrode along the surface of the balloon 1470 and a plurality of electrodes on a proximal or distal portion of the balloon 1470 (e.g., a conical end portion of the balloon 1470 ).
- the flex circuit 1476 can incorporate thermocouples and/or thermistors into the circuitry on the surface of the balloon 1470 to detect temperature at the treatment site before, during, and/or after energy application.
- FIG. 15 is an isometric side view of a distal portion of a therapeutic neuromodulation device 1502 (“device 1502 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1502 includes include various features generally similar to the features of the therapeutic neuromodulation devices 1302 and 1402 described above with reference to FIGS. 13 and 14 .
- the device 1502 includes a shaft 1508 and a therapeutic assembly 1512 at a distal portion 1508 b of the shaft 1508 .
- the therapeutic assembly 1512 includes a plurality of balloons 1578 positioned around an inner support member 1580 , and a plurality of energy delivery elements, such as electrodes 1544 disposed on one or more of the balloons 1578 .
- the balloons 1578 are independently inflatable.
- the device 1502 can include less than four balloons 1578 or more than four balloons 1578 arranged around the inner support member 1580 .
- the balloons 1578 can have different sizes and/or shapes, and can be positioned along various portions of the inner support member 1580 .
- the balloons 1578 re configured as struts that are attached at end portions to the inner support member 1580 and extend outwardly away from the inner support member 1580 when inflated (e.g., in a similar manner as the struts 440 of the therapeutic neuromodulation device 402 of FIG. 4 ).
- the electrodes 1544 can be configured to apply bipolar RF energy across the electrodes 1544 on different balloons 1578 and/or between electrodes 1544 on the same balloon 1578 .
- the electrodes 1544 apply energy in a sesquipolar manner.
- the inner support member 1580 can include a return electrode (not shown), and the electrodes 1544 on two or more of the balloons 1578 may be activated for sesquipolar RF energy delivery.
- FIG. 16 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device 1602 (“device 1602 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1602 includes various features generally similar to the features of the therapeutic neuromodulation devices described above.
- the device 1602 includes a shaft 1608 and a therapeutic assembly 1612 at a distal portion 1608 b of the shaft 1608 .
- the therapeutic assembly 1612 is configured to apply cryotherapeutic cooling to therapeutically modulate nerves at the target site. As shown in FIG.
- the cryotherapeutic assembly 1612 can include an expansion chamber 1682 (e.g., a balloon, inflatable body, etc.) in fluid communication with one or more supply tubes or lumens 1684 via corresponding orifices 1686 in the supply lumens 1684 .
- the supply lumens 1682 can extend along at least a portion of the shaft 1608 and be configured to transport a refrigerant in an at least a partially liquid state to the distal portion 1608 b of the shaft 1608 .
- An exhaust tube or lumen 1689 (e.g., defined by a portion of the shaft 1608 ) can be placed in fluid communication with the interior of the expansion chamber 1682 via an outlet 1688 such that the exhaust lumen 1689 can return the refrigerant to the proximal portion of the shaft 1608 .
- a vacuum (not shown) at the proximal portion of the shaft 1608 may be used to exhaust the refrigerant from the expansion chamber 1682 via the exhaust lumen 1689 .
- the refrigerant may be transported to the proximal portion of the shaft 1608 using other suitable mechanisms known to those having skill in the art.
- the orifices 1686 of the supply lumens 1684 can restrict refrigerant flow to provide a high pressure differential between the supply lumen 1684 and the expansion chamber 1682 , thereby facilitating the expansion of the refrigerant to the gas phase within the expansion chamber 1682 .
- the pressure drop as the liquid refrigerant passes through the orifices 1682 causes the refrigerant to expand to a gas and reduces the temperature to a therapeutically effective temperature that can modulate neural fibers proximate a treatment site within the nasal cavity.
- the expansion chamber 1682 includes heat transfer portions 1691 that contact and cool tissue at the target site at a rate sufficient to cause cryotherapeutic neuromodulation of postganglionic parasympathetic neural fibers that innervate the nasal mucosa.
- the therapeutic assembly 1602 can operate at temperatures of ⁇ 40° C., ⁇ 60° C., ⁇ 80° C., or lower. In other embodiments, the therapeutic assembly 1602 can operated at higher cryotherapeutic temperatures (e.g., 5° C. and ⁇ 15° C., ⁇ 20° C., etc.).
- the refrigerant used for cryogenic cooling in the device 1602 can be a compressed or condensed gas that is stored in at least a substantially liquid phase, such as nitrous oxide (N 2 O), carbon dioxide (CO 2 ), hydrofluorocarbon (e.g., FREON made available by E. I. du Pont de Nemours and Company of Wilmington, Del.), and/or other suitable fluids that can be stored at a sufficiently high pressure to be in at least a substantially liquid phase at about ambient temperature.
- nitrous oxide N 2 O
- CO 2 carbon dioxide
- hydrofluorocarbon e.g., FREON made available by E. I. du Pont de Nemours and Company of Wilmington, Del.
- R-410A a zeotropic, but near-azeotropic mixture of difluoromethane (CH 2 F 2 ; also known as HFC-32 or R-32) and pentafluoroethane (CHF 2 CF 3 ; also known as HFC-125 or R-125), can be in at least a substantially liquid phase at about ambient temperature when contained at a pressure of about 1.45 MPa (210 psi). Under proper conditions, these refrigerants can reach cryotherapeutic temperatures at or near their respective normal boiling points (e.g., approximately ⁇ 88° C. for nitrous oxide) to effectuate therapeutic neuromodulation.
- CH 2 F 2 also known as HFC-32 or R-32
- pentafluoroethane CHF 2 CF 3
- these refrigerants can reach cryotherapeutic temperatures at or near their respective normal boiling points (e.g., approximately ⁇ 88° C. for nitrous oxide) to effectuate therapeutic neuromodulation.
- the therapeutic assembly 1612 can include a cryotherapeutic applicator rather than the expansion chamber 1682 of FIG. 16 .
- a cryotherapeutic applicator can be used for very targeted treatment of the nerves.
- the device 1602 can also include a support member 1690 extending through the expansion chamber 1682 and configured to carry the distal portion of the expansion chamber 1682 .
- the support member 1690 can also include a channel extending along its length and an opening 1692 at the distal end portion of the support member 1690 to facilitate delivery of the therapeutic assembly 1612 to the treatment site via a guidewire GW.
- FIG. 17 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device 1702 (“device 1702 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1702 includes various features generally similar to the features of the therapeutic neuromodulation devices described above.
- the device 1702 includes a shaft 1708 and a therapeutic assembly 1712 at a distal portion 1708 b of the shaft 1708 .
- the therapeutic assembly 1712 is configured to apply direct conductive heating to thermally therapeutically modulate nerves at the target site. As shown in FIG.
- the therapeutic assembly 1712 can include a balloon 1770 in fluid communication with a supply tube or lumen 1794 (e.g., defined by a portion of the shaft 1708 ) via an outlet at a distal portion of the supply lumen 1794 .
- the supply lumen 1794 can extend along at least a portion of the shaft 1708 and be insulated to transport a heated fluid (e.g., heated saline) to the balloon 1770 at the distal portion 1708 b of the shaft 1708 .
- An exhaust or return tube or lumen 1796 (e.g., defined by a portion of the shaft 1708 ) can be placed in fluid communication with the interior of the balloon 1770 via an outlet such that the return lumen 1796 can exhaust the fluid to the proximal portion of the shaft 1708 (e.g., using a vacuum at the proximal portion of the shaft 1708 ).
- the supply lumen 1794 can supply a heated fluid to the balloon 1770 , and the exhaust lumen 1796 can be used to exhaust the fluid from the balloon 1770 such that the heated fluid circulates through the balloon 1770 (e.g., as indicated by the arrows).
- the heated fluid can be heated to a therapeutically effective temperature that causes time-dependent thermal damage (e.g., determined using the Arrhenius equation) to the target tissue at a treatment site within the nasal cavity and modulates neural fibers within or proximate to the heated target tissue.
- the wall of the balloon 1770 and/or portions thereof can contact and heat tissue at the target site at a rate and time sufficient to cause thermal damage to the target tissue to provide therapeutic neuromodulation of postganglionic parasympathetic neural fibers that innervate the nasal mucosa.
- the device 1702 can also include a support member 1790 extending through the balloon 1770 and configured to carry the distal portion of the balloon 1770 .
- the support member 1790 can also include a channel extending along its length and an opening 1792 at the distal end portion of the support member 1790 that can be used to facilitate delivery of the therapeutic assembly 1712 to the treatment site via a guidewire GW.
- FIG. 18 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device 1802 (“device 1802 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1802 includes various features generally similar to the features of the therapeutic neuromodulation devices described above.
- the device 1802 includes a shaft 1808 and a therapeutic assembly 1812 at a distal portion 1808 b of the shaft 1808 .
- the therapeutic assembly 1812 can include an inflatable balloon 1870 and a support member 1890 extending through the balloon 1870 .
- the support member 1890 may also include a channel with an opening 1892 that allows for guidewire delivery of the therapeutic assembly 1812 to the treatment site.
- the therapeutic assembly 1812 can apply therapeutically effective heating to tissue at a target site to cause time-dependent thermal tissue damage (e.g., determined using the Arrhenius equation) and modulate neural fibers within or proximate to the heated target tissue.
- heating is supplied via a heating element 1898 positioned within the balloon 1880 and carried by the support member 1890 and/or another feature of the therapeutic assembly 1812 .
- the heating element 1898 may be a plate or other structure heated using resistive heating (via a generator) and/or other suitable heating mechanism.
- the heat from the heating element 1898 can transfer from the heating element 1898 to the fluid within the balloon 1870 , and then through the wall of the balloon 1870 to the adjacent tissue at the treatment site.
- the fluid heated by the heating element 1898 can be heated to a therapeutically effective temperature that causes thermal damage to the target tissue at a treatment site within the nasal cavity and modulates neural fibers within or proximate to the heated target tissue.
- the balloon 1870 can include conductive features (e.g., metallic panels) on its surface to concentrate the heating effect at targeted regions of the balloon 1870 .
- the balloon 1870 can be heated via capacitive coupling to reach therapeutically effective temperatures that causes thermal damage to the target tissue at a treatment site within the nasal cavity and modulate neural fibers within or proximate to the heated target tissue.
- the balloon 1870 can be inflated with an isotonic solution, and the balloon 1870 can be ionically agitated at a high frequency to allow capacitive energy to discharge across the membrane of the balloon 1870 to the target tissue.
- FIG. 19 is a side view of a distal portion of a therapeutic neuromodulation device 1902 (“device 1902 ”) configured in accordance with an additional embodiment of the present technology.
- the device 1902 includes various features generally similar to the features of the therapeutic neuromodulation devices described above.
- the device 1902 includes a shaft 1908 and a therapeutic assembly 1912 at a distal portion 1908 b of the shaft 1908 .
- the therapeutic assembly 1912 is configured to apply plasma or laser ablation to therapeutically modulate nerves at the target site.
- the therapeutic assembly 1912 can include an ablation element 1999 (e.g., an electrode) on a distal end portion of the shaft 1908 .
- an ablation element 1999 e.g., an electrode
- the ablation element 1999 can apply high energy laser pulses to ionize molecules within the first few portion of the pulse. This process leads to a small bubble or field of plasma (e.g., 100-200 ⁇ m) that can be used to desiccate or otherwise destroy tissue and nerves at the target site.
- the ablation element 1999 can operate at temperatures lower than 100° C. and can limit the thermal effects on surrounding tissue.
- the ablation element 1999 can perform laser ablation of nerves at the target site.
- a nerve tracer e.g., indocyanine green (ICG)
- ICG indocyanine green
- the ablation element 1999 can be a laser that is tuned to absorb the spectrum of the nerve tracer and, thereby, ablate the dyed nerves in the target site.
- FIG. 20 is a partial cut-away side view illustrating target sites proximate to ostia of nasal sinuses for a therapeutic neuromodulation device configured in accordance with embodiments of the present technology.
- Any of the therapeutic modulation devices and system described above can be used to therapeutically modulate nerves that innervate the para-nasal sinuses to treat chronic sinusitis and/or similar indications. Referring to FIG.
- the para-nasal sinuses include the frontal sinuses FS, the sphenoidal sinuses SS, the maxillary sinuses (“MS”; not shown), and the ethmoidal sinuses or ethmoidal cells (not shown), which include the posterior ethmoidal cells (“PEC”), the middle ethmoidal cells (“MEC”), and the anterior ethmoidal cells (“AEC”).
- Each sinus opens to the nasal cavity at one or more discrete ostia.
- FIG. 20 illustrates the general locations of the ostium of the frontal sinus, the sphenoidal sinus, the maxillary sinus, and the ostia of posterior, middle, and anterior ethmoidal cells.
- Parasympathetic nerves innervate the mucosa of the sinuses and stimulate the production of mucus in the sinuses.
- Hyperactivity of the parasympathetic nerves innervating the sinuses can cause hyper production of mucus and the soft tissue engorgement.
- the inflammation of the soft tissue proximate to the sinuses can cause can obstruct the conduit between a sinus and the nasal cavity and block the ostium to the sinus.
- the hyperactive mucosa and/or the blockage of the ostium can cause the pooling of mucosal secretions within the sinus occurs due to the lack of drainage from the sinus. This can lead to infection and, eventually, a chronic sinusitis state.
- Therapeutic modulation the parasympathetic nerves that control autonomic function of the sinuses is expected to reduce or eliminate the hyperactive mucosal secretions and soft tissue engorgement and, thereby, treat chronic sinusitis or related indications.
- Any of the therapeutic neuromodulation devices described above can be used to apply therapeutically effective neuromodulation energy at or proximate to the ostia of the affected sphenoidal, maxillary, frontal, and/or ethmoidal sinuses to modulate the autonomic function of the sinuses.
- therapeutic neuromodulation devices can be used to apply RF energy, microwave energy, ultrasound energy, cryotherapeutic cooling, therapeutic heating, plasma ablation, and/or laser ablation to treatment sites at and around the ostia of the sinuses.
- the therapeutic neuromodulation devices can be delivered intraluminally via the nasal passage and through the superior, middle, and/or inferior meatuses to access the ostium or ostia of the desired sinus.
- neural mapping techniques similar to those described above with respect to FIGS. 6A-9 can be used to locate or detect the parasympathetic nerves that innervate the ostia before, during, and/or after treatment.
- the application of therapeutic neuromodulation at the target sites proximate to the sinus ostia can disrupt the parasympathetic signals to the sinus tissues, leading to the opening of the ostia and the ability to drain fluid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Optics & Photonics (AREA)
- Electromagnetism (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Plasma & Fusion (AREA)
- Thermal Sciences (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
- Surgical Instruments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Laser Surgery Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
- The present application claims priority to U.S. Provisional Patent Application No. 62/160,289, filed May 12, 2015, which is incorporated by reference herein in its entirety.
- The present technology relates generally to devices, systems, and methods for therapeutically modulating nerves in or associated with a nasal region of a patient. In particular, various embodiments of the present technology are related to therapeutic neuromodulation systems and methods for the treating rhinitis and other indications.
- Rhinosinusitis is characterized as an inflammation of the mucous membrane of the nose and refers to a group of conditions, including allergic rhinitis, non-allergic rhinitis, chronic rhinitis, chronic sinusitis, and medical resistant rhinitis. Symptoms of rhinosinusitis include nasal blockage, obstruction, congestion, nasal discharge (e.g., rhinorrhea and/or posterior nasal drip), facial pain, facial pressure, and/or reduction or loss of smell. Allergic rhinitis can include further symptoms, such as sneezing, watery rhinorrhea, nasal itching, and itchy or watery eyes. Severe rhinitis can lead to exacerbation of coexisting asthma, sleep disturbances, and impairment of daily activities. Depending on the duration and type of systems, rhinosinusitis can fall within four subtypes: acute rhinosinusitis, recurrent rhinosinusitis, chronic rhinosinusitis with nasal polyposis (i.e., soft, non-cancerous growths on the lining of the nasal passages or sinuses), and chronic rhinosinusitis without nasal polyposis. Acute rhinosinusitis refers to symptoms lasting for less than twelve weeks, whereas chronic rhinosinusitis (with and without nasal polyposis) refers to symptoms lasting longer than twelve weeks. Recurrent rhinosinusitis refers to four or more episodes of acute rhinosinusitis within a twelve-month period, with resolution of symptoms between each episode.
- There are numerous environmental and biological causes of rhinosinusitis. Non-allergic rhinosinusitis, for example, can be caused by environmental irritants (e.g., exhaust fumes, cleaning solutions, latex, perfume, dust, etc.), medications (e.g., NSAIDs, oral contraceptives, blood pressure medications including ACE inhibitors, antidepressants, etc.), foods (e.g., alcoholic beverages, spicy foods, etc.), hormonal changes (e.g., pregnancy and menstruation), and/or nasal septum deviation. Triggers of allergic rhinitis can include exposure to seasonal allergens (e.g., exposure to environmental allergens at similar times each year), perennial allergens that occur any time of year (e.g., dust mites, animal dander, molds, etc.), and/or occupational allergens (e.g., certain chemicals, grains, latex, etc.).
- The treatment of rhinosinusitis can include a general avoidance of rhinitis triggers, nasal irrigation with a saline solution, and/or drug therapies. Pharmaceutical agents prescribed for rhinosinusitis include, for example, oral H1 antihistamines, topical nasal H1 antihistamines, topical intranasal corticosteroids, systemic glucocorticoids, injectable corticosteroids, anti-leukotrienes, nasal or oral decongestants, topical anticholinergic, chromoglycate, and/or anti-immunoglobulin E therapies. However, these pharmaceutical agents have limited efficacy (e.g., 17% higher than placebo or less) and undesirable side effects, such as sedation, irritation, impairment to taste, sore throat, dry nose, epistaxis (i.e., nose bleeds), and/or headaches. Immunotherapy, including sublingual immunotherapy (“SLIT”), has also been used to treat allergic rhinitis by desensitizing the patient to particular allergens by repeated administration of an allergen extract. However, immunotherapy requires an elongated administration period (e.g., 3-5 years for SLIT) and may result in numerous side effects, including pain and swelling at the site of the injection, urticarial (i.e., hives), angioedema, asthma, and anaphylaxis.
- Surgical interventions have also been employed in an attempt to treat patients with drug therapy resistant, severe rhinitis symptoms. In the 1960's through 1980's, surgeries were performed to sever parasympathetic nerve fibers in the vidian canal to decrease parasympathetic tone in the nasal mucosa. More recent attempts at vidian neurectomies were found to be 50-88% effective for the treatment of rhinorrhea, with other ancillary benefits including improvements in symptoms of sneezing and nasal obstruction. These symptomatic improvements have also been correlated to histologic mucosal changes with reductions in stromal edema, eosinophilic cellular infiltration, mast cell levels, and histamine concentrations in denervated mucosa. However, despite the clinical and histologic efficacy of vidian neurectomy, resecting the vidian nerve failed to gain widespread acceptance largely due to the morbidities associated with its lack of anatomic and autonomic selectivity. For example, the site of neurectomy includes preganglionic secretomotor fibers to the lacrimal gland, and therefore the neurectomy often resulted in the loss of reflex tearing, i.e., lacrimation, which in severe cases can cause vision loss. Due to such irreversible complications, this technique was soon abandoned. Further, due passage of postganglionic pterygopalatine fibers through the retro-orbital plexus, the position of the vidian neurectomy relative to the target end organ (i.e., the nasal mucosa) may result in re-innervation via the autonomic plexus and otic ganglion projections traveling with the accessory meningeal artery.
- The complications associated with vidian neurectomies are generally attributed to the nonspecific site of autonomic denervation. Consequently, surgeons have recently shifted the site of the neurectomy to postganglionic parasympathetic rami that may have the same physiologic effect as a vidian neurectomy, while avoiding collateral injury to the lacrimal and sympathetic fibers. For example, surgeons in Japan have performed transnasal inferior turbinate submucosal resections in conjunction with resections of the posterior nasal nerves (“PNN”), which are postganglionic neural pathways located further downstream than the vidian nerve. (See, Kobayashi T, Hyodo M, Nakamura K, Komobuchi H, Honda N, Resection of peripheral branches of the posterior nasal nerve compared to conventional posterior neurectomy in severe allergic rhinitis. Auris Nasus Larynx. 2012 Feb. 15; 39:593-596.) The PNN neurectomies are performed at the sphenopalatine foramen, where the PNN is thought to enter the nasal region. These neurectomies are highly complex and laborious because of a lack of good surgical markers for identifying the desired posterior nasal nerves and, even if the desired nerves are located, resection of the nerves is very difficult because the nerves must be separated from the surrounding vasculature (e.g., the sphenopalatine artery).
- Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. For ease of reference, throughout this disclosure identical reference numbers may be used to identify identical or at least generally similar or analogous components or features.
-
FIG. 1A is a cut-away side view illustrating the anatomy of a lateral nasal wall. -
FIG. 1B is an enlarged side view of the nerves of the lateral nasal wall ofFIG. 1A . -
FIG. 1C is a front view of a left palatine bone illustrating geometry of microforamina in the left palatine bone. -
FIG. 2 is a partially schematic view of a therapeutic neuromodulation system for therapeutically modulating nerves in a nasal region in accordance with an embodiment of the present technology. -
FIGS. 3A-3E are partial cut-away side views illustrating various approaches for delivering a distal portion of a therapeutic neuromodulation device to a target site within a nasal region in accordance with embodiments of the present technology. -
FIG. 4 is an isometric view of a distal portion of a therapeutic neuromodulation device configured in accordance with an embodiment of the present technology. -
FIGS. 5A-5G are isometric views of electrode configurations of therapeutic neuromodulation devices for therapeutic neuromodulation in accordance with embodiments of the present technology. -
FIGS. 6A and 6B are partially schematic diagrams illustrating electrode configurations at a distal portion of a therapeutic neuromodulation device for nerve detection configured in accordance with embodiments of the present technology. -
FIG. 7 is a graph illustrating threshold levels of electrical conductivity of nasal tissue with respect to temperature. -
FIGS. 8 and 9 are isometric views of a distal portion of a therapeutic neuromodulation device configured in accordance with an embodiment of the present technology. -
FIG. 10A is an isometric view of a distal portion of a therapeutic neuromodulation device configured in accordance with another embodiment of the present technology, andFIG. 10B is an isometric view illustrating the therapeutic neuromodulation device ofFIG. 10A at a treatment site. -
FIGS. 11A-11D are isometric views illustrating a distal portion of a therapeutic neuromodulation device configured in accordance with yet another embodiment of the present technology. -
FIG. 12 is a side view of a distal portion of a therapeutic neuromodulation device configured in accordance with a further embodiment of the present technology. -
FIG. 13 is a side view of a distal portion of a therapeutic neuromodulation device configured in accordance with a still further embodiment of the present technology. -
FIG. 14 is an isometric side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology. -
FIG. 15 is an isometric side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology. -
FIG. 16 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology. -
FIG. 17 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology. -
FIG. 18 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology. -
FIG. 19 is a side view of a distal portion of a therapeutic neuromodulation device configured in accordance with an additional embodiment of the present technology. -
FIG. 20 is a partial cut-away side view illustrating target sites proximate to ostia of nasal sinuses for a therapeutic neuromodulation device configured in accordance with embodiments of the present technology. - The present technology is generally directed to devices for therapeutic nasal neuromodulation and associated systems and methods. The disclosed devices are configured to provide an accurate and localized non-invasive application of energy to disrupt the parasympathetic motor sensory function in the nasal region. Specific details of several embodiments of the present technology are described herein with reference to
FIGS. 1A-20 . Although many of the embodiments are described with respect to devices, systems, and methods for therapeutically modulating nerves in the nasal region for the treatment of rhinitis, other applications and other embodiments in addition to those described herein are within the scope of the present technology. For example, at least some embodiments of the present technology may be useful for the treatment of other indications, such as the treatment of chronic sinusitis and epitaxis. It should be noted that other embodiments in addition to those disclosed herein are within the scope of the present technology. Further, embodiments of the present technology can have different configurations, components, and/or procedures than those shown or described herein. Moreover, a person of ordinary skill in the art will understand that embodiments of the present technology can have configurations, components, and/or procedures in addition to those shown or described herein and that these and other embodiments can be without several of the configurations, components, and/or procedures shown or described herein without deviating from the present technology. - With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference relative positions of portions of a therapeutic neuromodulation device and/or an associated delivery device with reference to an operator and/or a location within the nasal cavity. For example, in referring to a delivery catheter suitable to deliver and position various prosthetic valve devices described herein, “proximal” can refer to a position closer to the operator of the device or access point at the entrance point of a patient's nostril, and “distal” can refer to a position that is more distant from the operator of the device or further from the access point at the entrance of the patient's nostril. Additionally, posterior, anterior, inferior and superior are used in accordance with standard medical terminology.
- As used herein, the terms “therapeutic modulation” of nerves and “therapeutic neuromodulation” refer to the partial or complete incapacitation or other effective disruption of neural activity, including partial or complete ablation of nerves. Therapeutic neuromodulation, for example, can include partially or completely inhibiting, reducing, and/or blocking neural communication along neural fibers.
-
FIG. 1A is a cut-away side view illustrating the anatomy of a lateral nasal wall, andFIG. 1B is an enlarged side view of the nerves of the lateral nasal wall ofFIG. 1A . The sphenopalatine foramen (“SPF”;FIG. 1A ) is an opening or conduit defined by the palatine bone and the sphenoid bone through which the sphenopalatine vessels and the posterior superior nasal nerves travel into the nasal cavity. More specifically, the orbital and sphenoidal processes of the perpendicular plate of the palatine bone define the sphenopalatine notch, which is converted into the SPF by the articulation with the surface of the body of the sphenoid bone. - The location of the SPF is highly variable within the posterior region of the lateral nasal cavity, which makes it difficult to visually locate the SPF. Typically, the SPF is located in the middle meatus (“MM”;
FIG. 1A ); however, anatomical variations also result in the SPF being located in the superior meatus (“SM”;FIG. 1A ) or at the transition of the superior and middle meatuses. In certain individuals, for example, the inferior border of the SPF has been measured at about 19 mm above the horizontal plate of the palatine bone (i.e., the nasal sill), which is about 13 mm above the horizontal lamina of the inferior turbinate (“IT”;FIG. 1A ), and the average distance from the nasal sill to the SPF is about 64.4 mm, resulting in an angle of approach from the nasal sill to the SPA of about 11.4°. However, studies to measure the precise location of the SPF are of limited practical application due to the wide variation of its location. - The anatomical variations of the SPF are expected to correspond to alterations of the autonomic and vascular pathways traversing into the nasal cavity. In general, it is thought that the posterior nasal nerves (also referred to as lateral posterior superior nasal nerves) branch from the pterygopalatine ganglion (“PPG”; also referred to as the sphenopalatine ganglion;
FIG. 1A ) through the SPF to enter the lateral nasal wall of the nasal cavity, and the sphenopalatine artery passes from the pterygopalatine fossa through the SPF on the lateral nasal wall. The sphenopalatine artery branches into two main portions: the posterior lateral nasal branch and the posterior septal branch. The main branch of the posterior lateral nasal artery travels inferiorly into the inferior turbinate IT (e.g., between about 1.0 mm and 1.5 mm from the posterior tip of the inferior turbinate IT), while another branch enters the middle turbinate MT and branches anteriorly and posteriorly. - Beyond the SPF, studies have shown that over 30% of human patients have one or more accessory foramen that also carries arteries and nerves into the nasal cavity. The accessory foramena are typically smaller than the SPF and positioned inferior to the SPF. For example, there can be one, two, three or more branches of the posterior nasal artery and posterior nasal nerves that extend through corresponding accessory foramen. The variability in location, size, and quantity associated with the accessory foramen and the associated branching arteries and nerves that travel through the accessory foramen gives rise to a great deal of uncertainty regarding the positions of the vasculature and nerves of the sphenopalatine region. Furthermore, the natural anatomy extending from the SPF often includes deep inferior and/or superior grooves that carry neural and arterial pathways, which make it difficult to locate arterial and neural branches. For example the grooves can extend more than 5 mm long, more than 2 mm wide, and more than 1 mm deep, thereby creating a path significant enough to carry both arteries and nerves. The variations caused by the grooves and the accessory foramen in the sphenopalatine region make locating and accessing the arteries and nerves (positioned posterior to the arteries) extremely difficult for surgeons.
- Recent microanatomic dissection of the pterygopalatine fossa (PPF) have further evidenced the highly variable anatomy of the region surrounding the SPF, showing that a multiplicity of efferent rami that project from the pterygopalatine ganglion (“PPG”;
FIG. 1 ) to innervate the orbit and nasal mucosa via numerous groups of small nerve fascicles, rather than an individual postganglionic autonomic nerves (e.g., the posterior nasal nerve). Studies have shown that at least 87% of humans have microforamina and micro rami in the palatine bone.FIG. 1C , for example, is a front view of a left palatine bone illustrating geometry of microforamina and micro rami in a left palatine bone. InFIG. 1C , the solid regions represent nerves traversing directly through the palatine bone, and the open circles represent nerves that were associated with distinct microforamina. Indeed,FIG. 1C illustrates that a medial portion of the palatine bone can include at least 25 accessory posterolateral nerves. - The respiratory portion of the nasal cavity mucosa is composed of a type of ciliated pseudostratified columnar epithelium with a basement membrane. Nasal secretions (e.g., mucus) are secreted by goblet cells, submucosal glands, and transudate from plasma. Nasal seromucous glands and blood vessels are highly regulated by parasympathetic innervation deriving from the vidian and other nerves. Parasympathetic (cholinergic) stimulation through acetylcholine and vasoactive intestinal peptide generally results in mucus production. Accordingly, the parasympathetic innervation of the mucosa is primarily responsible submucosal gland activation/hyper activation, venous engorgement (e.g., congestion), and increased blood flow to the blood vessels lining the nose. Accordingly, severing or modulating the parasympathetic pathways that innervate the mucosa are expected to reduce or eliminate the hyper activation of the submucosal glands and engorgement of vessels that cause symptoms associated with rhinosinusitis and other indications.
- As discussed above, postganglionic parasympathetic fibers that innervate the nasal mucosa (i.e., posterior superior nasal nerves) were thought to travel exclusively through the SPF as a sphenopalatine neurovascular bundle. The posterior nasal nerves are branches of the maxillary nerve that innervate the nasal cavity via a number of smaller medial and lateral branches extending through the mucosa of the superior and middle turbinates ST, MT (i.e., nasal chonchea) and to the nasal septum. The nasopalatine nerve is generally the largest of the medial posterior superior nasal nerves. It passes antero-inferiorly in a groove on the vomer to the floor of the nasal cavity. From here, it passes through the incisive fossa of the hard palate and communicates with the greater palatine nerve to supply the mucosa of the hard palate. The posterior superior nasal nerves pass through the pterygopalatine ganglion PPG without synapsing and onto the maxillary nerve via its ganglionic branches.
- Based on the understanding that the posterior nasal nerves exclusively traverse the SPF to innervate the nasal mucosa, surgeries have been performed to selectively sever the posterior nasal nerve as it exits the SPF. However, as discussed above, the sinonasal parasympathetic pathway actually comprises individual rami project from the pterygopalatine ganglion (PPG) to innervate the nasal mucosa via multiple small nerve fascicles (i.e., accessory posterolateral nerves), not a single branch extending through the SPF. These rami are transmitted through multiple fissures, accessory foramina, and microforamina throughout the palatine bone and may demonstrate anastomotic loops with both the SPF and other accessory nerves. Thus, if only the parasympathetic nerves traversing the SPF were severed, almost all patients (e.g., 90% of patients or more) would retain intact accessory secretomotor fibers to the posterolateral mucosa, which would result in the persistence of symptoms the neurectomy was meant to alieve.
- Accordingly, embodiments of the present technology are configured to therapeutically modulate nerves at precise and focused treatment sites corresponding to the sites of rami extending through fissures, accessory foramina, and microforamina throughout the palatine bone (e.g., target region T shown in
FIG. 1B ). In certain embodiments, the targeted nerves are postganglionic parasympathetic nerves that go on to innervate the nasal mucosa. This selective neural treatment is also expected to decrease the rate of postoperative nasal crusting and dryness because it allows a clinician to titrate the degree of anterior denervation through judicious sparing of the rami orbitonasalis. Furthermore, embodiments of the present technology are also expected to maintain at least some sympathetic tone by preserving a portion of the sympathetic contributions from the deep petrosal nerve and internal maxillary periarteriolar plexi, leading to improved outcomes with respect to nasal obstruction. In addition, embodiments of the present technology are configured to target a multitude of parasympathetic neural entry locations (e.g., accessory foramen, fissures, and microforamina) to the nasal region to provide for a complete resection of all anastomotic loops, thereby reducing the rate of long-term re-innervation. -
FIG. 2 is a partially schematic view of a therapeutic neuromodulation system 200 (“system 200”) for therapeutically modulating nerves in a nasal region in accordance with an embodiment of the present technology. Thesystem 200 includes a therapeutic neuromodulation catheter ordevice 202, aconsole 204, and acable 206 extending therebetween. Thetherapeutic neuromodulation device 202 includes ashaft 208 having aproximal portion 208 a, adistal portion 208 b, ahandle 210 at aproximal portion 208 a of theshaft 208, and a therapeutic assembly orelement 212 at thedistal portion 208 b of theshaft 208. Theshaft 208 is configured to locate thedistal portion 208 b intraluminally at a treatment or target site within a nasal region proximate to postganglionic parasympathetic nerves that innervate the nasal mucosa. The target site may be a region, volume, or area in which the target nerves are located and may differ in size and shape depending upon the anatomy of the patient. For example, the target site may be a 3 cm area inferior to the SPF. In other embodiments, the target site may be larger, smaller, and/or located elsewhere in the nasal cavity to target the desired neural fibers. Thetherapeutic assembly 212 can include at least oneenergy delivery element 214 configured to therapeutically modulate the postganglionic parasympathetic nerves. In certain embodiments, for example, thetherapeutic assembly 212 can therapeutically modulate the postganglionic parasympathetic nerves branching from the pterygopalatine ganglion and innervating the nasal region and nasal mucosa, such as parasympathetic nerves (e.g., the posterior nasal nerves) traversing the SPF, accessory foramen, and microforamina of a palatine bone. - As shown in
FIG. 2 , thetherapeutic assembly 212 includes at least oneenergy delivery element 214 configured to provide therapeutic neuromodulation to the target site. In certain embodiments, for example, theenergy delivery element 214 can include one or more electrodes configured to apply electromagnetic neuromodulation energy (e.g., RF energy) to target sites. In other embodiments, theenergy delivery element 214 can be configured to provide therapeutic neuromodulation using various other modalities, such as cryotherapeutic cooling, ultrasound energy (e.g., high intensity focused ultrasound (“HIFU”) energy), microwave energy (e.g., via a microwave antenna), direct heating, high and/or low power laser energy, mechanical vibration, and/or optical power. In further embodiments, thetherapeutic assembly 212 can be configured to deliver chemicals or drugs to the target site to chemically ablate or embolize the target nerves. For example, thetherapeutic assembly 212 can include a needle applicator extending through an access portion of theshaft 208 and/or a separate introducer, and the needle applicator can be configured to inject a chemical into the target site to therapeutically modulate the target nerves, such as botox, alcohol, guanethidine, ethanol, phenol, a neurotoxin, or another suitable agent selected to alter, damage, or disrupt nerves. - In certain embodiments, the
therapeutic assembly 212 can include one or more sensors (not shown), such as one or more temperature sensors (e.g., thermocouples, thermistors, etc.), impedance sensors, and/or other sensors. The sensor(s) and/or theenergy delivery element 214 can be connected to one or more wires (not shown; e.g., copper wires) extending through theshaft 208 to transmit signals to and from the sensor(s) and/or convey energy to theenergy delivery element 214. - The
therapeutic neuromodulation device 202 can be operatively coupled to theconsole 204 via a wired connection (e.g., via the cable 206) and/or a wireless connection. Theconsole 204 can be configured to control, monitor, supply, and/or otherwise support operation of thetherapeutic neuromodulation device 202. Theconsole 204 can further be configured to generate a selected form and/or magnitude of energy for delivery to tissue or nerves at the target site via thetherapeutic assembly 212, and therefore theconsole 204 may have different configurations depending on the treatment modality of thetherapeutic neuromodulation device 202. For example, whentherapeutic neuromodulation device 202 is configured for electrode-based, heat-element-based, and/or transducer-based treatment, theconsole 204 can include anenergy generator 216 configured to generate RF energy (e.g., monopolar, bipolar, or multi-polar RF energy), pulsed electrical energy, microwave energy, optical energy, ultrasound energy (e.g., intraluminally-delivered ultrasound and/or HIFU), direct heat energy, radiation (e.g., infrared, visible, and/or gamma radiation), and/or another suitable type of energy. When thetherapeutic neuromodulation device 202 is configured for cryotherapeutic treatment, theconsole 204 can include a refrigerant reservoir (not shown), and can be configured to supply thetherapeutic neuromodulation device 202 with refrigerant. Similarly, when thetherapeutic neuromodulation device 202 is configured for chemical-based treatment (e.g., drug infusion), theconsole 204 can include a chemical reservoir (not shown) and can be configured to supply thetherapeutic neuromodulation device 202 with one or more chemicals. - As further shown in
FIG. 2 , thesystem 200 can further include acontroller 218 communicatively coupled to thetherapeutic neuromodulation device 202. In the illustrated embodiment, thecontroller 218 is housed in theconsole 204. In other embodiments, thecontroller 218 can be carried by thehandle 210 of thetherapeutic neuromodulation device 202, thecable 206, an independent component, and/or another portion of thesystem 200. Thecontroller 218 can be configured to initiate, terminate, and/or adjust operation of one or more components (e.g., the energy delivery element 214) of thetherapeutic neuromodulation device 202 directly and/or via theconsole 204. Thecontroller 218 can be configured to execute an automated control algorithm and/or to receive control instructions from an operator (e.g., a clinician). For example, thecontroller 218 and/or other components of the console 204 (e.g., memory) can include a computer-readable medium carrying instructions, which when executed by thecontroller 218, causes thetherapeutic assembly 202 to perform certain functions (e.g., apply energy in a specific manner, detect impedance, detect temperature, detect nerve locations or anatomical structures, etc.). A memory includes one or more of various hardware devices for volatile and non-volatile storage, and can include both read-only and writable memory. For example, a memory can comprise random access memory (RAM), CPU registers, read-only memory (ROM), and writable non-volatile memory, such as flash memory, hard drives, floppy disks, CDs, DVDs, magnetic storage devices, tape drives, device buffers, and so forth. A memory is not a propagating signal divorced from underlying hardware; a memory is thus non-transitory. - Further, the
console 204 can be configured to provide feedback to an operator before, during, and/or after a treatment procedure via evaluation/feedback algorithms 220. For example, the evaluation/feedback algorithms 220 can be configured to provide information associated with the temperature of the tissue at the treatment site, the location of nerves at the treatment site, and/or the effect of the therapeutic neuromodulation on the nerves at the treatment site. In certain embodiments, the evaluation/feedback algorithm 220 can include features to confirm efficacy of the treatment and/or enhance the desired performance of thesystem 200. For example, the evaluation/feedback algorithm 220, in conjunction with thecontroller 218, can be configured to monitor temperature at the treatment site during therapy and automatically shut off the energy delivery when the temperature reaches a predetermined maximum (e.g., when applying RF energy) or predetermined minimum (e.g., when applying cryotherapy). In other embodiments, the evaluation/feedback algorithm 220, in conjunction with thecontroller 218, can be configured to automatically terminate treatment after a predetermined maximum time, a predetermined maximum impedance rise of the targeted tissue (i.e., in comparison to a baseline impedance measurement), a predetermined maximum impedance of the targeted tissue), and/or other threshold values for biomarkers associated with autonomic function. This and other information associated with the operation of thesystem 200 can be communicated to the operator via a display 222 (e.g., a monitor or touchscreen) on theconsole 204 and/or a separate display (not shown) communicatively coupled to theconsole 204. - In various embodiments, the
therapeutic assembly 212 and/or other portions of thesystem 200 can be configured to detect various parameters of the heterogeneous tissue at the target site to determine the anatomy at the target site (e.g., tissue types, tissue locations, vasculature, bone structures, foramen, sinuses, etc.), locate nerves and/or other structures, and allow for neural mapping. For example, thetherapeutic assembly 212 can be configured to detect impedance, dielectric properties, temperature, and/or other properties that indicate the presence of neural fibers in the target region. As shown inFIG. 2 , theconsole 204 can include a nerve monitoring assembly 221 (shown schematically) that receives the detected electrical and/or thermal measurements of tissue at the target site taken by thetherapeutic assembly 212, and process this information to identify the presence of nerves, the location of nerves, and/or neural activity at the target site. This information can then be communicated to the operator via a high resolution spatial grid (e.g., on the display 222) and/or other type of display. The nerve monitoring assembly 221 can be operably coupled to theenergy delivery element 214 and/or other features of thetherapeutic assembly 212 via signal wires (e.g., copper wires) that extend through thecable 206 and through the length of theshaft 208. In other embodiments, thetherapeutic assembly 212 can be communicatively coupled to the nerve monitoring assembly 221 using other suitable communication means. - The nerve monitoring assembly 221 can determine neural locations and activity before therapeutic neuromodulation to determine precise treatment regions corresponding to the positions of the desired nerves, during treatment to determine the effect of the therapeutic neuromodulation, and/or after treatment to evaluate whether the therapeutic neuromodulation treated the target nerves to a desired degree. This information can be used to make various determinations related to the nerves proximate to the target site, such as whether the target site is suitable for neuromodulation. In addition, the nerve monitoring assembly 221 can also compare the detected neural locations and/or activity before and after therapeutic neuromodulation, and compare the change in neural activity to a predetermined threshold to assess whether the application of therapeutic neuromodulation was effective across the treatment site. For example, the nerve monitoring assembly 221 can determine electroneurogram (ENG) signals based on recordings of electrical activity of neurons taken by the
therapeutic assembly 212 before and after therapeutic neuromodulation. Statistically meaningful (e.g., measurable or noticeable) decreases in the ENG signal(s) taken after neuromodulation can serve as an indicator that the nerves were sufficiently ablated. - The
system 200 can further include achannel 224 extending along at least a portion of theshaft 208 and aport 226 at thedistal portion 208 b of the shaft in communication with theport 226. In certain embodiments, thechannel 224 is a fluid pathway to deliver a fluid to thedistal portion 208 b of theshaft 208 via theport 226. For example, thechannel 224 can deliver saline solution or other fluids to rinse the intraluminal nasal pathway during delivery of thetherapeutic assembly 212, flush the target site before applying therapeutic neuromodulation to the target site, and/or deliver fluid to the target site during energy delivery to reduce heating or cooling of the tissue adjacent to theenergy delivery element 214. In other embodiments, thechannel 224 allows for drug delivery to the treatment site. For example, a needle (not shown) can project through theport 226 to inject or otherwise deliver a nerve block, a local anesthetic, and/or other pharmacological agent to tissue at the target site. - The
therapeutic neuromodulation device 202 provides access to target sites deep within the nasal region, such as at the immediate entrance of parasympathetic fibers into the nasal cavity to therapeutically modulate autonomic activity within the nasal cavity. In certain embodiments, for example, thetherapeutic neuromodulation device 202 can position thetherapeutic assembly 212 inferior to the SPF at the site of access foramen and/or microforamina (e.g., as shown inFIGS. 1B and 1C ). By manipulating theproximal portion 208 a of theshaft 208 from outside the entrance of the nose, a clinician may advance theshaft 208 through the tortuous intraluminal path through the nasal cavity and remotely manipulate thedistal portion 208 b of theshaft 208 via thehandle 210 to position thetherapeutic assembly 212 at the target site. In certain embodiments, theshaft 208 can be a steerable device (e.g., a steerable catheter) with a small bend radius (e.g., a 5 mm bend radius, a 4 mm bend radius, a 3 mm bend radius or less) that allows the clinician to navigate through the tortuous nasal anatomy. The steerable shaft can further be configured to articulate in at least two different directions. For example, thesteerable shaft 208 can include dual pull wire rings that allow a clinician to form thedistal portion 208 b of theshaft 208 into an “S”-shape to correspond to the anatomy of the nasal region. In other embodiments, the articulatingshaft 208 can be made from a substantially rigid material (e.g., a metal material) and include rigid links at thedistal portion 208 b of theshaft 208 that resist deflection, yet allow for a small bend radius (e.g., a 5 mm bend radius, a 4 mm bend radius, a 3 mm bend radius or less). In further embodiments, thesteerable shaft 208 may be a laser-cut tube made from a metal and/or other suitable material. The laser-cut tube can include one or more pull wires operated by the clinician to allow the clinician to deflect thedistal portion 208 b of theshaft 208 to navigate the tortuous nasal anatomy to the target site. - In various embodiments, the
distal portion 208 b of theshaft 208 is guided into position at the target site via a guidewire (not shown) using an over-the-wire (OTW) or a rapid exchange (RX) technique. For example, the distal end of thetherapeutic assembly 212 can include a channel for engaging the guidewire. Intraluminal delivery of thetherapeutic assembly 212 can include inserting the guide wire into an orifice in communication with the nasal cavity (e.g., the nasal passage or mouth), and moving theshaft 208 and/or thetherapeutic assembly 212 along the guide wire until thetherapeutic assembly 212 reaches a target site (e.g., inferior to the SPF). - In further embodiments, the
therapeutic neuromodulation device 202 can be configured for delivery via a guide catheter or introducer sheath (not shown) with or without using a guide wire. The introducer sheath can first be inserted intraluminally to the target site in the nasal region, and thedistal portion 208 b of theshaft 208 can then be inserted through the introducer sheath. At the target site, thetherapeutic assembly 212 can be deployed through a distal end opening of the introducer sheath or a side port of the introducer sheath. In certain embodiments, the introducer sheath can include a straight portion and a pre-shaped portion with a fixed curve (e.g., a 5 mm curve, a 4 mm curve, a 3 mm curve, etc.) that can be deployed intraluminally to access the target site. In this embodiment, the introducer sheath may have a side port proximal to or along the pre-shaped curved portion through which thetherapeutic assembly 212 can be deployed. In other embodiments, the introducer sheath may be made from a rigid material, such as a metal material coated with an insulative or dielectric material. In this embodiment, the introducer sheath may be substantially straight and used to deliver thetherapeutic assembly 212 to the target site via a substantially straight pathway, such as through the middle meatus MM (FIG. 1A ). - Image guidance may be used to aid the clinician's positioning and manipulation of the
distal portion 208 b of theshaft 208 and thetherapeutic assembly 212. For example, as described in further detail below with respect toFIGS. 3A-3E , an endoscope (not shown) can be positioned to visualize the target site, the positioning of thetherapeutic assembly 212 at the target site, and/or thetherapeutic assembly 212 during therapeutic neuromodulation. In certain embodiments, thedistal portion 208 b of theshaft 208 is delivered via a working channel extending through an endoscope, and therefore the endoscope can provide direct in-line visualization of the target site and thetherapeutic assembly 212. In other embodiments, an endoscope is incorporated with thetherapeutic assembly 212 and/or thedistal portion 208 b of theshaft 208 to provide in-line visualization of theassembly 212 and/or the surrounding nasal anatomy. In still further embodiments, image guidance can be provided with various other guidance modalities, such as image filtering in the infrared (IR) spectrum to visualize the vasculature and/or other anatomical structures, computed tomography (CT), fluoroscopy, ultrasound, optical coherence tomography (OCT), and/or combinations thereof. Further, in some embodiments, image guidance components may be integrated with thetherapeutic neuromodulation device 202 to provide image guidance during positioning of thetherapeutic assembly 212. - Once positioned at the target site, the therapeutic modulation may be applied via the
energy delivery element 214 and/or other features of thetherapeutic assembly 212 to precise, localized regions of tissue to induce one or more desired therapeutic neuromodulating effects to disrupt parasympathetic motor sensory function. Thetherapeutic assembly 212 can selectively target postganglionic parasympathetic fibers that innervate the nasal mucosa at a target or treatment site proximate to or at their entrance into the nasal region. For example, thetherapeutic assembly 212 can be positioned to apply therapeutic neuromodulation at least proximate to the SPF (FIG. 1A ) to therapeutically modulate nerves entering the nasal region via the SPF. Thetherapeutic assembly 212 can also be positioned to inferior to the SPF to apply therapeutic neuromodulation energy across accessory foramen and microforamina (e.g., in the palatine bone) through which smaller medial and lateral branches of the posterior superior lateral nasal nerve enter the nasal region. The purposeful application of the energy at the target site may achieve therapeutic neuromodulation along all or at least a portion of posterior nasal neural fibers entering the nasal region. The therapeutic neuromodulating effects are generally a function of, at least in part, power, time, and contact between the energy delivery elements and the adjacent tissue. For example, in certain embodiments therapeutic neuromodulation of autonomic neural fibers are produced by applying RF energy at a power of about 2-20 W (e.g., 5 W, 7 W, 10 W, etc.) for a time period of about 1-20 sections (e.g., 5-10 seconds, 8-10 seconds, 10-12 seconds, etc.). The therapeutic neuromodulating effects may include partial or complete denervation via thermal ablation and/or non-ablative thermal alteration or damage (e.g., via sustained heating and/or resistive heating). Desired thermal heating effects may include raising the temperature of target neural fibers above a desired threshold to achieve non-ablative thermal alteration, or above a higher temperature to achieve ablative thermal alteration. For example, the target temperature may be above body temperature (e.g., approximately 37° C.) but less than about 90° C. (e.g., 70-75° C.) for non-ablative thermal alteration, or the target temperature may be about 100° C. or higher (e.g., 110° C., 120° C., etc.) for the ablative thermal alteration. Desired non-thermal neuromodulation effects may include altering the electrical signals transmitted in a nerve. - Hypothermic effects may also provide neuromodulation. As described in further detail below, for example, a cryotherapeutic applicator may be used to cool tissue at a target site to provide therapeutically-effective direct cell injury (e.g., necrosis), vascular injury (e.g., starving the cell from nutrients by damaging supplying blood vessels), and sublethal hypothermia with subsequent apoptosis. Exposure to cryotherapeutic cooling can cause acute cell death (e.g., immediately after exposure) and/or delayed cell death (e.g., during tissue thawing and subsequent hyperperfusion). Embodiments of the present technology can include cooling a structure positioned at or near tissue such that the tissue is effectively cooled to a depth where the targeted postganglionic parasympathetic nerves reside. For example, the cooling structure is cooled to the extent that it causes therapeutically effective, cryogenic posterior nasal nerve modulation.
- In certain embodiments, the
system 200 can determine the locations of the nerves, accessory foramen, and/or microforamina before therapy such that the therapeutic neuromodulation can be applied to precise regions including parasympathetic neural fibers. For example, thesystem 200 may identify a target site that has a length and/or width of about 3 mm inferior to the SPF, and thetherapeutic assembly 212 can apply therapeutic neuromodulation to the identified target site via one or more applications of therapeutic neuromodulation. In other embodiments, the target site may be smaller or larger (e.g., a 3 cm-long target region) based on the detected locations of neural fibers and foramena. This neural and anatomical mapping allows thesystem 200 to accurately detect and therapeutically modulate the postganglionic parasympathetic neural fibers that innervate the mucosa at the numerous neural entrance points into the nasal cavity. Further, because there are not any clear anatomical markers denoting the location of the SPF, accessory foramen, and microforamina, the neural mapping allows the operator to identify and therapeutically modulate nerves that would otherwise be unidentifiable without intricate dissection of the mucosa. In addition, anatomical mapping can also allow the operator to identify certain structures that the operator may wish to avoid during therapeutic neural modulation (e.g., certain arteries). - Sufficiently modulating at least a portion of the parasympathetic nerves is expected to slow or potentially block conduction of autonomic neural signals to the nasal mucosa to produce a prolonged or permanent reduction in nasal parasympathetic activity. This is expected to reduce or eliminate activation or hyperactivation of the submucosal glands and venous engorgement and, thereby, reduce or eliminate the symptoms of rhinosinusitis. Further, because the
system 200 applies therapeutic neuromodulation to the multitude of branches of the posterior nasal nerves rather than a single large branch of the posterior nasal nerve branch entering the nasal cavity at the SPF, thesystem 200 provides a more complete disruption of the parasympathetic neural pathway that affects the nasal mucosa and results in rhinosinusitis. Accordingly, thesystem 200 is expected to have enhanced therapeutic effects for the treatment of rhinosinusitis and reduced re-innervation of the treated mucosa. - In other embodiments, the
system 200 can be configured to therapeutically modulate nerves and/or other structures to treat different indications. As discussed in further detail below, for example, thesystem 200 can be used to locate and/or therapeutically modulate nerves that innervate the para-nasal sinuses to treat chronic sinusitis. In further embodiments, thesystem 200 and the devices disclosed herein can be configured therapeutically modulate the vasculature within the nasal anatomy to treat other indications, such as epistaxis (i.e., excessive bleeding from the nose). For example, thesystem 200 and the therapeutic neuromodulation devices described herein can be used to apply therapeutically effective energy to arteries (e.g., the sphenopalatine artery and its branches) as they enter the nasal cavity (e.g., via the SPF, accessory foramen, etc.) to partially or completely coagulate or ligate the arteries. In other embodiments, thesystem 200 can be configured to partially or completely coagulate or ligate veins and/or other vessels. For such embodiments in which thetherapeutic assembly 212 ligates or coagulates the vasculature, thesystem 200 would be modified to deliver energy at significantly higher power (e.g., about 100 W) and/or longer times (e.g., 1 minute or longer) than would be required for therapeutic neuromodulation. In various embodiments, the system 100 could apply the anatomical mapping techniques disclosed herein to locate or detect the targeted vasculature and surrounding anatomy before, during, and/or after treatment. -
FIGS. 3A-3E are partial cut-away side views illustrating various approaches for delivering a distal portion of thetherapeutic neuromodulation device 202 ofFIG. 2 to a target site within a nasal region in accordance with embodiments of the present technology. As shown inFIG. 3A , in various embodiments thedistal portion 208 b of theshaft 208 extends into the nasal passage NP, through the inferior meatus IM between the inferior turbinate IT and the nasal sill NS, and around the posterior portion of the inferior turbinate IT where thetherapeutic assembly 212 is deployed at a treatment site. As shown inFIG. 3A , the treatment site can be located proximate to the access point or points of postganglionic parasympathetic nerves (e.g., branches of the posterior nasal nerve and/or other parasympathetic neural fibers that innervate the nasal mucosa) into the nasal cavity. In other embodiments, the target site can be elsewhere within the nasal cavity depending on the location of the target nerves. Anendoscope 330 and/or other visualization device is delivered proximate to the target site by extending through the nasal passage NP and through the middle meatus MM between the inferior and middle turbinates IT and MT. From the visualization location within the middle meatus MM, theendoscope 330 can be used to visualize the treatment site, surrounding regions of the nasal anatomy, and thetherapeutic assembly 212. - As further shown in
FIG. 3A , theshaft 208 of thetherapeutic neuromodulation device 202 can include apositioning member 332 positioned proximal to thetherapeutic assembly 212 and the target site. In the illustrated embodiment, the positioningmember 332 is a balloon that is expanded in an opening (e.g., in one of the meatuses) against opposing structures (e.g., between the turbinates) to consistently hold thedistal portion 208 b of theshaft 208 in a desired position relative to the target site and provide stability for deployment of thetherapeutic assembly 212. In other embodiments, the positioningmember 332 may include other expandable structures (e.g., a mesh baskets) or anchor features that can be deployed to maintain a desired position of theshaft 208 within the nasal cavity. In further embodiments, the positioningmember 332 can be positioned distal to thetherapeutic assembly 212 and expanded in a region distal to thetherapeutic assembly 212 and the treatment site. In still further embodiments, the positioningmember 332 is positioned on an introducer sheath (not shown) through which theshaft 208 and/or other devices (e.g., a fluid line for delivery of saline or local anesthetics, an endoscope, a sensor, etc.) can pass. The positioningmember 332 can be positioned proximal to the target site (e.g., similar to the position shown inFIG. 3A ) or distal to the treatment site. When positioned distally, the introducer sheath can include a side exit port through which thetherapeutic assembly 212 and other features can be deployed at the target site. When thepositioning member 332 is positioned on the introducer sheath, the positioningmember 332 can provide stability for delivery and deployment of thedistal portion 208 b of theshaft 208 and thetherapeutic assembly 212. The positioningmember 332 can be incorporated on theshaft 208, an associated introducer sheath, and/or other deliver features of the system 200 (FIG. 2 ) when thetherapeutic assembly 212 is delivered through different intraluminal passageways. -
FIG. 3B illustrates a differ embodiment in which thedistal portion 208 b of theshaft 208 extends into the nasal passage NP, through the middle meatus MM between the inferior turbinate IT and the middle turbinate, and in posterior direction where thetherapeutic assembly 212 is deployed at a treatment site. In this embodiment, theendoscope 330 and/or other visualization device is delivered alongside theshaft 208 through the same intraluminal pathway as thetherapeutic assembly 212. The pathway through the middle meatus MM may provide for generally straight access to the target site depending on the specific region of interest and anatomical variations of the patient. Accordingly, an approach through the middle meatus MM may require less steering and/or articulation of theshaft 208 and theendoscope 330. Further, because thedistal portion 208 b of theshaft 208 and theendoscope 330 travel along the same delivery path, the endoscope can provide in-line or side-by-side visualization of thetherapeutic assembly 212. - Similar to the embodiment shown in
FIG. 3B ,FIG. 3C illustrates another intraluminal pathway in which thedistal portion 208 b of theshaft 208 and theendoscope 330 travel next to each other such that theendoscope 330 can provide in-line or side-by-side visualization of thedistal portion 208 b of theshaft 208, thetherapeutic assembly 212, and/or the nasal anatomy. In the embodiment shown inFIG. 3C , however, the intraluminal pathway extends through the inferior meatus IM to a posterior treatment site. - As shown in
FIG. 3D , in other embodiments thedistal portion 208 b of theshaft 208 extends to the treatment site via the middle meatus MM, and theendoscope 330 extends through the inferior meatus IM to a position proximate to the target site. In this embodiment, theendoscope 330 may have an articulating, steerable, or curved distal end that directs theendoscope 330 superiorly to visualize the nasal anatomy and thetherapeutic assembly 332 at the target site. For example, the distal end portion of theendoscope 330 can be configured to bend at least 30° to visualize the treatment site. - As shown in
FIG. 3E , in further embodiments thedistal portion 208 b of theshaft 208 can be delivered to the treatment site via the mouth. In this embodiment, therapeutic neuromodulation can be applied at a treatment site posterior to the nasal cavity (e.g., posterior to the SPF). The endoscope 330 (not shown) can extend into the nasal passage NP, through the middle meatus MM or the inferior meatus IM to a position proximate to the treatment site. Alternatively, the endoscope 330 (not shown) can travel along the same pathway as theshaft 208. -
FIG. 4 is an isometric view of a distal portion of atherapeutic neuromodulation device 402 configured in accordance with an embodiment of the present technology. Thetherapeutic neuromodulation device 402 can be used in conjunction with thesystem 200 described above with respect toFIGS. 2-3E . As shown inFIG. 4 , thetherapeutic neuromodulation device 402 can include ashaft 408 having a proximal portion (not shown) and adistal portion 408 b, and atherapeutic assembly 412 at thedistal portion 408 b of theshaft 408. Thetherapeutic assembly 412 is transformable between a low-profile delivery state to facilitate intraluminal delivery of thetherapeutic assembly 412 to a treatment site within the nasal region and an expanded state (shown inFIG. 4 ). Thetherapeutic assembly 412 includes a plurality ofstruts 440 that are spaced apart from each other to form a frame orbasket 442 when thetherapeutic assembly 412 is in the expanded state. Thestruts 440 can carry one or more energy delivery elements, such as a plurality ofelectrodes 444. In the expanded state, thestruts 440 can position at least two of theelectrodes 444 against tissue at a target site within the nasal region (e.g., proximate to the palatine bone inferior to the SPF). Theelectrodes 444 can apply bipolar or multi-polar radiofrequency (RF) energy to the target site to therapeutically modulate postganglionic parasympathetic nerves that innervate the nasal mucosa proximate to the target site. In various embodiments, theelectrodes 444 can be configured to apply pulsed RF energy with a desired duty cycle (e.g., 1 second on/0.5 seconds off) to regulate the temperature increase in the target tissue. - In the embodiment illustrated in
FIG. 4 , thebasket 442 includes eightbranches 446 spaced radially apart from each other to form at least a generally spherical structure, and each of thebranches 446 includes twostruts 440 positioned adjacent to each other. In other embodiments, however, thebasket 442 can include fewer than eight branches 446 (e.g., two, three, four, five, six, or seven branches) or more than eightbranches 446. In further embodiments, eachbranch 446 of thebasket 442 can include asingle strut 440, more than twostruts 440, and/or the number ofstruts 440 per branch can vary. In still further embodiments, thebranches 446 and struts 440 can form baskets or frames having other suitable shapes for placing theelectrodes 444 in contact with tissue at the target site. For example, when in the expanded state, thestruts 440 can form an ovoid shape, a hemispherical shape, a cylindrical structure, a pyramid structure, and/or other suitable shapes. - As shown in
FIG. 4 , thetherapeutic assembly 412 can further include an internal orinterior support member 448 that extends distally from thedistal portion 408 b of theshaft 408. Adistal end portion 450 of thesupport member 448 can support the distal end portions of thestruts 440 to form the desired basket shape. For example, as shown inFIG. 4 , thestruts 440 can extend distally from thedistal portion 408 b of theshaft 408 and the distal end portions of thestruts 440 can attach to thedistal end portion 450 of thesupport member 448. In certain embodiments, thesupport member 448 can include an internal channel (not shown) through which electrical connectors (e.g., wires) coupled to theelectrodes 444 and/or other electrical features of thetherapeutic element 412 can run. In various embodiments, theinternal support member 448 can also carry an electrode (not shown) at thedistal end portion 450 and/or along the length of thesupport member 448. - The
basket 442 can transform from the low-profile delivery state to the expanded state (FIG. 4 ) by manipulating a handle (e.g., thehandle 210 ofFIG. 2 ) and/or other feature at the proximal portion of theshaft 408 and operably coupled to thebasket 442. For example, to move thebasket 442 from the expanded state to the delivery state, an operator can push thesupport member 448 distally to bring thestruts 440 inward toward thesupport member 448. An introducer or guide sheath (not shown) can be positioned over the low-profiletherapeutic assembly 412 to facilitate intraluminal delivery or removal of thetherapeutic assembly 412 from or to the target site. In other embodiments, thetherapeutic assembly 412 is transformed between the delivery state and the expanded state using other suitable means. - The individual struts 440 can be made from a resilient material, such as a shape-memory material (e.g., Nitinol) that allows the
struts 440 to self-expand into the desired shape of thebasket 442 when in the expanded state. In other embodiments, thestruts 440 can be made from other suitable materials and/or thetherapeutic assembly 412 can be mechanically expanded via a balloon or by proximal movement of thesupport member 448. Thebasket 442 and the associated struts 440 can have sufficient rigidity to support theelectrodes 444 and position or press theelectrodes 444 against tissue at the target site. In addition, the expandedbasket 442 can press against surrounding anatomical structures proximate to the target site (e.g., the turbinates, the palatine bone, etc.) and the individual struts 440 can at least partially conform to the shape of the adjacent anatomical structures to anchor thetherapeutic element 412 at the treatment site during energy delivery. In addition, the expansion and conformability of thestruts 440 can facilitate placing theelectrodes 444 in contact with the surrounding tissue at the target site. - At least one
electrode 444 is disposed onindividual struts 440. In the illustrated embodiment, twoelectrodes 444 are positioned along the length of eachstrut 440. In other embodiments, the number ofelectrodes 444 onindividual struts 440 be only one, more than two, zero, and/or the number ofelectrodes 444 on thedifferent struts 440 can vary. Theelectrodes 444 can be made from platinum, iridium, gold, silver, stainless steel, platinum-iridium, cobalt chromium, iridium oxide, polyethylenedioxythiophene (“PEDOT”), titanium, titanium nitride, carbon, carbon nanotubes, platinum grey, Drawn Filled Tubing (“DFT”) with a silver core made by Fort Wayne Metals of Fort Wayne, Ind., and/or other suitable materials for delivery RF energy to target tissue. - In certain embodiments, each
electrode 444 can be operated independently of theother electrodes 444. For example, each electrode can be individually activated and the polarity and amplitude of each electrode can be selected by an operator or a control algorithm (e.g., executed by thecontroller 218 ofFIG. 2 ). Various embodiments of such independently controlledelectrodes 444 are described in further detail below with reference toFIGS. 5A-5G . The selective independent control of theelectrodes 444 allows thetherapeutic assembly 412 to deliver RF energy to highly customized regions. For example, a select portion of theelectrodes 444 can be activated to target neural fibers in a specific region while theother electrodes 444 remain inactive. In certain embodiments, for example,electrodes 444 may be activated across the portion of thebasket 442 that is adjacent to tissue at the target site, and theelectrodes 444 that are not proximate to the target tissue can remain inactive to avoid applying energy to non-target tissue. Such configurations facilitate selective therapeutic modulation of nerves on the lateral nasal wall within one nostril without applying energy to structures in other portions of the nasal cavity. - The
electrodes 444 can be electrically coupled to an RF generator (e.g., thegenerator 216 ofFIG. 2 ) via wires (not shown) that extend from theelectrodes 444, through theshaft 408, and to the RF generator. When each of theelectrodes 444 is independently controlled, eachelectrode 444 couples to a corresponding wire that extends through theshaft 408. In other embodiments,multiple electrodes 444 can be controlled together and, therefore,multiple electrodes 444 can be electrically coupled to the same wire extending through theshaft 408. The RF generator and/or components operably coupled (e.g., a control module) thereto can include custom algorithms to control the activation of theelectrodes 444. For example, the RF generator can deliver RF power at about 200-300 W to theelectrodes 444, and do so while activating theelectrodes 444 in a predetermined pattern selected based on the position of thetherapeutic element 412 relative to the treatment site and/or the identified locations of the target nerves. In other embodiments, the RF generator delivers power at lower levels (e.g., less than 15 W, 15-50 W, 50-150 W, etc.) and/or higher power levels. - As shown in
FIG. 4 , thetherapeutic assembly 412 can further include one ormore temperature sensors 452 disposed on thestruts 440 and/or other portions of thetherapeutic assembly 412 and configured to detect the temperature adjacent to thetemperature sensor 452. Thetemperature sensors 452 can be electrically coupled to a console (e.g., theconsole 204 ofFIG. 2 ) via wires (not shown) that extend through theshaft 408. In various embodiments, thetemperature sensors 452 can be positioned proximate to theelectrodes 444 to detect the temperature at the interface between tissue at the target site and theelectrodes 444. In other embodiments, thetemperature sensors 452 can penetrate the tissue at the target site (e.g., a penetrating thermocouple) to detect the temperature at a depth within the tissue. The temperature measurements can provide the operator or the system with feedback regarding the effect of the therapeutic neuromodulation on the tissue. For example, in certain embodiments the operator may wish to prevent or reduce damage to the tissue at the treatment site (e.g., the nasal mucosa), and therefore thetemperature sensors 452 can be used to determine if the tissue temperature reaches a predetermined threshold for irreversible tissue damage. Once the threshold is reached, the application of therapeutic neuromodulation energy can be terminated to allow the tissue to remain intact. In certain embodiments, the energy delivery can automatically terminate based on an evaluation/feedback algorithm (e.g., the evaluation/feedback algorithm 220 ofFIG. 2 ) stored on a console (e.g., theconsole 204 ofFIG. 2 ) operably coupled to thetemperature sensors 452. -
FIGS. 5A-5G are isometric views of examples of electrode configurations of therapeutic neuromodulation devices (identified individually as first through fourth therapeutic neuromodulation devices 502 a-502 d, respectively; referred to collectively as therapeutic neuromodulation devices 502) for therapeutic neuromodulation in accordance with embodiments of the present technology. The therapeutic neuromodulation devices 502 ofFIGS. 5A-5G can include features generally similar to the features of thetherapeutic neuromodulation device 402 ofFIG. 4 . For example, the therapeutic neuromodulation devices 502 include a plurality ofstruts 440 that form abasket 442 when in an expanded state, and a plurality ofelectrodes 444 disposed on one or more of thestruts 440. In the illustrated embodiments, the first through third therapeutic neuromodulation device 502 a-c shown inFIGS. 5A-5E include asingle strut 440 corresponding to eachbranch 446 of thebasket 442, whereas the fourththerapeutic neuromodulation device 502 d shown inFIGS. 5F and 5G includes twoadjacent struts 440 in eachbranch 446 of thebasket 442. In other embodiments, however, thebranches 446 of the therapeutic neuromodulation devices 502 may have different quantities ofstruts 440, and apply RF energy in the same manner as described below with reference toFIGS. 5A-5G . As shown inFIGS. 5A-5G , theelectrodes 444 can be independently controlled and activated via instructions from a controller (e.g., thecontroller 218 ofFIG. 2 ) or a generator (e.g., thegenerator 216 ofFIG. 2 ) to apply RF energy across selected regions or segments of thetherapeutic assembly 412. - In the embodiment shown in
FIG. 5A , twoelectrodes 444 of thetherapeutic assembly 412 are activated in the firsttherapeutic neuromodulation device 502 a. More specifically, afirst electrode 444 a on afirst strut 440 a is activated at a positive polarity, and asecond electrode 444 b on asecond strut 440 b spaced radially apart from thefirst strut 440 a is activated at a negative polarity. The remainder of theelectrodes 444 remain inactive. Accordingly, as indicated by the arrows, current can flow from thefirst electrode 444 a to thesecond electrode 444 b through the target tissue across a circumferential or peripheral segment of thetherapeutic assembly 412. This configuration may be used to therapeutically modulate nerves positioned proximate to the peripheral segment. In other embodiments, different oradditional electrodes 444 can be activated to have a selected polarity to apply therapeutic neuromodulation across selected regions of thetherapeutic assembly 412 in a predetermined manner. - In the embodiment shown in
FIG. 5B , the firsttherapeutic neuromodulation device 502 a is configured to have three selectivelyactive electrodes 444. Afirst electrode 444 a on afirst strut 440 a is activated at a positive polarity, and second andthird electrodes third struts electrodes 444 remain inactive. As indicated by the arrows, current can flow through the tissue from thefirst electrode 444 a to the second andthird electrodes therapeutic assembly 412, and therefore therapeutically modulate nerves positioned proximate to the peripheral segment. In the illustrated embodiment, the second and thirdactivated electrodes struts first strut 440 a carrying the firstactive electrode 444 a. In other embodiments, however,electrodes 444 positioned onstruts 440 spaced further from thefirst strut 440 a to apply energy across a larger and/or wider segment of thetherapeutic assembly 412. - In the embodiment shown in
FIG. 5C , all of theelectrodes 444 in a firsthemispherical region 501 a of thetherapeutic assembly 412 are activated, while theelectrodes 444 of the secondhemispherical region 501 b are not activated. A first electrode on afirst strut 440 a is selectively activated at a positive polarity, and a plurality of electrodes 444 (identified individually as second throughfifth electrodes 444 b-444 e, respectively) within the firsthemispherical region 501 a are selectively activated at a negative polarity such that RF energy is applied across the firsthemispherical region 501 a. This electrode activation configuration may be used to apply RF energy across one side of thebasket 442 to therapeutically modulate nerves on the lateral nasal wall in one nostril. When thetherapeutic assembly 412 is positioned in the other nostril, a different set ofelectrodes 444 can be activated across a hemispherical region of thetherapeutic assembly 412 based on the orientation of thebasket 442 with respect to the lateral nasal wall. Further, because thebasket 442 has a generally symmetrical shape (e.g., circular, oval, etc.) and because theelectrodes 444 can be selectively activated, the orientation of thebasket 442 with respect to the target site on the lateral nasal wall does not matter. Instead, the operator can deploy thetherapeutic assembly 412 at the target site irrespective of orientation, and selectively activate theelectrodes 444 in a desired arrangement to apply RF energy across the target site. - In the embodiment shown in
FIG. 5D , the secondtherapeutic neuromodulation device 502 b is configured to selectively control the polarity of a plurality of theelectrodes 444 across at least a portion of thetherapeutic assembly 412 to apply RF energy in a sesquipolar fashion (i.e., the sequential or transient bipolar pairing of electrodes). In the illustrated embodiment, afirst electrode 444 a is biased at a positive polarity and second throughseventh electrodes 444 b-444 g are controlled to have negative polarities. The second throughseventh electrodes 444 b-444 g are spaced substantially equal distances apart from thefirst electrode 444 a such that theelectrodes 444 are dimensionally predisposed to multiplex in sequence. In operation, the first throughseventh electrodes 444 a-444 g are concurrently activated. However, rather than all of thenegative electrodes 444 pairing or multiplexing with the positivefirst electrode 444 a simultaneously, thefirst electrode 444 a will pair with the individualnegative electrodes 444 in a sequential manner based on the path of least resistance. This path of least resistance is dictated by the natural anatomy of the treatment site in contact with theelectrodes 444. For example, based on the anatomy at the target site, thefirst electrode 444 a may initially pair with thesecond electrode 444 b. After this initial pairing preference has dissipated, a second pairing (e.g., with thethird electrode 444 c) will occur based on the path of least resistance. Thefirst electrode 444 a will continue to sequentially pair with the remaining activated negative electrodes in a similar manner until a threshold is reached and theelectrodes 444 are in a state of equilibrium in which there is homogenized current flow between all of the electrode pairs. With each sequential pairing, thetherapeutic assembly 412 increases the size of the ablation zone (i.e., the region in which therapeutic neuromodulation energy is applied). As indicated by the numbers 1-6 inFIG. 5D , this sequential pairing of theelectrodes 444 may occur in a circular direction (e.g., in a counter clockwise or clockwise direction) based on the impedance changes between theelectrodes 444. In other embodiments, the sequential pairing ofelectrodes 444 may occur in a different pattern based on the anatomical surroundings and/or the positioning of theelectrodes 444. For example, in the illustrated embodiment, the activatedelectrodes 444 are positioned in a quadrant of thetherapeutic element 412 with equal radial distances between the individual electrode pairs. In other embodiments, the activatedelectrodes 444 can be positioned across larger or smaller regions of thetherapeutic element 412 to apply energy across larger or smaller treatment regions. - The sesquipolar application of RF energy allows the
therapeutic assembly 412 to intelligently apply RF energy across a target site to therapeutically modulate nerves proximate to the treatment site. For example, when in an equidistant radial relationship to each other, the naturally occurring impedance changes between the electrode pairs cause thetherapeutic assembly 412 to radially increase the zone of energy application with each pairing. In other embodiments, theelectrodes 444 can be configured to sequentially pair with each other in a manner such that the zone of energy application increases in a transverse and/or longitudinal manner based on the naturally occurring impedance changes between theelectrodes 444. Further, due to the sequential impedance-based pairing of theelectrodes 444, the sesquipolar arrangement of thetherapeutic assembly 412 can inherently limit the energy applied to tissue at the target site because once the impedance exceeds a threshold in one electrode pairing, the next electrode pairing will occur with a lower impedance. In other embodiments, a controller (e.g., thecontroller 218 ofFIG. 2 ) can include instructions (e.g., software) that provides for the sequential pairing of electrodes in a radial, transverse, longitudinal, and/or spiral manner. - In further embodiments, portions of the
struts 440 themselves can define theelectrodes 444. In this embodiment, thestruts 440 are made from an electrically conductive material and coated with an insulative material (e.g., poly-xylene polymers, including Paralyene C). Portions of thestruts 440 can remain uncoated to defineelectrodes 444. The locations of the uncoated portions of the struts 440 (i.e., the electrodes 444) can be selected to provide a desired neuromodulation pattern. For example, the uncoated portions can be spaced equally apart from acentral electrode 444 to allow for sesquipolar RF application. In this embodiment, theconductive struts 440 serve as the electrical connectors and, therefore, thetherapeutic assembly 412 does not require as many wires as if theelectrodes 444 were separate elements positioned on thestruts 440. - In the embodiment shown in
FIG. 5E , the thirdtherapeutic neuromodulation device 502 c includes areturn electrode 503 at thedistal end portion 450 of thesupport member 448 and selective polarity control of theindividual electrodes 444 on thestruts 440 to provide radial multiplexing of theelectrodes 444. Thereturn electrode 503 has a negative polarity, and theother electrodes 444 have a positive polarity. In the illustrated embodiment, all of theelectrodes 444 are activated, but in other embodiments theelectrodes 444 can be selectively activated based on a desired energy application zone. As indicated by the arrows, this configuration applies RF energy across a distal hemispherical region of thebasket 442. In other embodiments, thereturn electrode 503 can be positioned elsewhere on thetherapeutic assembly 412, and theelectrodes basket 442. In further embodiments, thereturn electrode 503 can be activated in conjunction with two or more of theelectrodes 444 on the struts to apply RF energy in a sesquipolar manner. - In the embodiment shown in
FIG. 5F , the fourththerapeutic neuromodulation device 502 d includesbranches 446 having twoadjacent struts 440, and theelectrodes 444 on the adjacent struts are spaced apart from each other in a longitudinal direction and selectively activated to apply energy in a radial direction across discrete zones. For example, afirst electrode 444 a on afirst strut 440 a of afirst branch 446 a may be selectively activated to have a first polarity and asecond electrode 444 b on the adjacentsecond strut 440 b of thefirst branch 446 a may be selectively activated to have a second polarity opposite the first polarity. As indicated by the arrows inFIG. 5F , the first andsecond electrodes therapeutic assembly 412. - As further shown in
FIG. 5F , the individual struts 440 can includemultiple electrodes 444 disposed thereon, and theadjacent strut 440 in thesame branch 446 can have a corresponding quantity ofelectrodes 444 to allow for bipolar coupling of each of the electrode pairs along discrete regions of thebranch 446. In certain embodiments, the electrodes of onestrut 440 can all have the same polarity (e.g., coupled to a first wire; not shown), and theelectrodes 444 of theadjacent strut 440 in thesame branch 446 can all have the opposite polarity (e.g., coupled to a second wire; not shown). In other embodiments, theelectrodes 444 on anindividual strut 440 can be independently controlled to have a desired polarity. - In various embodiments, the electrode pairing configurations shown in
FIG. 5F can be used to detect impedance across selected regions of thetherapeutic assembly 412 defined by the bipolar electrode pairs. The impedance measurements can then be used to identify the presence of neural fibers in the selected regions. If nerves are detected in one or more specific regions associated with an electrode pair, the same electrode pair can be used to apply RF energy to that region and therapeutically modulate the nerves in that region. - In the embodiment shown in
FIG. 5G , the fourththerapeutic neuromodulation device 502 d is configured to selectively control the polarity of a plurality of theelectrodes 444 across at least a portion of thetherapeutic assembly 412 to apply RF energy in a multi-polar manner in a circular or spiral pattern. As shown inFIG. 5G ,electrodes 444 of onebranch 446 can be activated to have negative polarities andelectrodes 444 of anotherbranch 446 can be activated to have positive polarities. The arrangement of theelectrodes 444 and the variable distances between theelectrodes 444 can differ such that the energy application zone has a different shape or pattern. In other embodiments, the positive andnegative electrodes 444 are spaced apart from each other at variable distances. Impedance changes resulting from the surrounding anatomical structures causes the electrodes to pair with each other in a sequential manner and, thereby, continuously increase the zone or region in which energy is applied in a radial direction and in a generally spiral manner. - Energy generally travels deeper into the adjacent target tissue the further the positive and negative electrode pairs are spaced apart from each other. Thus, the depth of influence of the therapeutic neuromodulation energy is expected to increase as the coupled electrode pairs are spaced further apart from each other on the
basket 442. In the embodiment illustrated inFIG. 5G , for example, electrode pairs at the distal and proximal regions of thebasket 442 apply energy to shallower depths in the target tissue than the electrode pairs positioned on the medial region of thebasket 442. Accordingly, the electrodes pairs positioned closer together can therapeutically modulate nerves at shallower depths than the electrode pairs spaced further apart from each other. As shown in the illustrated embodiment, some of theelectrodes 444 and/orentire branches 446 of thebasket 442 can remain inactive to achieve the desired depth of energy application and/or neuromodulation pattern. - Various embodiments of the present technology can include features that measure bio-electric, dielectric, and/or other properties of heterogeneous tissue at target sites within the nasal region to determine the presence, location, and/or activity of neural fibers and, optionally, map the locations of the detected nerves. The features discussed below can be incorporated into any of the systems and/or devices disclosed herein to provide an accurate depiction of nerves at the target site.
- Neural detection can occur (a) before the application of a therapeutic neuromodulation energy to determine the presence or location of nerves at the target site and/or record baseline levels of neural activity; (b) during therapeutic neuromodulation to determine the effect of the energy application on the neural fibers at the treatment site; and/or (c) after therapeutic neuromodulation to confirm the efficacy of the treatment on the targeted nerves. Due to the anatomical variations of the number and locations of the parasympathetic neural fibers that innervate the nasal cavity and the numerous access points (e.g., the SPF, accessory foramen, and microforamina) through which they enter the nasal cavity, such neural detection and mapping can provide an accurate representation of the neural anatomy to adequately treat the parasympathetic nerves, not just the one or two main branches of the posterior nasal nerves traversing the SPF.
- In certain embodiments, the systems disclosed herein can use bioelectric measurements, such as impedance, resistance, voltage, current density, and/or other parameters (e.g., temperature) to determine the anatomy, in particular the neural anatomy, at the target site. The location of the neural anatomy can then be used to determine where the treatment site(s) should be with respect to various anatomical structures for therapeutically effective neuromodulation of the targeted parasympathetic nasal nerves. For example, the information can be used to determine the treatment site(s) with respect to the location of the turbinates or meatuses.
- The bioelectric properties can be detected via electrodes (e.g., the
electrodes 444 of the therapeutic neuromodulation devices 402-502 d ofFIGS. 4-5G ). The electrode pairings on a device (e.g., thetherapeutic assemblies 412 described with respect toFIGS. 4-5G ) can be selected to obtain the bioelectric data at specific zones or regions and at specific depths of the targeted regions.FIGS. 6A and 6B , for example, are partially schematic diagrams illustrating configurations ofelectrodes 644 for nerve detection configured in accordance with embodiments of the present technology. As shown inFIG. 6A , the further theelectrodes 644 are apart from each other, the deeper into the tissue the current flows. Accordingly,electrodes 644 can be selectively activated based on the depth at which the desired measurements should be taken. As shown inFIG. 6B , the spacing between theelectrodes 644 along a plane (e.g., the surface of the tissue, can affect the region in which the measurements are taken. Thus,electrodes 644 can be selectively activated to obtain information (e.g., impedance) at a desired depth and across a desired region. In other embodiments, the bioelectric properties can be detected using optical coherent tomography (OCT), ultrasound, and/or other suitable detection modalities. - The measurement of bioelectric properties can provide information associated not only with neural fiber locations, but also the identification of gross anatomy (e.g., turbinates, meatuses, bone, etc.), which can be used to facilitate system delivery and identification of the target nerves with respect to the gross anatomy. For example, gross target identification can be determined by evaluating of the incident electromagnetic field on soft and hard tissues within the nasal region, which is in turn dependent upon the local geometry and the dielectric properties of those features. For example, because of the layered structure of the anatomy of the nasal cavity (e.g., nasal mucosa, submucosa, periosteum, and bony plates), there are large distinctions in the relative conductance of the soft and hard tissues that can be used to differentiate the “deeper” mucosal tissue on the turbinates from the “shallow” tissue off the turbinates.
- In certain embodiments, measurements for neuro-mapping can be obtained by applying a constant current to electrodes and measuring the voltage differences between adjacent pairs of electrodes to produce a spectral profile or map the tissues at the target site. Impedance data can be obtained while applying high, medium, and/or low frequencies to the target tissue. At high frequencies, the current passes directly through cell membranes, and the resultant measurements are indicative of the tissue and liquids both inside and outside the cells. At low frequencies, cell membranes impede current flow to provide different defining characteristics of the tissue. Accordingly, bioimpedance can be used to measure targeted shapes or electrical properties of tissue and/or other structures of the nasal cavity. In addition, complex neural mapping can be performed using frequency difference reconstruction, which requires measurement data (e.g., impedance) at two different frequencies.
- When detecting neural locations and activity via bioelectric properties, the spatial orientation, direction, and activity of the detected nerve bundles can be used to further identify and characterize the nerves. For example, the measured bioelectric properties can distinguish between terminating axons (i.e., entering a detection region, but not exiting), branching axons (i.e., entering the detection region and increasing in number upon exiting the detecting region), travelling axons (i.e., entering and exiting the detection region within no change in geometry or numerical value), and/or other properties of nerves. In addition, axon orientations relative to the electrode array can be identified to indicate whether the neural fibers extend parallel (X direction), perpendicular (Y direction), depth penetrating (Z direction), and/or any relative position or angulation to these parameters. This information can then be used to selectively treat specific neural fibers. For example, selected electrode configurations can be applied to treat a specific region and/or the therapeutic assembly can be moved or manipulated to treat the nerves from a different orientation or location.
- In certain embodiments, temperature measurements can be taken to determine the effect of therapeutic neuromodulation on nasal tissue.
FIG. 7 , for example, is a graph illustrating threshold levels of electrical conductivity of nasal tissue with respect to temperature. Afirst curve 701 depicts the electrical conductivity (σ) of tissue in response to temperature and indicates that a temperature of about 70° C. corresponds to a first threshold of the irreversible change in impedance of the tissue. Asecond curve 703 shows that the electrical conductivity of the tissue permanently increases significantly (i.e., impedance decreases) after the tissue has been exposed to temperatures of 70° C., as it may during therapeutic neuromodulation. If the therapeutic neuromodulation was stopped when the tissue temperature was detected to be about 70° C., it is expected that there would be a permanent measurable change in the conductivity of the tissue without reaching a phase in which the tissue is structurally changed or damaged (e.g., due to vaporization, desiccation, etc.). However, if the tissue is exposed to temperatures above a second thermal threshold of about 90° C., the tissue undergoes a high degree of tissue desiccation, and thus a significant decrease in electrical conductivity (i.e., and a higher level of in the electrical impedance). Athird curve 705 illustrates this lower electrical conductivity of the tissue after exposure to temperatures above 90° C. Accordingly, in various embodiments, systems disclosed herein can be configured to stop neuromodulation when the temperature reaches about 70° C. (e.g., 70-80° C.) to avoid structural changes or damage to the mucosa, but still providing what is expected to be therapeutically effective neuromodulation. - Neural detection and mapping can provide a pre-procedural assessment of the neural anatomy, a mid-procedure assessment and feedback on temporal changes in tissue during neuromodulation, and/or a post procedural assessment of the neural activity as a confirmation of effectiveness. In various embodiments, the bioelectric measurements taken pre-, mid-, and post-procedurally can be taken multiple times during each stage of the procedure to assess and confirm findings. Pre-procedural assessment can be used to evaluate the bioelectric properties of the native/host tissue to determine a baseline for subsequent actions and as a reference guide against source biological signatures to identify anatomical targets of interest (e.g., nerves, microforamina, etc.). This information can be determined by placing a multi-electrode array in a known spatial configuration to detect and then map electro-anatomical characteristics (e.g., variations in the impedance of different tissue types). The resultant anatomical mapping can comprise a composition of multiple (high density) activation sequence in multiple planes, relying on the variations in impedance to identify different tissue types and structures. During the procedure, the impedance measurements can be used to confirm that the electrodes maintain good contact with tissue at the target site. During and after the procedure, the data can be used to determine whether the mid- or post-procedural recorded spectra has a shape consistent with the expected tissue types. Post-procedurally, the information can be used to determine whether the targeted nerves were therapeutically treated.
- In other embodiments, the action potentials of neural fibers can be detected via electrodes and or other contacts to dynamically map the locations and/or activity of nerves in the target region. For example, the recorded action potentials can be used to numerically measure, map, and/or produce images of fast neuronal depolarization to generate an accurate picture of neural activity. In general, the depolarization of the neuronal membrane can cause drops in voltage of about 110 μV, has about 2 ms, and have an impedance/resistance from 1000 Ωcm to 25 Ωcm. In further embodiments, the metabolic recovery processes associated with action potential activity (i.e., to restore ionic gradients to normal) can also be detected and used for dynamically mapping nerves at the target site. The detection of the bioelectric properties associated with these features has the advantage that the changes are much larger (e.g., approximately a thousand times larger) and, therefore, easier to measure.
- In various embodiments, a nontherapeutic stimulation (e.g., RF energy) can be applied to the tissue at the detection region via two or more electrodes of an electrode array to enhance the recording of action potentials. The stimulating energy application can temporarily activate the neural fibers and the resultant action potential can be recorded. For example, two or more electrodes of a therapeutic assembly can deliver a stimulating pulse of energy, and two or more other electrodes can be configured to detect the resultant action potential. The stimulating energy pulses are expected to enhance the action potential signal, making it easier to record.
-
FIGS. 8 and 9 are isometric views of a distal portion of a therapeutic neuromodulation device 802 (“device 802”) configured in accordance with an embodiment of the present technology. Thedevice 802 can include various features generally similar to the features of thetherapeutic neuromodulation devices 402 and 502 a-d described above with reference toFIGS. 4-5G . For example, thedevice 802 includes atherapeutic assembly 812 at adistal portion 408 b of ashaft 408. Thetherapeutic assembly 812 includes a plurality ofstruts 440 that formbranches 446 and define an expandable frame orbasket 442, and one ormore electrodes 444 disposed on one or more of thestruts 440. As shown inFIGS. 8 and 9 , the device 902 can further include an expandable member 856 (e.g., a balloon) carried by thesupport member 448 and expandable within thebasket 442. Theexpandable member 856 can include a plurality ofelectrodes 858 disposed on the outer surface of theexpandable member 856. Theelectrodes 858 can be used for detection of bioelectric features (e.g., impedance) to allow for mapping of the neural anatomy at the target site before, during, and/or after therapeutic neuromodulation via theother electrodes 444. In other embodiments, theelectrodes 858 can be configured to apply energy for therapeutic neuromodulation. - As shown in
FIGS. 8 and 9 , theelectrodes 858 can be positioned on theexpandable member 856 in a substantially symmetrical manner and a uniform distribution. This provides an expansive array with which impedance and/or other properties can be detected across the tissue and, therefore, may provide a more detailed mapping of the tissue and nerves at the treatment site. In other embodiments, theelectrodes 858 can be clustered toward the medial portion of theexpandable member 856 and/or around different portions of theexpandable member 856. In certain embodiments, theelectrodes 858 can be selectively activated at a specific polarity, and therefore the electrode array can be configured in a variety of static configurations and a dynamically change sequences (e.g., sesquipolar application of current) that may be advantageous for mapping functions. - In operation, the
expandable member 856 can be inflated or otherwise expanded (FIG. 9 ) to place at least a portion of theelectrodes 858 into contact with tissue at the target site. Theelectrodes 858 can measure various bioelectric properties of the tissue (e.g., impedance, action potentials, etc.) to detect, locate, and/or map the nerves at the treatment site. In certain embodiments, theelectrodes 444 on thestruts 440 and/or a portion of theelectrodes 858 on theexpandable member 856 can apply a stimulating pulse of RF energy, and theelectrodes 858 can detect the resultant neural response. After mapping, theexpandable member 856 can be deflated or collapsed (FIG. 8 ), and theelectrodes 444 on thestruts 440 can apply therapeutically effective neuromodulation energy to the target site. For example, the ablation pattern of theelectrodes 444 can be based on the neural locations identified via the information detected from thesensing electrodes 858 on theexpandable member 856. In other embodiments, theexpandable member 856 may remain expanded during neuromodulation, and theelectrodes 858 can detect neural activity during the neuromodulation procedure or theelectrodes 858 can themselves be configured to apply neuromodulation energy to the treatment site. After applying the neuromodulation energy, theelectrodes 858 on theexpandable member 856 can again be placed into contact with tissue at the target site, and used to record bioelectric properties (e.g., impedance). The detected properties (e.g., impedances) taken before, during, and/or after neuromodulation can be compared to each other to determine whether the neuromodulation was therapeutically effective. If not, theelectrodes 444 can again apply therapeutic neuromodulation energy to the same treatment site, or the configuration of theactive electrodes 444 can be changed to apply therapeutic neuromodulation energy in a different pattern or sequence, and/or thetherapeutic assembly 812 can be moved to a different treatment site. -
FIG. 10A is an isometric view of a distal portion of a therapeutic neuromodulation device 1002 (“device 1002”) configured in accordance with another embodiment of the present technology, andFIG. 10B is an isometric view illustrating thetherapeutic neuromodulation device 1002 ofFIG. 10A at a treatment site. Thedevice 1002 can include various features generally similar to the features of thetherapeutic neuromodulation devices 402, 502 a-d, and 802 described above with reference toFIGS. 4-5G, 8 and 9 . For example, thedevice 1002 includes ashaft 1008 and atherapeutic assembly 1012 at adistal portion 1008 b of theshaft 1008. Thetherapeutic assembly 1012 includes a plurality ofstruts 1040 that formbranches 1046 and define an expandable frame orbasket 1042, and one ormore electrodes 1044 disposed on one or more of thestruts 1040. As shown inFIG. 10A , thedevice 1002 can further include a secondary or returnelectrode 1060 disposed along the distal portion of theshaft 1008. In the illustrated embodiment, thereturn electrode 1060 is a ring electrode having a ring-like shape, but in other embodiments thereturn electrode 1060 may have other shapes or configurations. - The
return electrode 1060 may be biased at a negative polarity, and at least a portion of theelectrodes 1044 on thestruts 1040 and/or on other portions of thetherapeutic assembly 1012 may be biased at a positive polarity. As indicated by the arrows inFIG. 10A , bipolar RF energy can flow across a region spanning from thetherapeutic assembly 1012 to thereturn electrode 1060 on thisdistal portion 1008 b of theshaft 1008. In various embodiments, the RF energy can be applied in a sesquipolar manner (i.e., imbalanced bipolar energy). - As shown in
FIG. 10B , thetherapeutic assembly 1012 can be positioned inferior to the SPF and superior to the inferior turbinate IT and at least a portion of the microforamina MF and nerves N traversing the palatine bone. Thereturn electrode 1060 can be positioned inferior to the inferior turbinate IT and at least a portion of the microforamina NIF and nerves N traversing the palatine bone. RF energy can then be applied across a wide region spanning from thetherapeutic assembly 1012 to thereturn electrode 1060. As shown inFIG. 10B , for example, thedevice 1002 can apply energy across the top and bottom portions of the inferior turbinate, where a high density of microforamina reside. -
FIGS. 11A-11D are isometric views illustrating distal portions of therapeutic neuromodulation devices 1102 (referred to individually as afirst device 1102 a and asecond device 1102 b) configured in accordance with further embodiments of the present technology. Thefirst device 1102 a can include various features generally similar to the features of thetherapeutic neuromodulation devices 402, 502 a-d, 802 and 1002 described above with reference toFIGS. 4-5G and 8-10B . For example, thefirst device 1102 a includes ashaft 1108 and atherapeutic assembly 1112 at adistal portion 1108 b of theshaft 1108. Thetherapeutic assembly 1112 includes aflexible membrane 1162 that carries a plurality ofelectrodes 1144 and/or other energy delivery elements arranged in an array across theflexible membrane 1162. - As shown in
FIGS. 11A-11C , theflexible membrane 1162 can be configured to transform from a low-profile delivery state (FIG. 11A ), to an expanded state (FIG. 11B ) via self-expansion or mechanical expansion means, and back to the low-profile delivery or retrieval state (FIG. 11C ) for removal of the device from the nasal cavity. In the expanded state shown inFIG. 11B , the flexible membrane can conform to the irregular anatomy of the nasal space (e.g., turbinates, sinus, and/or other para-nasal) to enhance the contact area between the flexible membrane 1162 (and theelectrodes 1144 disposed thereon) with the non-planar anatomy. Theflexible membrane 1162 can be made from a flexible and dynamic material to support theelectrodes 1144. For example, in certain embodiments theflexible membrane 1162 can comprise polymer filaments and/or other materials that add support and structure to theflexible membrane 1162. In various embodiments, theflexible membrane 1162 can have pre-set geometry to retain a predetermined shape. For example, theflexible membrane 1162 and/or the electrode array on theflexible membrane 1162 can retain spherical curvature (e.g., as shown inFIG. 11A ). - In various embodiments, the
shaft 1108 can be movable relative to theflexible membrane 1162 to allow for deployment and recapture of theflexible membrane 1162. For example, theflexible membrane 1162 may be curled or otherwise folded into a circular shape when in the delivery state (FIG. 11A ). To move to the expanded state (FIG. 11B ), components of theshaft 1108 can be rotated and/or moved axially relative to theflexible membrane 1162 to unwind or otherwise expand theflexible membrane 1162 such that theflexible membrane 1162 at least partially opens and conforms to the structures of the surrounding anatomy to place theelectrodes 1144 into contact with tissue at the target site. To recapture the device to the retracted state (FIG. 11C ), theshaft 1108 can again be moved axially or rotational manner to close wind or otherwise fold theflexible membrane 1162. - As shown in
FIGS. 11A-11C , theelectrodes 1144 may be interconnected through a plurality ofconnectors 1164, such as nano-ribbons, nano-wires, direct inking, multidirectional printing/deposition, and/or other suitable electrical connectors. In various embodiments, theinterconnections 1164 between theelectrodes 1144 can include periodic undulating conduits or lines having a “U”, “S”, or elliptical shapes. These undulatingconnectors 1164 may form a multidimensional spring within theflexible membrane 1162 and/or impose a predetermined shape on theflexible membrane 1162 that facilitates apposition of theflexible membrane 1162 to the tissue at the target site to improve energy conductivity/transference. - The
electrodes 1144 may be surface mounted on theflexible membrane 1162 or embedded within a multi-layered composite structure of theflexible membrane 1162. In various embodiments, theelectrodes 1144 may be relatively small in size, having diameters ranging from 50-2,000 microns. Theelectrodes 1144 may be configured to deliver energy in a mono-polar, bipolar, or multipolar manner. For example, multipolar electrodes can be used in a bipolar arrangement and in a quad-polar arrangement to facilitate a linear and an angulated (diagonal) energy connectivity between theelectrodes 1144. - The
electrodes 1144 can be connected to a connection pad (not shown) housed within theshaft 1108 and/or features connected to proximal portions of theshaft 1108, such as a handle or console. Theelectrodes 1144 can be connected to the connection pad through a conductive connector cable (e.g., a metallic cable, a polymeric cable, and/or combinations thereof). - In certain embodiments, the
flexible membrane 1162 may also house a feedback system (not shown) to control the delivery of the RF energy and maintain predefined treatment parameters. For example, the electronic circuits of theflexible membrane 1162 may include thermal sensors that provide temperature feedback to control energy dissipation and depth penetration of the RF energy. The features of electronic circuits of theflexible membrane 1162 may also measure resistance and temperature at the treatment site to determine the effects of the therapeutic energy application. This information may be used to regulate energy application and avoid collateral damage to host tissue. For example, energy delivery via theelectrodes 1144 may be automatically terminated if the detected temperature and/or resistance reaches a predetermined threshold maximum (e.g., a threshold temperature associated with tissue damage). Energy delivery via theelectrodes 1144 may be automatically or manually adjusted if the detected temperature and/or resistance is below a predetermined threshold range indicative of parameters associated with therapeutically effective modulation of the parasympathetic nasal nerves. In other embodiments, the feedback system can be incorporated to components communicatively coupled with theelectrodes 1144 and any additional sensors on theflexible membrane 1162. For example, the feedback system can be stored on theconsole 204 ofFIG. 2 and executed by the controller 218 (FIG. 2 ). - In the embodiment shown in
FIG. 11D , thesecond device 1102 b can include various features generally similar to the features of thefirst device 1102 a described above with reference toFIGS. 11A-11C . For example, thedevice 1102 b ofFIG. 11D includes theflexible membrane 1162 that carries a plurality ofelectrodes 1144 and associatedelectrical connectors 1164 disposed on or embedded in theflexible membrane 1162. Thedevice 1102 b further includes anexpandable frame 1166 carrying theflexible membrane 1162. Theframe 1166 may have a U-shape and can be made from a shape memory material (e.g., Nitinol). In other embodiments, the frame may have different shapes and/or be made from different materials suitable for supporting theflexible membrane 1162. - In operation, the
frame 1166 facilitates the deployment of theflexible membrane 1162 against the anatomy of the nasal cavity, and provides support for theflexible membrane 1162 and the associated array ofelectrodes 1144. TheU-shaped frame 1166 can enhance the ability of theflexible membrane 1162 to contact the non-planar anatomy at the target site. In various embodiments, for example, theframe 1166 may act as a cantilever spring to establish a positive directional apposition of themembrane 1162 to the target surface tissue to improve energy conductivity/transference from theelectrodes 1144 to the target tissue. -
FIG. 12 is a side view of a distal portion of a therapeutic neuromodulation device 1202 (“device 1202”) configured in accordance with a further embodiment of the present technology. Thedevice 1202 includes include various features generally similar to the features of thetherapeutic neuromodulation devices 402, 502 a-d, 802, 1002 and 1102 described above with reference toFIGS. 4-5G and 8-11 . For example, thedevice 1202 includes ashaft 1208 and a therapeutic assembly 1212 including a plurality of energy delivery elements, such aselectrodes 1244, at adistal portion 1208 b of theshaft 1208. In the illustrated embodiment, the therapeutic assembly 1212 includes fourelectrodes 1244 are arranged along a spiral/helical section 1268 at thedistal portion 1208 b of theshaft 1208. In other embodiments, however, the therapeutic assembly 1212 may include one, two, three, or more than fourelectrodes 1244, and/or may include different energy delivery elements. The therapeutic assembly 1212 can also include a temperature sensor 1252 (e.g., a thermocouple) and/or other type of sensor to detect various properties at the treatment site before, during, and/or after applying therapeutic neuromodulation energy, and provide feedback that may be used to control the operation of the therapeutic assembly 1212. Such sensors can be incorporated in any of the other embodiments of therapeutic assemblies disclosed herein. - During delivery of the therapeutic assembly 1212, the spiral/helical section 1168 of the
shaft 1208 is positioned in a low-profile delivery state in which thesection 1268 is substantially straitened or flattened within an introducer sheath and/or via mechanical components associated with theshaft 1208. At the target site, the operator can transform the spiral/helical section 1268 to an expanded state (shown inFIG. 12 ) to place one or more of theelectrodes 1244 in contact with the target tissue. One or more of theelectrodes 1244 can then be selectively activated to apply RF energy (e.g., monopolar and/or bipolar RF energy) to tissue at a target site in the nasal region to therapeutically modulate nerves proximate to the treatment site. In other embodiments, the distal section of theshaft 1208 can have other suitable shapes, sizes, and/or configurations that facilitate placing theelectrodes 1244 in contact with tissue at the target site. For example, in further embodiments, thedistal portion 1208 b of theshaft 1208 can have a semi-circular, curved, bent, or straight shape and/or the therapeutic assembly 1212 can include multiple support members configured to carry one or more of theelectrodes 1244. -
FIG. 13 is a side view of a distal portion of a therapeutic neuromodulation device 1302 (“device 1302”) configured in accordance with a still further embodiment of the present technology. Thedevice 1302 includes include various features generally similar to the features of thetherapeutic neuromodulation devices 402, 502 a-d, 802, 1002, 1102 and 1202 described above with reference toFIGS. 4-5G and 8-12 . For example, thedevice 1302 includes ashaft 1308 and atherapeutic assembly 1312 including a plurality of energy delivery elements, such as an array ofelectrodes 1344, at adistal portion 1308 b of theshaft 1308. In the embodiment illustrated inFIG. 13 , thetherapeutic assembly 1312 includes aballoon 1370 that carries theelectrodes 1344. Asupport member 1372 can extend through the length of theballoon 1370 to support theballoon 1370 and, optionally, include a channel through which a guidewire (not shown) can extend to facilitate delivery of thetherapeutic assembly 1312 to the target site. In other embodiments, thesupport member 1372 may be omitted. - The
electrodes 1344 can be made from conductive ink that is printed, sprayed, and/or otherwise disposed on the surface of theballoon 1370. Such conductive ink electrodes facilitates the use of complex electrode configurations. In addition, thermocouples (not shown) can also be incorporated onto the surface of theballoon 1370 using conductive ink and/or other suitable methods. In other embodiments, theelectrodes 1344 can be made from foil and adhered to the surface of theballoon 1370. In further embodiments, theelectrodes 1344 can be made from other suitable materials that may be disposed on the surface of theballoon 1370 and/or embedded within the material of theballoon 1370. - The
balloon 1370 can be made from various different materials and have various different shapes. As shown inFIG. 13 , for example, theballoon 1370 can have an ovoid shape when in the expanded state, which is expected to improve the conformance to anatomical variations at the target site within the nasal cavity. In other embodiments, theballoon 1370 can have a circular shape, a spherical shape, an irregular shape, and/or other suitable shape for expansion within the nasal anatomy. Theballoon 1370 can be made from a compliant material (e.g., a urethane material) that allows theballoon 1370 to conform to anatomical variances when expanded within the nasal region. In other embodiments, the balloon may be made from a non-compliant material (e.g., polyethylene terephthalate, nylon, etc.) that allows theballoon 1370 to have a defined shape when expanded and facilitates the attachment ofelectrodes 1344 to the balloon surface. In further embodiments, theballoon 1370 may be dip-coated and form a bulbous tip at the distal end of theshaft 1308. - The
balloon 1370 may be inflated with a fluid via an opening orport 1374 in thesupport member 1372 and/or an opening in theshaft 1308 in fluid communication with the interior of theballoon 1370. For example, thesupport member 1372 and/or theshaft 1308 can include a channel extending along the length of theshaft 1308 and connected to a fluid supply at the proximal portion of theshaft 1308 such that fluid can be delivered to theballoon 1370. Theballoon 1370 can inflate against the nasal anatomy at the target site to places theelectrodes 1344 in contact with tissue at the target site. - At the target site, the
electrodes 1344 deliver RF energy to tissue to therapeutically modulate nerves at the treatment site. In certain embodiments, the array ofelectrodes 1344 can be arranged on theballoon 1370 and/or selectively activated to apply transverse bipolar RF energy across a radial regions of the balloon 1370 (i.e., extending around circumferential portions of the balloon 1370). In other embodiments, the array ofelectrodes 1344 can be arranged on theballoon 1370 and/or selectively activated to apply longitudinal bipolar RF energy across longitudinal regions of the balloon 1370 (i.e., extending between proximal and distal portions of the balloon 1370). - In various embodiments, the
therapeutic assembly 1312 may include features that facilitate with positioning of theballoon 1370 within the nasal anatomy and proper placement of theelectrodes 1344 at the treatment site. As shown inFIG. 13 , for example, anendoscope 1371 may be positioned on the surface of theballoon 1370 to provide direct, in-line visualization of theballoon 1370 and the target site during placement at the target site. Thetherapeutic assembly 1312 can also include graduatedmarkings 1373 along thesupport member 1372 and/or the surface of theballoon 1370 to depict spatial orientation and/or depth positioning of thetherapeutic assembly 1312. - In certain embodiments, the
balloon 1370 can be configured to allow for a slow perfusion of fluid through the balloon wall to cool theelectrodes 1344 while energy is applied to the target tissue. For example, such a “weeping”balloon 1370 can include laser-driller holes and/or other small openings or pores along at least a portion of theballoon 1370 to allow for the slow perfusion of a fluid (e.g., saline solution) through the balloon wall. When the balloon perfuses saline solution, the saline solution is expected to improve the electrical conductivity between theelectrodes 1344 and the target tissue and may enhance the effect of the RF energy on the nerves at the target site. In other embodiments, a cooled fluid can be circulated through theballoon 1470 during activation of theelectrodes 1444 to cool theelectrodes 1444 and the surrounding tissue during energy delivery. -
FIG. 14 is a side view of a distal portion of a therapeutic neuromodulation device 1402 (“device 1402”) configured in accordance with an additional embodiment of the present technology. Thedevice 1402 includes include various features generally similar to the features of thetherapeutic neuromodulation device 1302 described above with reference toFIG. 13 . For example, thedevice 1402 includes ashaft 1408 and atherapeutic assembly 1412 at adistal portion 1408 b of theshaft 1408. Thetherapeutic assembly 1412 includes aballoon 1470, asupport member 1472 supporting theballoon 1470, and a plurality of energy delivery elements, such as an array ofelectrodes 1444 disposed on theballoon 1470. In the embodiment illustrated inFIG. 14 , theelectrodes 1444 are part of aflex circuit 1476 adhered to the surface of theballoon 1470. Theflex circuit 1476 facilitates the creation of complex electrode arrays that can create highly customizable neuromodulation patterns. In certain embodiments, for example, theflex circuit 1476 can include a conductive return electrode along the surface of theballoon 1470 and a plurality of electrodes on a proximal or distal portion of the balloon 1470 (e.g., a conical end portion of the balloon 1470). In addition, theflex circuit 1476 can incorporate thermocouples and/or thermistors into the circuitry on the surface of theballoon 1470 to detect temperature at the treatment site before, during, and/or after energy application. -
FIG. 15 is an isometric side view of a distal portion of a therapeutic neuromodulation device 1502 (“device 1502”) configured in accordance with an additional embodiment of the present technology. Thedevice 1502 includes include various features generally similar to the features of thetherapeutic neuromodulation devices FIGS. 13 and 14 . For example, thedevice 1502 includes ashaft 1508 and atherapeutic assembly 1512 at adistal portion 1508 b of theshaft 1508. Thetherapeutic assembly 1512 includes a plurality ofballoons 1578 positioned around aninner support member 1580, and a plurality of energy delivery elements, such aselectrodes 1544 disposed on one or more of theballoons 1578. In certain embodiments, theballoons 1578 are independently inflatable. This allows for asymmetrical or variable inflation of theballoons 1578 and, thereby, enhances the ability of thetherapeutic assembly 1512 to conform to the irregular geometry of the nasal region at the target site and facilitates apposition of theelectrodes 1544 against tissue at the target site. - In the illustrated embodiment, four independently inflated
balloons 1578 are positioned around the perimeter of theinner support member 1580. In other embodiments, however, thedevice 1502 can include less than fourballoons 1578 or more than fourballoons 1578 arranged around theinner support member 1580. In further embodiments, theballoons 1578 can have different sizes and/or shapes, and can be positioned along various portions of theinner support member 1580. In still further embodiments, theballoons 1578 re configured as struts that are attached at end portions to theinner support member 1580 and extend outwardly away from theinner support member 1580 when inflated (e.g., in a similar manner as thestruts 440 of thetherapeutic neuromodulation device 402 ofFIG. 4 ). - During energy delivery, the
electrodes 1544 can be configured to apply bipolar RF energy across theelectrodes 1544 ondifferent balloons 1578 and/or betweenelectrodes 1544 on thesame balloon 1578. In other embodiments, theelectrodes 1544 apply energy in a sesquipolar manner. For example, theinner support member 1580 can include a return electrode (not shown), and theelectrodes 1544 on two or more of theballoons 1578 may be activated for sesquipolar RF energy delivery. -
FIG. 16 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device 1602 (“device 1602”) configured in accordance with an additional embodiment of the present technology. Thedevice 1602 includes various features generally similar to the features of the therapeutic neuromodulation devices described above. For example, thedevice 1602 includes ashaft 1608 and atherapeutic assembly 1612 at adistal portion 1608 b of theshaft 1608. In the embodiment illustrated inFIG. 16 , thetherapeutic assembly 1612 is configured to apply cryotherapeutic cooling to therapeutically modulate nerves at the target site. As shown inFIG. 16 , thecryotherapeutic assembly 1612 can include an expansion chamber 1682 (e.g., a balloon, inflatable body, etc.) in fluid communication with one or more supply tubes orlumens 1684 via correspondingorifices 1686 in thesupply lumens 1684. The supply lumens 1682 can extend along at least a portion of theshaft 1608 and be configured to transport a refrigerant in an at least a partially liquid state to thedistal portion 1608 b of theshaft 1608. An exhaust tube or lumen 1689 (e.g., defined by a portion of the shaft 1608) can be placed in fluid communication with the interior of the expansion chamber 1682 via anoutlet 1688 such that theexhaust lumen 1689 can return the refrigerant to the proximal portion of theshaft 1608. For example, in one embodiment, a vacuum (not shown) at the proximal portion of theshaft 1608 may be used to exhaust the refrigerant from the expansion chamber 1682 via theexhaust lumen 1689. In other embodiments, the refrigerant may be transported to the proximal portion of theshaft 1608 using other suitable mechanisms known to those having skill in the art. - During cryotherapy, the
orifices 1686 of thesupply lumens 1684 can restrict refrigerant flow to provide a high pressure differential between thesupply lumen 1684 and the expansion chamber 1682, thereby facilitating the expansion of the refrigerant to the gas phase within the expansion chamber 1682. The pressure drop as the liquid refrigerant passes through the orifices 1682 causes the refrigerant to expand to a gas and reduces the temperature to a therapeutically effective temperature that can modulate neural fibers proximate a treatment site within the nasal cavity. In the illustrated embodiment, the expansion chamber 1682 includesheat transfer portions 1691 that contact and cool tissue at the target site at a rate sufficient to cause cryotherapeutic neuromodulation of postganglionic parasympathetic neural fibers that innervate the nasal mucosa. For example, thetherapeutic assembly 1602 can operate at temperatures of −40° C., −60° C., −80° C., or lower. In other embodiments, thetherapeutic assembly 1602 can operated at higher cryotherapeutic temperatures (e.g., 5° C. and −15° C., −20° C., etc.). - The refrigerant used for cryogenic cooling in the
device 1602 can be a compressed or condensed gas that is stored in at least a substantially liquid phase, such as nitrous oxide (N2O), carbon dioxide (CO2), hydrofluorocarbon (e.g., FREON made available by E. I. du Pont de Nemours and Company of Wilmington, Del.), and/or other suitable fluids that can be stored at a sufficiently high pressure to be in at least a substantially liquid phase at about ambient temperature. For example, R-410A, a zeotropic, but near-azeotropic mixture of difluoromethane (CH2F2; also known as HFC-32 or R-32) and pentafluoroethane (CHF2CF3; also known as HFC-125 or R-125), can be in at least a substantially liquid phase at about ambient temperature when contained at a pressure of about 1.45 MPa (210 psi). Under proper conditions, these refrigerants can reach cryotherapeutic temperatures at or near their respective normal boiling points (e.g., approximately −88° C. for nitrous oxide) to effectuate therapeutic neuromodulation. - In other embodiments, the
therapeutic assembly 1612 can include a cryotherapeutic applicator rather than the expansion chamber 1682 ofFIG. 16 . Such a cryotherapeutic applicator can be used for very targeted treatment of the nerves. - As further shown in
FIG. 16 , thedevice 1602 can also include asupport member 1690 extending through the expansion chamber 1682 and configured to carry the distal portion of the expansion chamber 1682. Thesupport member 1690 can also include a channel extending along its length and anopening 1692 at the distal end portion of thesupport member 1690 to facilitate delivery of thetherapeutic assembly 1612 to the treatment site via a guidewire GW. -
FIG. 17 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device 1702 (“device 1702”) configured in accordance with an additional embodiment of the present technology. Thedevice 1702 includes various features generally similar to the features of the therapeutic neuromodulation devices described above. For example, thedevice 1702 includes ashaft 1708 and atherapeutic assembly 1712 at adistal portion 1708 b of theshaft 1708. In the embodiment illustrated inFIG. 17 , thetherapeutic assembly 1712 is configured to apply direct conductive heating to thermally therapeutically modulate nerves at the target site. As shown inFIG. 17 , thetherapeutic assembly 1712 can include aballoon 1770 in fluid communication with a supply tube or lumen 1794 (e.g., defined by a portion of the shaft 1708) via an outlet at a distal portion of thesupply lumen 1794. Thesupply lumen 1794 can extend along at least a portion of theshaft 1708 and be insulated to transport a heated fluid (e.g., heated saline) to theballoon 1770 at thedistal portion 1708 b of theshaft 1708. An exhaust or return tube or lumen 1796 (e.g., defined by a portion of the shaft 1708) can be placed in fluid communication with the interior of theballoon 1770 via an outlet such that thereturn lumen 1796 can exhaust the fluid to the proximal portion of the shaft 1708 (e.g., using a vacuum at the proximal portion of the shaft 1708). - During thermal therapeutic neural modulation, the
supply lumen 1794 can supply a heated fluid to theballoon 1770, and theexhaust lumen 1796 can be used to exhaust the fluid from theballoon 1770 such that the heated fluid circulates through the balloon 1770 (e.g., as indicated by the arrows). The heated fluid can be heated to a therapeutically effective temperature that causes time-dependent thermal damage (e.g., determined using the Arrhenius equation) to the target tissue at a treatment site within the nasal cavity and modulates neural fibers within or proximate to the heated target tissue. In the illustrated embodiment, for example, the wall of theballoon 1770 and/or portions thereof can contact and heat tissue at the target site at a rate and time sufficient to cause thermal damage to the target tissue to provide therapeutic neuromodulation of postganglionic parasympathetic neural fibers that innervate the nasal mucosa. - As shown in
FIG. 17 , thedevice 1702 can also include asupport member 1790 extending through theballoon 1770 and configured to carry the distal portion of theballoon 1770. Thesupport member 1790 can also include a channel extending along its length and anopening 1792 at the distal end portion of thesupport member 1790 that can be used to facilitate delivery of thetherapeutic assembly 1712 to the treatment site via a guidewire GW. -
FIG. 18 is a cross-sectional side view of a distal portion of a therapeutic neuromodulation device 1802 (“device 1802”) configured in accordance with an additional embodiment of the present technology. Thedevice 1802 includes various features generally similar to the features of the therapeutic neuromodulation devices described above. For example, thedevice 1802 includes ashaft 1808 and atherapeutic assembly 1812 at adistal portion 1808 b of theshaft 1808. Thetherapeutic assembly 1812 can include aninflatable balloon 1870 and asupport member 1890 extending through theballoon 1870. Thesupport member 1890 may also include a channel with anopening 1892 that allows for guidewire delivery of thetherapeutic assembly 1812 to the treatment site. - Similar to the
therapeutic assembly 1712 ofFIG. 17 , thetherapeutic assembly 1812 can apply therapeutically effective heating to tissue at a target site to cause time-dependent thermal tissue damage (e.g., determined using the Arrhenius equation) and modulate neural fibers within or proximate to the heated target tissue. In the embodiment illustrated inFIG. 18 , however, heating is supplied via aheating element 1898 positioned within the balloon 1880 and carried by thesupport member 1890 and/or another feature of thetherapeutic assembly 1812. Theheating element 1898 may be a plate or other structure heated using resistive heating (via a generator) and/or other suitable heating mechanism. In operation, the heat from theheating element 1898 can transfer from theheating element 1898 to the fluid within theballoon 1870, and then through the wall of theballoon 1870 to the adjacent tissue at the treatment site. The fluid heated by theheating element 1898 can be heated to a therapeutically effective temperature that causes thermal damage to the target tissue at a treatment site within the nasal cavity and modulates neural fibers within or proximate to the heated target tissue. In certain embodiments, theballoon 1870 can include conductive features (e.g., metallic panels) on its surface to concentrate the heating effect at targeted regions of theballoon 1870. - In other embodiments, the
balloon 1870 can be heated via capacitive coupling to reach therapeutically effective temperatures that causes thermal damage to the target tissue at a treatment site within the nasal cavity and modulate neural fibers within or proximate to the heated target tissue. For example, theballoon 1870 can be inflated with an isotonic solution, and theballoon 1870 can be ionically agitated at a high frequency to allow capacitive energy to discharge across the membrane of theballoon 1870 to the target tissue. -
FIG. 19 is a side view of a distal portion of a therapeutic neuromodulation device 1902 (“device 1902”) configured in accordance with an additional embodiment of the present technology. The device 1902 includes various features generally similar to the features of the therapeutic neuromodulation devices described above. For example, the device 1902 includes ashaft 1908 and atherapeutic assembly 1912 at adistal portion 1908 b of theshaft 1908. In the embodiment illustrated inFIG. 19 , thetherapeutic assembly 1912 is configured to apply plasma or laser ablation to therapeutically modulate nerves at the target site. As shown inFIG. 19 , thetherapeutic assembly 1912 can include an ablation element 1999 (e.g., an electrode) on a distal end portion of theshaft 1908. Theablation element 1999 can apply high energy laser pulses to ionize molecules within the first few portion of the pulse. This process leads to a small bubble or field of plasma (e.g., 100-200 μm) that can be used to desiccate or otherwise destroy tissue and nerves at the target site. Theablation element 1999 can operate at temperatures lower than 100° C. and can limit the thermal effects on surrounding tissue. - In other embodiments, the
ablation element 1999 can perform laser ablation of nerves at the target site. For example, a nerve tracer (e.g., indocyanine green (ICG)) can be injected at the target site to dye nerves at the target site. Theablation element 1999 can be a laser that is tuned to absorb the spectrum of the nerve tracer and, thereby, ablate the dyed nerves in the target site. -
FIG. 20 is a partial cut-away side view illustrating target sites proximate to ostia of nasal sinuses for a therapeutic neuromodulation device configured in accordance with embodiments of the present technology. Any of the therapeutic modulation devices and system described above can be used to therapeutically modulate nerves that innervate the para-nasal sinuses to treat chronic sinusitis and/or similar indications. Referring toFIG. 20 , the para-nasal sinuses include the frontal sinuses FS, the sphenoidal sinuses SS, the maxillary sinuses (“MS”; not shown), and the ethmoidal sinuses or ethmoidal cells (not shown), which include the posterior ethmoidal cells (“PEC”), the middle ethmoidal cells (“MEC”), and the anterior ethmoidal cells (“AEC”). Each sinus opens to the nasal cavity at one or more discrete ostia.FIG. 20 illustrates the general locations of the ostium of the frontal sinus, the sphenoidal sinus, the maxillary sinus, and the ostia of posterior, middle, and anterior ethmoidal cells. - Parasympathetic nerves innervate the mucosa of the sinuses and stimulate the production of mucus in the sinuses. Hyperactivity of the parasympathetic nerves innervating the sinuses can cause hyper production of mucus and the soft tissue engorgement. The inflammation of the soft tissue proximate to the sinuses can cause can obstruct the conduit between a sinus and the nasal cavity and block the ostium to the sinus. In addition, the hyperactive mucosa and/or the blockage of the ostium can cause the pooling of mucosal secretions within the sinus occurs due to the lack of drainage from the sinus. This can lead to infection and, eventually, a chronic sinusitis state.
- Therapeutic modulation the parasympathetic nerves that control autonomic function of the sinuses is expected to reduce or eliminate the hyperactive mucosal secretions and soft tissue engorgement and, thereby, treat chronic sinusitis or related indications. Any of the therapeutic neuromodulation devices described above can be used to apply therapeutically effective neuromodulation energy at or proximate to the ostia of the affected sphenoidal, maxillary, frontal, and/or ethmoidal sinuses to modulate the autonomic function of the sinuses. For example, therapeutic neuromodulation devices can be used to apply RF energy, microwave energy, ultrasound energy, cryotherapeutic cooling, therapeutic heating, plasma ablation, and/or laser ablation to treatment sites at and around the ostia of the sinuses. Similar to the devices described above, the therapeutic neuromodulation devices can be delivered intraluminally via the nasal passage and through the superior, middle, and/or inferior meatuses to access the ostium or ostia of the desired sinus. In various embodiments, neural mapping techniques similar to those described above with respect to
FIGS. 6A-9 can be used to locate or detect the parasympathetic nerves that innervate the ostia before, during, and/or after treatment. The application of therapeutic neuromodulation at the target sites proximate to the sinus ostia can disrupt the parasympathetic signals to the sinus tissues, leading to the opening of the ostia and the ability to drain fluid. - This disclosure is not intended to be exhaustive or to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without deviating from the present technology, as those of ordinary skill in the relevant art will recognize. In some cases, well-known structures and functions have not been shown and/or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of methods may be presented herein in a particular order, in alternative embodiments the steps may have another suitable order. Similarly, certain aspects of the present technology disclosed in the context of particular embodiments can be combined or eliminated in other embodiments. Furthermore, while advantages associated with certain embodiments may have been disclosed in the context of those embodiments, other embodiments can also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages or other advantages disclosed herein to fall within the scope of the present technology. Accordingly, this disclosure and associated technology can encompass other embodiments not expressly shown and/or described herein.
- Throughout this disclosure, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. Similarly, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout this disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or one or more additional types of features are not precluded. Directional terms, such as “upper,” “lower,” “front,” “back,” “vertical,” and “horizontal,” may be used herein to express and clarify the relationship between various elements. It should be understood that such terms do not denote absolute orientation. Reference herein to “one embodiment,” “an embodiment,” or similar formulations means that a particular feature, structure, operation, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present technology. Thus, the appearances of such phrases or formulations herein are not necessarily all referring to the same embodiment. Furthermore, various particular features, structures, operations, or characteristics may be combined in any suitable manner in one or more embodiments.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/382,889 US20190239957A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160289P | 2015-05-12 | 2015-05-12 | |
US15/153,217 US11026746B2 (en) | 2015-05-12 | 2016-05-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/382,889 US20190239957A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/153,217 Continuation US11026746B2 (en) | 2015-05-12 | 2016-05-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190239957A1 true US20190239957A1 (en) | 2019-08-08 |
Family
ID=56113051
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/153,217 Active 2038-05-30 US11026746B2 (en) | 2015-05-12 | 2016-05-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/382,845 Pending US20190231429A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
US16/382,877 Pending US20190239956A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
US16/382,865 Pending US20190239955A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
US16/382,889 Pending US20190239957A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
US16/382,802 Active 2039-05-11 US11690672B2 (en) | 2015-05-12 | 2019-04-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/382,830 Active 2039-04-13 US11771497B2 (en) | 2015-05-12 | 2019-04-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/703,348 Pending US20200107882A1 (en) | 2015-05-12 | 2019-12-04 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/703,325 Pending US20200100838A1 (en) | 2015-05-12 | 2019-12-04 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/153,217 Active 2038-05-30 US11026746B2 (en) | 2015-05-12 | 2016-05-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/382,845 Pending US20190231429A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
US16/382,877 Pending US20190239956A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
US16/382,865 Pending US20190239955A1 (en) | 2015-05-12 | 2019-04-12 | Devices for Therapeutic Nasal Neuromodulation and Associated Methods and Systems |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/382,802 Active 2039-05-11 US11690672B2 (en) | 2015-05-12 | 2019-04-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/382,830 Active 2039-04-13 US11771497B2 (en) | 2015-05-12 | 2019-04-12 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/703,348 Pending US20200107882A1 (en) | 2015-05-12 | 2019-12-04 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US16/703,325 Pending US20200100838A1 (en) | 2015-05-12 | 2019-12-04 | Devices for therapeutic nasal neuromodulation and associated methods and systems |
Country Status (8)
Country | Link |
---|---|
US (9) | US11026746B2 (en) |
EP (1) | EP3294410A2 (en) |
JP (3) | JP6854015B2 (en) |
CN (2) | CN115040232A (en) |
AU (3) | AU2016262085B2 (en) |
CA (2) | CA2984207C (en) |
HK (1) | HK1252823A1 (en) |
WO (1) | WO2016183337A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021103506A1 (en) | 2021-02-15 | 2022-08-18 | Olympus Winter & Ibe Gmbh | Bipolar HF applicator and HF application system |
US11419671B2 (en) | 2018-12-11 | 2022-08-23 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11690672B2 (en) | 2015-05-12 | 2023-07-04 | National University Of Ireland, Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US11883091B2 (en) | 2020-04-09 | 2024-01-30 | Neurent Medical Limited | Systems and methods for improving sleep with therapeutic nasal treatment |
US11896818B2 (en) | 2020-04-09 | 2024-02-13 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011053757A1 (en) * | 2009-10-30 | 2011-05-05 | Sound Interventions, Inc. | Method and apparatus for treatment of hypertension through percutaneous ultrasound renal denervation |
US10722282B2 (en) * | 2011-06-14 | 2020-07-28 | Aerin Medical, Inc. | Methods and devices to treat nasal airways |
JP6441679B2 (en) | 2011-12-09 | 2018-12-19 | メタベンション インコーポレイテッド | Therapeutic neuromodulation of the liver system |
CA2881462C (en) | 2012-08-09 | 2020-07-14 | University Of Iowa Research Foundation | Catheters, catheter systems, and methods for puncturing through a tissue structure |
WO2014197625A1 (en) | 2013-06-05 | 2014-12-11 | Metavention, Inc. | Modulation of targeted nerve fibers |
US9687288B2 (en) | 2013-09-30 | 2017-06-27 | Arrinex, Inc. | Apparatus and methods for treating rhinitis |
EP3091921B1 (en) | 2014-01-06 | 2019-06-19 | Farapulse, Inc. | Apparatus for renal denervation ablation |
EP3139997B1 (en) | 2014-05-07 | 2018-09-19 | Farapulse, Inc. | Apparatus for selective tissue ablation |
EP3154463B1 (en) | 2014-06-12 | 2019-03-27 | Farapulse, Inc. | Apparatus for rapid and selective transurethral tissue ablation |
WO2015192018A1 (en) | 2014-06-12 | 2015-12-17 | Iowa Approach Inc. | Method and apparatus for rapid and selective tissue ablation with cooling |
US9763743B2 (en) | 2014-07-25 | 2017-09-19 | Arrinex, Inc. | Apparatus and method for treating rhinitis |
WO2016060983A1 (en) | 2014-10-14 | 2016-04-21 | Iowa Approach Inc. | Method and apparatus for rapid and safe pulmonary vein cardiac ablation |
US10130423B1 (en) * | 2017-07-06 | 2018-11-20 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
US10660702B2 (en) | 2016-01-05 | 2020-05-26 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
US10172673B2 (en) | 2016-01-05 | 2019-01-08 | Farapulse, Inc. | Systems devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue |
US20170189097A1 (en) | 2016-01-05 | 2017-07-06 | Iowa Approach Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
US11602260B2 (en) | 2016-02-11 | 2023-03-14 | Arrinex, Inc. | Method and device for image guided post-nasal nerve ablation |
US10638976B2 (en) | 2016-04-28 | 2020-05-05 | Biosense Webster (Israel) Ltd | Method of constructing irrigated balloon catheter |
US10660700B2 (en) | 2016-04-28 | 2020-05-26 | Biosense Webster (Israel) Ltd. | Irrigated balloon catheter with flexible circuit electrode assembly |
US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
CN113616277A (en) * | 2016-06-15 | 2021-11-09 | 阿里内克斯股份有限公司 | Device for treating the lateral surface of the nasal cavity |
WO2017218734A1 (en) | 2016-06-16 | 2017-12-21 | Iowa Approach, Inc. | Systems, apparatuses, and methods for guide wire delivery |
US10939965B1 (en) | 2016-07-20 | 2021-03-09 | Arrinex, Inc. | Devices and methods for treating a nerve of the nasal cavity using image guidance |
US20180056074A1 (en) * | 2016-08-25 | 2018-03-01 | Boston Scientific Scimed, Inc. | Systems and methods for reversible nerve block to relieve disease symptoms |
US11253312B2 (en) | 2016-10-17 | 2022-02-22 | Arrinex, Inc. | Integrated nasal nerve detector ablation-apparatus, nasal nerve locator, and methods of use |
US10485609B2 (en) * | 2016-10-18 | 2019-11-26 | Acclarent, Inc. | Dilation balloon with RF energy delivery feature |
CA3041440A1 (en) * | 2016-11-11 | 2018-05-17 | National University Of Ireland, Galway | Devices, systems, and methods for specializing, monitoring, and/or evaluating therapeutic nasal neuromodulation |
US11400205B2 (en) | 2016-11-23 | 2022-08-02 | Biosense Webster (Israel) Ltd. | Balloon-in-balloon irrigation balloon catheter |
US20180161093A1 (en) * | 2016-12-08 | 2018-06-14 | Biosense Webster (Israel) Ltd. | Irrigated balloon catheter with support spines and variable shape |
US11364072B2 (en) * | 2017-01-27 | 2022-06-21 | Medtronic, Inc. | Catheter electrodes for energy management |
EP3614940A4 (en) | 2017-04-28 | 2021-01-20 | Arrinex, Inc. | Systems and methods for locating blood vessels in the treatment of rhinitis |
US10617867B2 (en) | 2017-04-28 | 2020-04-14 | Farapulse, Inc. | Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue |
CN110662483B (en) * | 2017-04-28 | 2023-05-12 | 波士顿科学医学有限公司 | Systems, devices, and methods for delivering pulsed electric field ablation energy to endocardial tissue |
RU2662925C1 (en) * | 2017-07-11 | 2018-07-31 | Климентина Ивановна Нестерова | Method of treatment of adenorinosinusitis |
US20190029880A1 (en) * | 2017-07-26 | 2019-01-31 | Brian R. DuBois | Devices and Methods for Treating Epistaxis |
US11052246B2 (en) * | 2017-07-28 | 2021-07-06 | Medtronic, Inc. | Expandable elements for delivery of electric fields |
CN115844523A (en) | 2017-09-12 | 2023-03-28 | 波士顿科学医学有限公司 | Systems, devices, and methods for ventricular focal ablation |
US20190117969A1 (en) * | 2017-10-23 | 2019-04-25 | Cardiac Pacemakers, Inc. | Medical devices for treatment of cancer with electric fields |
US11338135B2 (en) | 2017-10-23 | 2022-05-24 | Cardiac Pacemakers, Inc. | Medical devices for cancer therapy with electric field shaping elements |
US11304749B2 (en) * | 2017-11-17 | 2022-04-19 | Medtronic Ardian Luxembourg S.A.R.L. | Systems, devices, and associated methods for neuromodulation with enhanced nerve targeting |
EP3740148A1 (en) * | 2018-01-18 | 2020-11-25 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
JP7399881B2 (en) | 2018-05-07 | 2023-12-18 | ファラパルス,インコーポレイテッド | epicardial ablation catheter |
WO2019217433A1 (en) | 2018-05-07 | 2019-11-14 | Farapulse, Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
EP3790483A1 (en) | 2018-05-07 | 2021-03-17 | Farapulse, Inc. | Systems, apparatuses, and methods for filtering high voltage noise induced by pulsed electric field ablation |
US20190365451A1 (en) * | 2018-06-05 | 2019-12-05 | Cryterion Medical, Inc. | Mapping assembly for cryogenic balloon catheter system |
US11622805B2 (en) | 2018-06-08 | 2023-04-11 | Acclarent, Inc. | Apparatus and method for performing vidian neurectomy procedure |
US20210369320A1 (en) * | 2018-06-26 | 2021-12-02 | Arrinex, Inc. | Systems, Devices, and Methods for Treatment of Nasal Disorders |
US10687892B2 (en) | 2018-09-20 | 2020-06-23 | Farapulse, Inc. | Systems, apparatuses, and methods for delivery of pulsed electric field ablative energy to endocardial tissue |
JP2020089723A (en) * | 2018-12-07 | 2020-06-11 | アヴェント インコーポレイテッド | Device and method for selectively and reversibly modulating nervous system structure to inhibit perception of pain |
US11786296B2 (en) | 2019-02-15 | 2023-10-17 | Accularent, Inc. | Instrument for endoscopic posterior nasal nerve ablation |
US12011213B2 (en) * | 2019-03-29 | 2024-06-18 | Acclarent, Inc. | System and method for treating epistaxis |
US11534235B2 (en) | 2019-04-04 | 2022-12-27 | Acclarent, Inc. | Needle instrument for posterior nasal neurectomy ablation |
EP3946123B1 (en) * | 2019-04-04 | 2024-05-29 | Boston Scientific Scimed, Inc. | Apparatus for focal ablation |
JP7410176B2 (en) | 2019-04-22 | 2024-01-09 | ボストン サイエンティフィック サイムド,インコーポレイテッド | System for delivering electrical stimulation to treat cancer |
EP4378519A1 (en) | 2019-04-22 | 2024-06-05 | Boston Scientific Scimed, Inc. | Electrical stimulation devices for cancer treatment |
EP4356955A3 (en) | 2019-04-23 | 2024-07-17 | Boston Scientific Scimed, Inc. | Electrodes for electrical stimulation to treat cancer |
WO2020219521A1 (en) | 2019-04-23 | 2020-10-29 | Boston Scientific Scimed, Inc. | Electrical stimulation with thermal treatment or thermal monitoring |
US11607542B2 (en) | 2019-04-23 | 2023-03-21 | Boston Scientific Scimed, Inc. | Electrical stimulation for cancer treatment with internal and external electrodes |
USD968421S1 (en) | 2019-05-31 | 2022-11-01 | Biosense Webster (Israel) Ltd. | Display screen with a graphical user interface |
USD969138S1 (en) | 2019-05-31 | 2022-11-08 | Biosense Webster (Israel) Ltd. | Display screen with a graphical user interface |
USD968422S1 (en) | 2019-05-31 | 2022-11-01 | Biosense Webster (Israel) Ltd. | Display screen with transitional graphical user interface |
US11464567B2 (en) | 2019-06-07 | 2022-10-11 | Valam Corporation | Device and methods of laser treatment for rhinitis |
US11317970B2 (en) | 2019-06-07 | 2022-05-03 | Valam Corporation | Device and methods of laser treatment for rhinitis |
WO2020260950A2 (en) | 2019-06-28 | 2020-12-30 | Neurent Medical Limited | Systems and methods for targeted therapeutic nasal neuromodulation |
US20210059743A1 (en) * | 2019-08-27 | 2021-03-04 | Biosense Webster (Israel) Ltd. | Estimation of Electrode-Tissue Contact Using Stem and Edge Electrodes |
US10625080B1 (en) | 2019-09-17 | 2020-04-21 | Farapulse, Inc. | Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation |
US20210077183A1 (en) * | 2019-09-18 | 2021-03-18 | Biosense Webster (Israel) Ltd. | Catheter with thin-film electrodes on expandable mechanical structure |
US11065047B2 (en) | 2019-11-20 | 2021-07-20 | Farapulse, Inc. | Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses |
US11497541B2 (en) | 2019-11-20 | 2022-11-15 | Boston Scientific Scimed, Inc. | Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses |
US10842572B1 (en) | 2019-11-25 | 2020-11-24 | Farapulse, Inc. | Methods, systems, and apparatuses for tracking ablation devices and generating lesion lines |
EP4110455B1 (en) | 2020-02-24 | 2024-05-22 | Boston Scientific Scimed, Inc. | Systems for treatment of pancreatic cancer |
EP4129387A4 (en) * | 2020-03-31 | 2024-05-01 | Toray Industries, Inc. | Balloon catheter and balloon catheter system |
WO2021205231A1 (en) | 2020-04-09 | 2021-10-14 | Neurent Medical Limited | Systems and methods for identifying and characterizing tissue and providing targeted treatment thereof |
US10857364B1 (en) * | 2020-04-14 | 2020-12-08 | Soin Neuroscience, LLC | Neuromodulation system and method with feedback optimized electrical field generation |
WO2021229876A1 (en) * | 2020-05-14 | 2021-11-18 | 株式会社カネカ | Balloon catheter and balloon catheter system having same |
US20210369337A1 (en) * | 2020-05-27 | 2021-12-02 | PAVmed Inc. | Systems and Methods for Minimally-Invasive Division of Fibrous Structures |
US20220022951A1 (en) | 2020-06-26 | 2022-01-27 | Neurent Medical Limited | Systems and methods for targeted tissue treatment |
US20220047326A1 (en) * | 2020-08-13 | 2022-02-17 | Biosense Webster (Israel) Ltd. | Applying Bipolar Ablation Energy Between Shorted Electrode Groups |
US12016612B2 (en) | 2020-08-19 | 2024-06-25 | Acclarent, Inc. | ENT ablation instrument with electrode loop |
US20230277236A1 (en) | 2020-08-31 | 2023-09-07 | Neurent Medical Limited | Device for therapeutic sino-nasal treatment |
WO2022056310A1 (en) * | 2020-09-10 | 2022-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatment and devices for repair of inflammatory, neurotransmitter, endocrine or metabolic issues |
US20220079656A1 (en) * | 2020-09-17 | 2022-03-17 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US20220087736A1 (en) * | 2020-09-23 | 2022-03-24 | Biosense Webster (Israel) Ltd. | Electrode shorting |
EP4225185A1 (en) | 2020-10-05 | 2023-08-16 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US20220104866A1 (en) * | 2020-10-06 | 2022-04-07 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
WO2022074460A1 (en) | 2020-10-06 | 2022-04-14 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US20220104862A1 (en) | 2020-10-06 | 2022-04-07 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US20220104869A1 (en) * | 2020-10-06 | 2022-04-07 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US11974803B2 (en) | 2020-10-12 | 2024-05-07 | Biosense Webster (Israel) Ltd. | Basket catheter with balloon |
US11957852B2 (en) | 2021-01-14 | 2024-04-16 | Biosense Webster (Israel) Ltd. | Intravascular balloon with slidable central irrigation tube |
EP4043071A1 (en) * | 2021-02-12 | 2022-08-17 | Scientia Biotech S.L. | Non-invasive cancer treatment |
WO2022192459A1 (en) * | 2021-03-10 | 2022-09-15 | Pulse Biosciences, Inc. | Pulse application for treatment and prevention of restenosis |
US20240164822A1 (en) * | 2021-03-22 | 2024-05-23 | Pavmed, Inc. | Continuous flow balloon catheter systems and methods of use |
WO2022214953A1 (en) * | 2021-04-06 | 2022-10-13 | Acclarent, Inc. | Ent instrument with rf electrodes on wire frame |
US20230133359A1 (en) | 2021-11-04 | 2023-05-04 | Neurent Medical Limited | Systems and methods for treating chronic sinusitis |
US20230181232A1 (en) * | 2021-12-14 | 2023-06-15 | Metrum Cryoflex Sp.z.o.o., Sp.k. | Surgical cryoprobe for treating cryolesions in the sacroiliac joint area |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023225265A1 (en) * | 2022-05-19 | 2023-11-23 | Icahn School Of Medicine At Mount Sinai | Non-invasive intranasal neuromodulation system |
US20230404648A1 (en) * | 2022-06-21 | 2023-12-21 | Varian Medical Systems, Inc. | Ablation probes including flexible circuits for heating and sensing |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
US20240138895A1 (en) * | 2022-10-28 | 2024-05-02 | Dorna Hakimimehr | Neuromodulation of nasal nerves to treat diseases |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
KR20240088074A (en) * | 2022-12-13 | 2024-06-20 | 주식회사 스킨그랩 | Ultrasonic generator for irradiating ultrasound to the parasympathetic nerve, method and program |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3987795A (en) * | 1974-08-28 | 1976-10-26 | Valleylab, Inc. | Electrosurgical devices having sesquipolar electrode structures incorporated therein |
US5588429A (en) * | 1991-07-09 | 1996-12-31 | Rensselaer Polytechnic Institute | Process for producing optimal current patterns for electrical impedance tomography |
US6142991A (en) * | 1998-03-31 | 2000-11-07 | Galil Medical, Ltd. | High resolution cryosurgical method and apparatus |
US20060055942A1 (en) * | 2003-02-27 | 2006-03-16 | Beat Krattiger | Method and optical system for measuring the topography of a test object |
US20140303665A1 (en) * | 2008-11-12 | 2014-10-09 | Lawrence J. Gerrans | Fluid Source with Physiological Feedback |
Family Cites Families (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5385544A (en) | 1992-08-12 | 1995-01-31 | Vidamed, Inc. | BPH ablation method and apparatus |
US5697281A (en) | 1991-10-09 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
IL103442A (en) | 1991-10-18 | 1998-01-04 | Ethicon Inc | Adhesion barrier applicator |
US5383874A (en) | 1991-11-08 | 1995-01-24 | Ep Technologies, Inc. | Systems for identifying catheters and monitoring their use |
US6063079A (en) | 1995-06-07 | 2000-05-16 | Arthrocare Corporation | Methods for electrosurgical treatment of turbinates |
US6053172A (en) | 1995-06-07 | 2000-04-25 | Arthrocare Corporation | Systems and methods for electrosurgical sinus surgery |
US5697882A (en) * | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
US5184625A (en) | 1992-04-16 | 1993-02-09 | Cordis Corporation | Biopsy forceps device having improved handle |
US5456662A (en) | 1993-02-02 | 1995-10-10 | Edwards; Stuart D. | Method for reducing snoring by RF ablation of the uvula |
US5800429A (en) | 1994-06-24 | 1998-09-01 | Somnus Medical Technologies, Inc. | Noninvasive apparatus for ablating turbinates |
US5823197A (en) | 1994-06-24 | 1998-10-20 | Somnus Medical Technologies, Inc. | Method for internal ablation of turbinates |
US5827277A (en) | 1994-06-24 | 1998-10-27 | Somnus Medical Technologies, Inc. | Minimally invasive apparatus for internal ablation of turbinates |
US6464689B1 (en) | 1999-09-08 | 2002-10-15 | Curon Medical, Inc. | Graphical user interface for monitoring and controlling use of medical devices |
US5836947A (en) | 1994-10-07 | 1998-11-17 | Ep Technologies, Inc. | Flexible structures having movable splines for supporting electrode elements |
CN2275461Y (en) * | 1996-02-01 | 1998-03-04 | 梁喜 | Appliance for radical curing rhinitis |
US6139527A (en) | 1996-03-05 | 2000-10-31 | Vnus Medical Technologies, Inc. | Method and apparatus for treating hemorrhoids |
US6332880B1 (en) | 1996-12-19 | 2001-12-25 | Ep Technologies, Inc. | Loop structures for supporting multiple electrode elements |
US6139546A (en) * | 1997-10-06 | 2000-10-31 | Somnus Medical Technologies, Inc. | Linear power control with digital phase lock |
US6045532A (en) * | 1998-02-20 | 2000-04-04 | Arthrocare Corporation | Systems and methods for electrosurgical treatment of tissue in the brain and spinal cord |
US6106518A (en) | 1998-04-09 | 2000-08-22 | Cryocath Technologies, Inc. | Variable geometry tip for a cryosurgical ablation device |
US6322584B2 (en) * | 1998-07-31 | 2001-11-27 | Surx, Inc. | Temperature sensing devices and methods to shrink tissues |
US6366813B1 (en) * | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US20010007070A1 (en) | 1999-04-05 | 2001-07-05 | Medtronic, Inc. | Ablation catheter assembly and method for isolating a pulmonary vein |
US6352533B1 (en) | 1999-05-03 | 2002-03-05 | Alan G. Ellman | Electrosurgical handpiece for treating tissue |
US6626899B2 (en) | 1999-06-25 | 2003-09-30 | Nidus Medical, Llc | Apparatus and methods for treating tissue |
US7935108B2 (en) | 1999-07-14 | 2011-05-03 | Cardiofocus, Inc. | Deflectable sheath catheters |
JP2001120565A (en) | 1999-10-22 | 2001-05-08 | Olympus Optical Co Ltd | High frequency treatment ingredient |
US6529756B1 (en) | 1999-11-22 | 2003-03-04 | Scimed Life Systems, Inc. | Apparatus for mapping and coagulating soft tissue in or around body orifices |
WO2001067597A1 (en) | 2000-03-06 | 2001-09-13 | Fujitsu Limited | Preamplifier |
US20010031981A1 (en) | 2000-03-31 | 2001-10-18 | Evans Michael A. | Method and device for locating guidewire and treating chronic total occlusions |
CA2413529C (en) | 2000-06-23 | 2008-12-02 | Cryocath Technologies, Inc. | Cryotreatment device and method |
US6638277B2 (en) | 2000-07-06 | 2003-10-28 | Scimed Life Systems, Inc. | Tumor ablation needle with independently activated and independently traversing tines |
US7387628B1 (en) | 2000-09-15 | 2008-06-17 | Boston Scientific Scimed, Inc. | Methods and systems for focused bipolar tissue ablation |
CN100518685C (en) | 2001-05-10 | 2009-07-29 | 脉管动力股份有限公司 | RF tissue ablation apparatus and method |
US6771996B2 (en) | 2001-05-24 | 2004-08-03 | Cardiac Pacemakers, Inc. | Ablation and high-resolution mapping catheter system for pulmonary vein foci elimination |
US20060155261A1 (en) | 2001-09-19 | 2006-07-13 | Curon Medical, Inc. | Systems and methods for treating tissue regions of the body |
US20030088240A1 (en) | 2001-11-02 | 2003-05-08 | Vahid Saadat | Methods and apparatus for cryo-therapy |
US6980858B2 (en) | 2001-12-31 | 2005-12-27 | Biosense Webster, Inc. | Method and system for atrial defibrillation |
US7967816B2 (en) | 2002-01-25 | 2011-06-28 | Medtronic, Inc. | Fluid-assisted electrosurgical instrument with shapeable electrode |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8774913B2 (en) * | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US6746474B2 (en) | 2002-05-31 | 2004-06-08 | Vahid Saadat | Apparatus and methods for cooling a region within the body |
US20060100620A1 (en) | 2002-08-21 | 2006-05-11 | Daniel Steven A | Thermal hemostasis and/or coagulation of tissue |
AU2003297691A1 (en) | 2002-12-03 | 2004-06-23 | Arthrocare Corporation | Devices and methods for selective orientation of electrosurgical devices |
US7416549B2 (en) | 2003-10-10 | 2008-08-26 | Boston Scientific Scimed, Inc. | Multi-zone bipolar ablation probe assembly |
US7476242B2 (en) | 2004-01-30 | 2009-01-13 | Ams Research Corporation | Electrically heated/phase change probe temperature control |
US7251531B2 (en) | 2004-01-30 | 2007-07-31 | Ams Research Corporation | Heating method for tissue contraction |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US8864787B2 (en) | 2004-04-21 | 2014-10-21 | Acclarent, Inc. | Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US9101384B2 (en) | 2004-04-21 | 2015-08-11 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat |
US8764729B2 (en) | 2004-04-21 | 2014-07-01 | Acclarent, Inc. | Frontal sinus spacer |
US20190314620A1 (en) | 2004-04-21 | 2019-10-17 | Acclarent, Inc. | Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures |
US20050283148A1 (en) | 2004-06-17 | 2005-12-22 | Janssen William M | Ablation apparatus and system to limit nerve conduction |
US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
US20120191003A1 (en) * | 2004-10-15 | 2012-07-26 | Robert Garabedian | Flexible neural localization devices and methods |
US7524318B2 (en) | 2004-10-28 | 2009-04-28 | Boston Scientific Scimed, Inc. | Ablation probe with flared electrodes |
US7200445B1 (en) | 2005-10-21 | 2007-04-03 | Asthmatx, Inc. | Energy delivery devices and methods |
US8617152B2 (en) | 2004-11-15 | 2013-12-31 | Medtronic Ablation Frontiers Llc | Ablation system with feedback |
US8600521B2 (en) * | 2005-01-27 | 2013-12-03 | Cyberonics, Inc. | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity |
US7794455B2 (en) | 2005-04-29 | 2010-09-14 | Medtronic Cryocath Lp | Wide area ablation of myocardial tissue |
WO2007008954A2 (en) | 2005-07-11 | 2007-01-18 | Ablation Frontiers | Low power tissue ablation system |
JP5826450B2 (en) | 2005-07-22 | 2015-12-02 | ザ ファウンドリー, エルエルシー | Systems and methods for delivery of therapeutic agents |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US7655243B2 (en) | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US10314583B2 (en) | 2005-07-26 | 2019-06-11 | Ethicon Llc | Electrically self-powered surgical instrument with manual release |
US20070031341A1 (en) * | 2005-08-08 | 2007-02-08 | Dimauro Thomas M | Methods of delivering therapeutics to the brain |
EP1928517B1 (en) | 2005-09-27 | 2016-12-07 | Allegiance Corporation | Medical suction and irrigation device handpiece |
US8696656B2 (en) * | 2005-11-18 | 2014-04-15 | Medtronic Cryocath Lp | System and method for monitoring bioimpedance and respiration |
US7842031B2 (en) * | 2005-11-18 | 2010-11-30 | Medtronic Cryocath Lp | Bioimpedance measurement system and method |
US20070299433A1 (en) | 2006-06-27 | 2007-12-27 | C2 Therapeutics | Barrett's Esophagus Cryogenic Ablation System |
EP2455036B1 (en) * | 2006-10-18 | 2015-07-15 | Vessix Vascular, Inc. | Tuned RF energy and electrical tissue characterization for selective treatment of target tissues |
US8280514B2 (en) * | 2006-10-31 | 2012-10-02 | Advanced Neuromodulation Systems, Inc. | Identifying areas of the brain by examining the neuronal signals |
US8463359B2 (en) | 2007-04-25 | 2013-06-11 | Nidus Medical, Llc | Shape-sensing expandable member |
US8460181B2 (en) | 2008-01-17 | 2013-06-11 | Nidus Medical, Llc | Epicardial access and treatment systems |
KR20110000654A (en) | 2008-03-13 | 2011-01-04 | 보스톤 싸이엔티픽 싸이메드 인코포레이티드 | Cryo-ablation refrigerant distribution catheter |
WO2009154456A1 (en) | 2008-06-18 | 2009-12-23 | Kerphos B.V. | A flexible electronic system for producing a stimulation signal to the human body. |
US20090318914A1 (en) | 2008-06-18 | 2009-12-24 | Utley David S | System and method for ablational treatment of uterine cervical neoplasia |
WO2010014686A1 (en) * | 2008-07-30 | 2010-02-04 | Aleva Neurotherapeutics, S.A. | Apparatus and method for optimized stimulation of a neurological target |
US8690839B2 (en) * | 2008-08-01 | 2014-04-08 | Tian Xia | Devices for delivering a medicament and connector for same |
US9603652B2 (en) | 2008-08-21 | 2017-03-28 | Covidien Lp | Electrosurgical instrument including a sensor |
US20100057048A1 (en) | 2008-09-04 | 2010-03-04 | Stephen Eldredge | Apparatus, System, and Method for Treating Atypical Headaches |
US8382753B2 (en) | 2008-10-21 | 2013-02-26 | Hermes Innovations, LLC | Tissue ablation methods |
US8295902B2 (en) * | 2008-11-11 | 2012-10-23 | Shifamed Holdings, Llc | Low profile electrode assembly |
US8382746B2 (en) | 2008-11-21 | 2013-02-26 | C2 Therapeutics, Inc. | Cryogenic ablation system and method |
WO2010070766A1 (en) | 2008-12-19 | 2010-06-24 | 有限会社日本エレクテル | Balloon catheter system |
US8712550B2 (en) | 2008-12-30 | 2014-04-29 | Biosense Webster, Inc. | Catheter with multiple electrode assemblies for use at or near tubular regions of the heart |
EP2432422A4 (en) | 2009-05-18 | 2018-01-17 | PneumRx, Inc. | Cross-sectional modification during deployment of an elongate lung volume reduction device |
US8986211B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
AU2010315396B2 (en) | 2009-10-27 | 2016-05-05 | Nuvaira, Inc | Delivery devices with coolable energy emitting assemblies |
US20110160740A1 (en) * | 2009-12-28 | 2011-06-30 | Acclarent, Inc. | Tissue Removal in The Paranasal Sinus and Nasal Cavity |
US20110238057A1 (en) | 2010-02-16 | 2011-09-29 | Angiodynamics, Inc. | Dual Bracketed Energy Delivery Probe and Method of Use |
CN102905639B (en) | 2010-04-06 | 2015-05-06 | 赫莱拉公司 | System and method for pulmonary treatment |
JP5760079B2 (en) | 2010-04-14 | 2015-08-05 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Device for delivering denervation therapy to the renal arteries |
US9498278B2 (en) | 2010-09-08 | 2016-11-22 | Covidien Lp | Asymmetrical electrodes for bipolar vessel sealing |
CA2812507A1 (en) * | 2010-09-24 | 2012-03-29 | Entrigue Surgical, Inc. | Systems, devices and methods for providing therapy to an anatomical structure using high frequency pressure waves and/or cryogenic temperatures |
US8911434B2 (en) | 2010-10-22 | 2014-12-16 | Medtronic Cryocath Lp | Balloon catheter with deformable fluid delivery conduit |
US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
US8747401B2 (en) | 2011-01-20 | 2014-06-10 | Arthrocare Corporation | Systems and methods for turbinate reduction |
AU2012364792A1 (en) | 2011-04-08 | 2013-11-21 | Covidien Lp | Flexible microwave catheters for natural or artificial lumens |
TW201242570A (en) | 2011-04-25 | 2012-11-01 | Medtronic Ardian Luxembourg | Apparatus and methods related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
US9415194B2 (en) | 2011-06-14 | 2016-08-16 | Aerin Medical Inc. | Post nasal drip treatment |
US10722282B2 (en) | 2011-06-14 | 2020-07-28 | Aerin Medical, Inc. | Methods and devices to treat nasal airways |
US8986301B2 (en) * | 2012-06-13 | 2015-03-24 | Aerin Medical Inc. | Methods and devices to treat nasal airways |
US10456185B2 (en) | 2011-06-14 | 2019-10-29 | Aerin Medical, Inc. | Methods and devices to treat nasal airways |
US11241271B2 (en) | 2011-06-14 | 2022-02-08 | Aerin Medical Inc. | Methods of treating nasal airways |
US11033318B2 (en) | 2011-06-14 | 2021-06-15 | Aerin Medical, Inc. | Methods and devices to treat nasal airways |
US8936594B2 (en) | 2011-06-14 | 2015-01-20 | Aerin Medical Inc. | Methods and devices to treat nasal airways |
US11304746B2 (en) | 2011-06-14 | 2022-04-19 | Aerin Medical Inc. | Method of treating airway tissue to reduce mucus secretion |
US9084592B2 (en) | 2011-07-11 | 2015-07-21 | C2 Therapeutics, Inc. | Focal ablation assembly |
US9351790B2 (en) * | 2011-09-17 | 2016-05-31 | M.O.E. Medical Devices Llc | Electrode geometries and method for applying electric field treatment to parts of the body |
US8498686B2 (en) | 2011-10-04 | 2013-07-30 | Biosense Webster (Israel), Ltd. | Mapping catheter with spiral electrode assembly |
US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
CN104244856B (en) | 2011-12-23 | 2017-03-29 | 维西克斯血管公司 | The method and apparatus of the tissue rebuild near the tissue or body passageway of body passage |
US20130172877A1 (en) * | 2011-12-28 | 2013-07-04 | Boston Scientific Scimed, Inc. | Balloon expandable multi-electrode rf ablation catheter |
AU2012369170A1 (en) | 2012-02-10 | 2014-07-24 | Dolor Technologies, L.L.C. | Systems and apparatus for facilitating intranasal treatment of a patient |
EP2822494B1 (en) | 2012-03-04 | 2022-08-03 | Medtronic Ireland Manufacturing Unlimited Company | Generator assemblies for neuromodulation therapy |
US20130253387A1 (en) | 2012-03-08 | 2013-09-26 | Sonitec, LLC | Vibratory energy systems and methods for occluded body cavities |
WO2013134780A1 (en) | 2012-03-09 | 2013-09-12 | Petersohn M D Jeffrey | Device for therapeutic delivery of radio frequency energy |
EP2641580B1 (en) | 2012-03-20 | 2020-06-03 | Chordate Medical AB | Electroactive vibration device |
US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
WO2014005155A1 (en) | 2012-06-30 | 2014-01-03 | Cibiem, Inc. | Carotid body ablation via directed energy |
US9381063B2 (en) | 2012-07-13 | 2016-07-05 | Magnetecs Inc. | Method and apparatus for magnetically guided catheter for renal denervation employing MOSFET sensor array |
EP2874555A1 (en) * | 2012-07-17 | 2015-05-27 | Boston Scientific Scimed, Inc. | Renal nerve modulation catheter design |
CN103656843A (en) * | 2012-09-04 | 2014-03-26 | 杭州朗佑医疗科技有限公司 | Targeted dilatation forming balloon catheter |
US9433461B2 (en) | 2012-09-07 | 2016-09-06 | Covidien Lp | Instruments, systems, and methods for sealing tissue structures |
US11234760B2 (en) | 2012-10-05 | 2022-02-01 | Medtronic Advanced Energy Llc | Electrosurgical device for cutting and removing tissue |
EP4230162A1 (en) * | 2012-11-02 | 2023-08-23 | Neurotronic, Inc. | Chemical ablation formulations and methods of treatments for various diseases |
US9615878B2 (en) | 2012-12-21 | 2017-04-11 | Volcano Corporation | Device, system, and method for imaging and tissue characterization of ablated tissue |
US9254166B2 (en) | 2013-01-17 | 2016-02-09 | Arthrocare Corporation | Systems and methods for turbinate reduction |
WO2014118733A2 (en) | 2013-01-31 | 2014-08-07 | David Prutchi | Ablation catheter with insulation |
US20140228875A1 (en) | 2013-02-08 | 2014-08-14 | Nidus Medical, Llc | Surgical device with integrated visualization and cauterization |
US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
US9179973B2 (en) | 2013-03-15 | 2015-11-10 | St. Jude Medical, Cardiology Division, Inc. | Feedback systems and methods for renal denervation utilizing balloon catheter |
AU2014253754C1 (en) | 2013-04-19 | 2015-07-30 | Oculeve, Inc. | Nasal stimulation devices and methods |
WO2014197625A1 (en) | 2013-06-05 | 2014-12-11 | Metavention, Inc. | Modulation of targeted nerve fibers |
US9852230B2 (en) | 2013-06-29 | 2017-12-26 | Google Llc | Asynchronous message passing for large graph clustering |
EP3019105B1 (en) * | 2013-07-11 | 2017-09-13 | Boston Scientific Scimed, Inc. | Devices for nerve modulation |
WO2015013252A1 (en) * | 2013-07-22 | 2015-01-29 | Wedge Therapeutics, Llc | Treatment of alzheimer's disease |
US20150031946A1 (en) * | 2013-07-24 | 2015-01-29 | Nidus Medical, Llc | Direct vision cryosurgical probe and methods of use |
US9326816B2 (en) * | 2013-08-30 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods |
US9687288B2 (en) | 2013-09-30 | 2017-06-27 | Arrinex, Inc. | Apparatus and methods for treating rhinitis |
US10433902B2 (en) | 2013-10-23 | 2019-10-08 | Medtronic Ardian Luxembourg S.A.R.L. | Current control methods and systems |
JP2016534842A (en) | 2013-10-25 | 2016-11-10 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Embedded thermocouples in denervation flex circuits |
US9918789B2 (en) * | 2013-10-25 | 2018-03-20 | Covidien Lp | Unfurling electrode devices with the protection element |
US9352134B2 (en) | 2013-11-01 | 2016-05-31 | Biosense Webster (Israel) Ltd. | Segmented balloon catheter |
KR20160094953A (en) | 2013-12-05 | 2016-08-10 | 프랙스에어 에스.티. 테크놀로지, 인코포레이티드 | Improved and modified tungsten-titanium sputtering targets |
US9510743B2 (en) | 2013-12-17 | 2016-12-06 | Biovision Technologies, Llc | Stabilized surgical device for performing a sphenopalatine ganglion block procedure |
US10463424B2 (en) | 2014-03-11 | 2019-11-05 | Medtronic Ardian Luxembourg S.A.R.L. | Catheters with independent radial-expansion members and associated devices, systems, and methods |
US9579149B2 (en) | 2014-03-13 | 2017-02-28 | Medtronic Ardian Luxembourg S.A.R.L. | Low profile catheter assemblies and associated systems and methods |
CA3200528A1 (en) | 2014-03-20 | 2015-09-24 | Electrophysiology Frontiers S.P.A. | Ablation catheter and ablation apparatus |
US9925359B2 (en) | 2014-03-21 | 2018-03-27 | Medtronic Cryocath Lp | Balloon design to reduce distal length |
US20150289750A1 (en) | 2014-04-11 | 2015-10-15 | Jeremy Stigall | Imaging and treatment device |
CN106659531A (en) | 2014-05-07 | 2017-05-10 | 毕达哥拉斯医疗有限公司 | Controlled tissue ablation techniques |
AU2015270223B2 (en) | 2014-06-02 | 2019-10-10 | Terumo Medical Corporation | Systems and methods for suture delivery |
US9763743B2 (en) | 2014-07-25 | 2017-09-19 | Arrinex, Inc. | Apparatus and method for treating rhinitis |
US10660699B2 (en) | 2014-10-31 | 2020-05-26 | Medtronic, Inc. | Ablation therapy to disrupt coordinated bladder contractions |
EP3226795B1 (en) | 2014-12-03 | 2020-08-26 | Metavention, Inc. | Systems for modulating nerves or other tissue |
US20160250474A1 (en) | 2015-02-11 | 2016-09-01 | Interventional Autonomics Corporation | Intravascular Electrode System and Method |
WO2016134264A1 (en) | 2015-02-20 | 2016-08-25 | Boston Scientific Scimed Inc. | Tissue contact sensing using a medical device |
EP3267955A4 (en) | 2015-03-10 | 2018-10-31 | PAVmed Inc. | Continuous flow balloon catheter systems and methods of use |
EP3264839B1 (en) | 2015-05-06 | 2023-10-25 | Huawei Technologies Co., Ltd. | Positioning method, positioning server and positioning system |
CA2984207C (en) | 2015-05-12 | 2024-05-21 | National University Of Ireland Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US10497092B2 (en) | 2015-11-19 | 2019-12-03 | Camtek Ltd | Continuous light inspection |
US11602260B2 (en) | 2016-02-11 | 2023-03-14 | Arrinex, Inc. | Method and device for image guided post-nasal nerve ablation |
WO2017139609A1 (en) | 2016-02-12 | 2017-08-17 | Aerin Medical, Inc. | Hyaline cartilage shaping |
US10252048B2 (en) | 2016-02-19 | 2019-04-09 | Oculeve, Inc. | Nasal stimulation for rhinitis, nasal congestion, and ocular allergies |
WO2017152061A1 (en) | 2016-03-04 | 2017-09-08 | Aerin Medical, Inc. | Eustachian tube modification |
EP3426338A4 (en) | 2016-03-09 | 2019-10-30 | Cardionomic, Inc. | Cardiac contractility neurostimulation systems and methods |
US10736692B2 (en) | 2016-04-28 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the treatment of cancer |
CN113616277A (en) | 2016-06-15 | 2021-11-09 | 阿里内克斯股份有限公司 | Device for treating the lateral surface of the nasal cavity |
CN106308927A (en) | 2016-08-22 | 2017-01-11 | 北京市肿瘤防治研究所 | Multi-tip extension type radiofrequency ablation electrode needle |
US11253312B2 (en) * | 2016-10-17 | 2022-02-22 | Arrinex, Inc. | Integrated nasal nerve detector ablation-apparatus, nasal nerve locator, and methods of use |
CA3041440A1 (en) | 2016-11-11 | 2018-05-17 | National University Of Ireland, Galway | Devices, systems, and methods for specializing, monitoring, and/or evaluating therapeutic nasal neuromodulation |
AU2017382212A1 (en) | 2016-12-22 | 2019-07-04 | Aerin Medical, Inc. | Soft palate treatment |
EP3614940A4 (en) | 2017-04-28 | 2021-01-20 | Arrinex, Inc. | Systems and methods for locating blood vessels in the treatment of rhinitis |
US11096738B2 (en) | 2017-05-05 | 2021-08-24 | Aerin Medical, Inc. | Treatment of spinal tissue |
US20190076185A1 (en) | 2017-09-08 | 2019-03-14 | Aerin Medical, Inc. | Reconfigurable design for multiple airway treatments |
US11478298B2 (en) | 2018-01-24 | 2022-10-25 | Medtronic Ardian Luxembourg S.A.R.L. | Controlled irrigation for neuromodulation systems and associated methods |
US20210315627A1 (en) | 2018-08-01 | 2021-10-14 | Adagio Medical, Inc. | Ablation catheter having an expandable treatment portion |
US10350025B1 (en) | 2018-09-06 | 2019-07-16 | Gyrus Acmi, Inc. | System and method for preventing reuse of medical device |
US20200129223A1 (en) | 2018-10-31 | 2020-04-30 | Aerin Medical, Inc. | Electrosurgical device console |
US11701167B2 (en) | 2018-12-11 | 2023-07-18 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
WO2020190693A1 (en) | 2019-03-15 | 2020-09-24 | Boston Scientific Scimed, Inc. | Waveform generator and control for selective cell ablation |
WO2021205231A1 (en) | 2020-04-09 | 2021-10-14 | Neurent Medical Limited | Systems and methods for identifying and characterizing tissue and providing targeted treatment thereof |
US11896818B2 (en) | 2020-04-09 | 2024-02-13 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US20220022951A1 (en) | 2020-06-26 | 2022-01-27 | Neurent Medical Limited | Systems and methods for targeted tissue treatment |
-
2016
- 2016-05-12 CA CA2984207A patent/CA2984207C/en active Active
- 2016-05-12 EP EP16727879.5A patent/EP3294410A2/en active Pending
- 2016-05-12 WO PCT/US2016/032132 patent/WO2016183337A2/en active Application Filing
- 2016-05-12 US US15/153,217 patent/US11026746B2/en active Active
- 2016-05-12 JP JP2018511345A patent/JP6854015B2/en active Active
- 2016-05-12 CA CA3234408A patent/CA3234408A1/en active Pending
- 2016-05-12 CN CN202210451693.0A patent/CN115040232A/en active Pending
- 2016-05-12 AU AU2016262085A patent/AU2016262085B2/en active Active
- 2016-05-12 CN CN201680041384.9A patent/CN107835705B/en active Active
-
2018
- 2018-09-20 HK HK18112151.0A patent/HK1252823A1/en unknown
-
2019
- 2019-04-12 US US16/382,845 patent/US20190231429A1/en active Pending
- 2019-04-12 US US16/382,877 patent/US20190239956A1/en active Pending
- 2019-04-12 US US16/382,865 patent/US20190239955A1/en active Pending
- 2019-04-12 US US16/382,889 patent/US20190239957A1/en active Pending
- 2019-04-12 US US16/382,802 patent/US11690672B2/en active Active
- 2019-04-12 US US16/382,830 patent/US11771497B2/en active Active
- 2019-12-04 US US16/703,348 patent/US20200107882A1/en active Pending
- 2019-12-04 US US16/703,325 patent/US20200100838A1/en active Pending
-
2021
- 2021-01-19 AU AU2021200322A patent/AU2021200322B2/en active Active
- 2021-03-08 JP JP2021035965A patent/JP7347832B2/en active Active
-
2023
- 2023-03-22 AU AU2023201779A patent/AU2023201779A1/en active Pending
- 2023-08-31 JP JP2023141234A patent/JP2023164491A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3987795A (en) * | 1974-08-28 | 1976-10-26 | Valleylab, Inc. | Electrosurgical devices having sesquipolar electrode structures incorporated therein |
US5588429A (en) * | 1991-07-09 | 1996-12-31 | Rensselaer Polytechnic Institute | Process for producing optimal current patterns for electrical impedance tomography |
US6142991A (en) * | 1998-03-31 | 2000-11-07 | Galil Medical, Ltd. | High resolution cryosurgical method and apparatus |
US20060055942A1 (en) * | 2003-02-27 | 2006-03-16 | Beat Krattiger | Method and optical system for measuring the topography of a test object |
US20140303665A1 (en) * | 2008-11-12 | 2014-10-09 | Lawrence J. Gerrans | Fluid Source with Physiological Feedback |
Non-Patent Citations (5)
Title |
---|
Edward Lee and Pravin Varaiya, "Sampling and Reconstruction" In: Structure and Interpretation of Signals and Systems, Reading, MA: Addison-Wesley, ISBN: 0-201-74551-8, Pearson Education, Inc., pp 373-392 (Year: 2003) * |
Horesh, Lior "Some novel approaches in modelling and image reconstruction for multi-frequency Electrical Impedance Tomography of the human brain", Thesis (Ph.D.)--University of London, University College London (United Kingdom), 2006.; Publication Number: AAT U592053 (Year: 2006) * |
Min, M., Parve, T., Pliquett, U.F. "Impedance Detection" In: Li, D. (eds) Encyclopedia of Microfluidics and Nanofluidics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5491-5_1783, pp 1333-1472 (Year: 2015) * |
Paterno AS, Stiz RA, Bertemes-Filho P. "Frequency-domain reconstruction of signals in electrical bioimpedance spectroscopy", Med Biol Eng Comput. 2009 Oct;47(10):1093-102. doi: 10.1007/s11517-009-0533-1. PMID: 19820978. (Year: 2009) * |
Yang "Electrical Impedance Tomography: Algorithms and Application", University of Bath, 2014 (Year: 2014) * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11690672B2 (en) | 2015-05-12 | 2023-07-04 | National University Of Ireland, Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US11771497B2 (en) | 2015-05-12 | 2023-10-03 | National University Of Ireland, Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US11547473B2 (en) | 2018-12-11 | 2023-01-10 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11576719B2 (en) | 2018-12-11 | 2023-02-14 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11666378B2 (en) | 2018-12-11 | 2023-06-06 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11684414B2 (en) | 2018-12-11 | 2023-06-27 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11547472B2 (en) | 2018-12-11 | 2023-01-10 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11701167B2 (en) | 2018-12-11 | 2023-07-18 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11419671B2 (en) | 2018-12-11 | 2022-08-23 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US12004800B2 (en) | 2018-12-11 | 2024-06-11 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
US11883091B2 (en) | 2020-04-09 | 2024-01-30 | Neurent Medical Limited | Systems and methods for improving sleep with therapeutic nasal treatment |
US11896818B2 (en) | 2020-04-09 | 2024-02-13 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
US11998262B1 (en) | 2020-04-09 | 2024-06-04 | Neurent Medical Limited | Systems and methods for improving sleep with therapeutic nasal treatment |
DE102021103506A1 (en) | 2021-02-15 | 2022-08-18 | Olympus Winter & Ibe Gmbh | Bipolar HF applicator and HF application system |
Also Published As
Publication number | Publication date |
---|---|
US20190239953A1 (en) | 2019-08-08 |
US20200107882A1 (en) | 2020-04-09 |
US11026746B2 (en) | 2021-06-08 |
EP3294410A2 (en) | 2018-03-21 |
US20190239954A1 (en) | 2019-08-08 |
JP2021087861A (en) | 2021-06-10 |
CN107835705A (en) | 2018-03-23 |
AU2023201779A1 (en) | 2023-04-20 |
JP2018515314A (en) | 2018-06-14 |
WO2016183337A3 (en) | 2016-12-29 |
HK1252823A1 (en) | 2019-06-06 |
US11771497B2 (en) | 2023-10-03 |
JP6854015B2 (en) | 2021-04-07 |
US20200100838A1 (en) | 2020-04-02 |
AU2021200322A1 (en) | 2021-03-18 |
CN115040232A (en) | 2022-09-13 |
CA2984207A1 (en) | 2016-11-17 |
CA3234408A1 (en) | 2016-11-17 |
AU2016262085B2 (en) | 2020-10-22 |
AU2021200322B2 (en) | 2022-12-22 |
CN107835705B (en) | 2022-05-13 |
US20190239955A1 (en) | 2019-08-08 |
JP2023164491A (en) | 2023-11-10 |
US20190231429A1 (en) | 2019-08-01 |
CA2984207C (en) | 2024-05-21 |
US11690672B2 (en) | 2023-07-04 |
US20160331459A1 (en) | 2016-11-17 |
AU2016262085A1 (en) | 2018-01-04 |
US20190239956A1 (en) | 2019-08-08 |
WO2016183337A2 (en) | 2016-11-17 |
JP7347832B2 (en) | 2023-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11690672B2 (en) | Devices for therapeutic nasal neuromodulation and associated methods and systems | |
US10806921B2 (en) | Devices, systems, and methods for specializing, monitoring, and/or evaluating therapeutic nasal neuromodulation | |
CN113710181A (en) | Systems and methods for therapeutic nasal neuromodulation | |
US20210169566A1 (en) | Devices for therapeutic nasal neuromodulation and associated methods and systems | |
US20200405383A1 (en) | Systems and methods for treating at least one of rhinitis, congestion, and rhinorrhea | |
CA3145166A1 (en) | Systems and methods for targeted therapeutic nasal neuromodulation | |
EP4225185A1 (en) | Systems and methods for therapeutic nasal treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL UNIVERSITY OF IRELAND, GALWAY, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOWNLEY, DAVID;SHIELDS, BRIAN;FARRELL, CONOR;AND OTHERS;SIGNING DATES FROM 20160512 TO 20160713;REEL/FRAME:050036/0899 Owner name: NATIONAL UNIVERSITY OF IRELAND, GALWAY, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KEOGH, IVAN;REEL/FRAME:050036/0868 Effective date: 20160512 |
|
AS | Assignment |
Owner name: NATIONAL UNIVERSITY OF IRELAND, GALWAY, IRELAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND PROPERTY NUMBER PREVIOUSLY RECORDED AT REEL: 50036 FRAME: 868. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:KEOGH, IVAN;REEL/FRAME:050119/0422 Effective date: 20160512 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |